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Cysteine cathepsins are powerful proteases involved in tissue destructive disease 
progression, including angiogenesis and pathogenic vascular remodeling, and some of their 
functions and mechanisms in biological processes have yet to be discovered. Their 
potential role in polymerizing and degrading fibrin, an essential blood clotting protein and 
commonly used biomaterial scaffold for tissue repair, have not been characterized well. I 
hypothesize that cysteine cathepsins have unique fibrin(ogen)olytic properties which can 
facilitate fibrin matrix remodeling. The objective of this research is to study cathepsin-
mediated fibrin(ogen)olysis in the context of fibrin-based microvascular network 
destabilization and novel blood clotting mechanisms. 
Overall, this dissertation has uncovered fibrin as a novel substrate for cysteine 
cathepsins. A unique property was identified where cathepsin L adsorbed to fibrin, which 
served as a bioactive reservoir to sustain cathepsin activity for extended periods of time. 
This knowledge can be expanded to have an impact in two areas: tissue engineering and 
clinical applications. It will (1) help us understand the role of cathepsin-mediated fibrin 
degradation in vitro and how cathepsins remodel matrix of microvascular networks and (2) 
improve our understanding of cathepsin involvement in coagulation in sickle cell anemia 
(SCA). 
 This work is innovative because, within the field of regenerative medicine, cysteine 
cathepsins have not fully been considered as mediators in remodeling and destabilizing the 
extracellular matrix (ECM) of fibrin-based constructs. While several factors (growth 
factors and biomechanical cues) have been perturbed in studies, researchers typically focus 
on matrix metalloproteinases (MMPs) proteolytic activity. When constructing tissue-
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engineered constructs, protease expression and activity can be perturbed by factors 
including matrix composition, cell-cell contact, and shear stress. This work provides 
insight into upregulated proteases in microvascular networks, which can help improve 
designs to prevent microvessel regression. 
Researchers need to better understand how chronic coagulation activation leads to 
the pathophysiology of SCA. Studies using anticoagulants and antiplatelet therapeutics 
have not helped prevent or treat hypercoagulation and vaso-occlusive conditions in people 
with SCA. This work has identified upregulated plasma cathepsin levels that could perturb 
the coagulation cascade. Identifying this mechanism can provide insight into the role 
cathepsins could play in coagulation, with further implications to uncover novel blood 
clotting mechanisms and abnormal fibrinolysis in cardiovascular diseases that have not 







CHAPTER 1  INTRODUCTION AND SPECIFIC AIMS 
 Cysteine cathepsins are powerful proteases first discovered in lysosomes involved 
in non-specific protein turnover or degradation, and are secreted by various cell types in 
tissue destructive diseases such as cancer/tumor metastasis, atherosclerosis, arthritis, and 
tendinopathy [1-8]. These enzymes degrade extracellular matrix (ECM) proteins and are 
some of the most powerful collagenases and elastases [7, 9]. Cysteine cathepsins have 
substrate redundancy [2], however few studies have identified their proteolytic potential 
on fibrin(ogen)  [10-12], an essential blood clotting protein and commonly used biomaterial 
scaffold for tissue repair. To identify the putative role of cathepsins in cleaving fibrinogen 
and degrading fibrin, fibrin-based constructs were used as a biological mimicking test bed 
and sickle cell disease (SCD) for a pathological condition. 
 In tissue engineering, fibrin-based tissue constructs are favored due to controllable 
gelation time and network geometry. This makes fibrin a promising scaffold for 
multicellular engineered living systems such as vascular tissue engineered constructs and 
vascularized organ-on-a-chip systems [13-17]. Proteolytic activity is needed for matrix 
remodeling during vasculogenesis [18-20]. Matrix metalloproteinases (MMPs) are 
commonly studied in these processes [21-23], but other proteases like cysteine cathepsins 
could facilitate remodeling, seeing as they have been implicated in angiogenesis [24-28]. 
Cathepsins are secreted by several cell types, including ECs and fibroblasts [28, 29], which 
are both used to develop microvascular networks. Through biomechanical and biochemical 
inhibition strategies, the role of cathepsins were characterized in matrix remodeling during 
microvascular network development. This was a unique model to study fibrin matrix as a 
bioactive reservoir for cathepsins using an in vitro platform. 
 2 
 Sickle cell anemia (SCA) is red blood cell disorder, where people are in a state of 
chronic coagulation activation, also known as hypercoagulation. Etiology of SCA-
mediated hypercoagulation is not well understood, but can contribute to the canonical 
problem, sickle pain crisis [30-34]. There is a need to understand mechanisms underlying 
the hypercoagulable state in SCA to develop effective anticoagulant therapies, specific to 
the SCA population. Thrombin is the canonical protease in the coagulation cascade that 
cleaves fibrinopeptide A and B from fibrinogen, promoting fibrin polymerization and 
coagulation [35-37]. It has been reported that people with SCA have increased plasma 
concentrations of fibrinopeptide A (FpA) [38, 39], a biomarker of clotting activation, 
however, researchers suggest it is not solely due to thrombin activity [39]. Our lab has 
shown that cathepsins are upregulated in sickle cell disease (SCD) [28, 40, 41]. Based on 
computational docking algorithms, cathepsin K has putative binding and cleavage sites on 
fibrinogen within the central E-domain where FpA is found and cleavage occurs [42]. Also, 
SCA activates peripheral blood mononuclear cells to induce and upregulate cathepsin K 
activity in endothelial cells [40]. Combining these observations, it is suggested that 
elevated circulating FpA plasma levels in SCA is due to cysteine cathepsin cleavage of 
fibrinogen, contributing to chronic coagulation activation. 
 
  Research Objectives and Specific Aims 
 The objective of this dissertation is to study cathepsin-mediated 
fibrin(ogen)olysis to better understand enzymology of cathepsins on a novel substrate. It is 
important to understand how cathepsins remodel fibrin, as there are implications for 
cathepsins in fibrin-based microvascular network matrix remodeling and aberrant blood 
clotting mechanisms. Researchers have not fully considered fibrin polymerization and 
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degradation by proteases other than thrombin and plasmin, respectively, the canonical 
proteases involved in the coagulation cascade and fibrinolysis. Cathepsins are not normally 
associated with the coagulation cascade, however, they are implicated in homeostasis to 
facilitate tissue remodeling, acting on various matrix proteins including collagen and 
elastin. The goal is to investigate novel hydrolysis and regulatory mechanisms between 
cathepsins and fibrin(ogen). The central hypothesis of this dissertation is that cysteine 
cathepsins have unique fibrin(ogen)olytic properties that contribute to fibrin-based 
microvascular network matrix remodeling and aberrant blood clotting in SCD. This work 
could lead to design strategies to improve longevity of fibrin-based tissue engineered 
microvessels, as well as help improve treatment options to reduce chronic coagulation 
activation in SCD. 
 
Aim 1: Determine fibrinolytic activity of cathepsins K, L, and S. Hypothesis: 
Cathepsins hydrolyze fibrin and degrade the α, β, or γ fibrin polypeptide chains. Fibrin 
gels were formed and used to assess fibrinolytic activity of cathepsins (cat) K, L, and S. 
Fibrin gels were polymerized, then incubated with increasing amounts of recombinant cat 
K, L, or S, or plasmin as a control, for 24 hours. Samples were run on SDS-PAGE and 
multiplex cathepsin zymography to assess fibrin cleavage into smaller molecular weight 
products and  amounts of active cathepsins, respectively. These studies demonstrate that 
cat K, L, and S were fibrinolytic, and specifically degraded the α and β fibrin polypeptide 
chains, in cleavage patterns that differ from plasmin. Incubating fibrin gels with increasing 
amounts of catL correlated with increased amount of active catL in the supernatant at 
higher molecular sizes (37-75 kDa) than the size at which catL normally produces a signal 
(20 kDa). The larger molecular weight appearance of active catL observed in the 
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zymography was most likely catL bound to fibrin and fibrin degradation products, which 
was unique for catL among the others, suggesting that fibrin can serve as a substrate to 
prolong active catL. Chapter 3 discusses these findings.  
 
Aim 2: Determine the role of cathepsin activity in microvascular network matrix 
remodeling. Hypothesis: Cysteine cathepsin, secreted by ECs and fibroblasts, hydrolyze 
fibrin and other matrix proteins facilitating microvascular network matrix remodeling.  
ECs and fibroblasts were cultured in a fibrin gel within a PDMS platform. Microvascular 
networks formed via a vasculogenesis-like process over ~7days, then half of the devices 
were exposed to continuous flow, inducing a low shear stress for 48hrs. Endothelial or 
stromal cells were examined to identify which cell type produced more cathepsins, and if 
fibrin could sustain active cathepsins in vitro, by culturing ECs and fibroblasts on fibrin 
gels. Microvascular networks exposed to luminal flow have a significantly lower amount 
of active cathepsins compared to networks grown under static conditions. There was more 
catL present in networks developed under flow, which was accompanied by an increased 
amount of cystatin C. ECs and fibroblasts separately cultured on fibrin had increased 
amounts of active cathepsins in supernatants and homogenates, however, there was more 
catL present in fibroblasts compared to ECs. Active cathepsins were significantly increased 
in statically cultured microvascular networks which regress over time, as evidenced by 
thinning of microvessels by day 10. Taken together, this suggests that fibrin in the 
microvascular networks matrix may stabilize cathepsin activity in the system. This work 
demonstrates the need to consider novel cathepsin inhibition strategies to control 
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Aim 3: Determine fibrinogenolytic activity of cysteine cathepsins in promoting 
chronic coagulation activation due to sickle cell disease (SCD). Hypothesis: Cathepsin 
K can release fibrinopeptides A (FpA) by cleaving the Gly-Pro-Arg (GPR) sequence on 
fibrinogen, which contributes to hypercoagulation in sickle cell disease.  The amounts of 
active cathepsins and FpA in plasma were quantified in Townes’ humanized sickle cell 
mouse model: wildtype (AA), sickle cell trait (AS), and sickle cell anemia (SS) genotypes. 
To determine if cysteine cathepsins, and specifically cathepsin K (catK), were causal 
agents of increased FpA, mice were injected daily with E-64, cathepsin inhibitor, from 1 
month to 3 months of age. Plasma was collected from untreated and E-64 treated mice. 
Samples were run on multiplex cathepsin zymography to assess amount of active 
cathepsins in plasma, and ELISA was used to quantify concentrations of FpA in plasma. 
Untreated 1-month SS mice had increased amounts of active cathepsins compared to 1-
month AA and AS mice, and 3-month SS mice had more active cathepsins compared to 1-
month SS mice. Preliminary data showed plasma from male untreated SS mice may contain 
higher amounts of circulating FpA compared to AA and AS mice. E-64 treatment reduced 
amounts of active cathepsins in plasma accompanied by a reduction in plasma FpA in SS 
male mice. These data support that SCA mediates increased levels of active catK in the 
plasma that cleaves FpA from circulating fibrinogen, promoting the hypercoagulable state. 
Inhibiting catK with E-64 treatment not only reduced the active cathepsins, but also 
reduced circulating FpA in this humanized sickle cell mouse model, implicating SCA-
induced cathepsin-mediated fibrinogenolysis. This data can be applied to help us 
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understand chronic coagulation activation in SCA, and sex differences in disease 
complications. Chapter 5 discusses these findings. 
 
 Significance of Results 
This dissertation is innovative because it focuses on the role cathepsins play in 
polymerization and degradation of fibrin, and will provide a foundation for understanding 
cathepsin-mediated fibrin(ogen)olysis. This work is giving more consideration to a novel 
class of proteases involved in fibrin(ogen)olysis, as there have been limited studies on 
cathepsin-mediated fibrin polymerization and degradation. The concept that the same 
protease can not only degrade, but also polymerize the same protein is interesting, 
especially considering that cathepsins are involved in tissue remodeling for homeostasis as 
well as destructive disease states. This knowledge can be used to develop cathepsin 
inhibition strategies for improving microvascular network design to improve network 







































Figure 1-1: Overview of Specific Aims 
 8 
CHAPTER 2  LITERATURE REVIEW 
 Cysteine Cathepsins 
Proteolysis, the irreversible hydrolysis of peptide bonds, is a mechanism used by 
cells to regulate cell function and fate. Proteases are needed to maintain homeostasis 
processes; endogenous inhibitors, pH, and inactive zymogen activation help control and 
regulate them [43]. Proteases are destructive, and when improperly regulated, this can lead 
to alterations in cell function, apoptosis, and tissue degradation [44]. Proteases are defined 
by their active site hydrolysis mechanism (amino acid sequences found in the catalytic 
triad). There are five major types of proteases: aspartic, cysteine, metallo, serine, and 
threonine [45].  
2.1.1 An Overview of Cathepsins  
Within the past few decades, researchers have identified that cathepsins play key 
roles in the regulation of cellular processes, protein turnover, and progression of diseases 
[2, 3, 46, 47]. Cysteine cathepsins are members of the C1 family of papain-like peptidases 
[2]; currently,  11 human cysteine cathepsins have been identified (B, C, F, H, K, L, V, O, 
S, W, X/Z). Our studies will focus on cathepsins K, L, and S, which share more than 60% 
sequence identity [1-3, 48, 49] yet have unique cellular functions, catalytic efficiencies, 
and target substrate redundancy [2, 50].  
Various cell types, including those found in vasculature or used in developing 
engineered microvessels, produce cathepsins- specifically, this includes endothelial cells, 
fibroblasts, and macrophages [6, 51-53]. Cathepsins are implicated in extracellular matrix 
(ECM) degradation in tissue destructive diseases including arthritis, atherosclerosis, 
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osteoporosis, and tumor metastasis [4-7, 51, 52]. These enzymes degrade ECM proteins 
and are some of the most powerful collagenases and elastases [7, 9, 54, 55]. 
2.1.2 Regulation of Cysteine Cathepsins  
Cysteine cathepsins were first discovered in lysosomes; they are proteolytically 
optimal in acidic and reducing environments, a property that prevents unnecessary 
proteolysis if they escape from the lysosome [1, 2, 47]. Due to their high potency, 
cathepsins are highly regulated. In the endoplasmic reticulum, cathepsins are translated as 
an inactive zymogen or propeptide. The propeptide sequence serves as a signaling molecule 
to traffic cathepsins to the Golgi [45]. Cathepsins are trafficked through the ER to the Golgi 
through a prepropeptide sequence, which serves as a signaling molecule.  During transport, 
the pre-region is cleaved, and, in the Golgi, the pro-cathepsin is post-translationally 
modified via glycosylation to prevent autodigestion or self-activation [2, 7]. After, the 
cathepsin is targeted to endolysosomal or lysosomal compartments where it is activated or 
secreted into the extracellular space [45]. While in the pro-cathepsin form, the propeptide 
sequence blocks the active site. Upon cleavage of the propeptide, the enzyme will be in its 
mature, active form where it can bind to and cleave substrate This propeptide is critical to 
prevent cathepsins from being continuously catalytically active when it is not needed for 
degrading substrate. Cathepsins are optimally active at acidic pH; under these conditions, 
cathepsins can self-cleave their own propeptide or other proteases can cleave the 
propeptide [1, 2, 56].  
Cells can endogenously produce inhibitors for cathepsins to regulate cathepsin 
activity. Cystatin C is a competitive inhibitor that binds reversible and tightly to active sites 
of cathepsins to prevent substrate degradation [57]. Cathepsins and cystatin C, are found 
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within the same space extracellularly, where they can interact through activation, 
inhibition, or enhancement of proteolytic functions [1, 7, 49, 57]. Dysregulation of inhibitor 
levels can contribute to ECM degradation, dysfunction, and disease progression [3, 19, 43, 
44].  
 Proteases and Fibrin(ogen) 
2.2.1 Fibrin(ogen) Structure 
Fibrinogen has an important role in hemostasis, a process to prevent or stop 
bleeding. It forms a clot to prevent blood loss and serves as a substrate to facilitate tissue 
repair where it helps maintain blood vessel tone, angiogenesis, cell migration, and 
proliferation of cells including fibroblasts and smooth muscle cells [36]. Fibrinogen is a 
340kDa hexameric protein, composed of three pairs of symmetrical polypeptide chains, 
Aα, Bβ, and γ, and held together by numerous disulfide bonds. Fibrinogen has a central E 
region where the N-terminus meets with a coiled-coiled region to the side D domain and 
Aα protuberances (further extension of the Aα chain) that coil back to the central E domain 
(Fig 2-1A) [58, 59]. The domains contain binding sites to facilitate different processes 
including fibrinogen conversion into fibrin, fibrin cross linking, and platelet adhesion [37]. 
The coagulation cascade is initiated after vascular injury and EC damage; an amplification 
cascade where various serine proteases cleave factors to produce activated factors, that 
ends in thrombin activation, which cleaves fibrinogen [35].  
2.2.2 Fibrin Formation During the Coagulation Cascade 
Hemostasis and the clotting cascade are defined by a series of proteolytic reactions, 
dominated by serine proteases [60],  resulting in cleavage of fibrinogen. Fibrinogen is 
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hydrolyzed by thrombin, which releases fibrinopeptides A (FpA) and B (FpB) from the N-
terminal part of the Aα and Bβ chains of fibrinogen resulting in a fibrin monomer [61, 62]. 
Specifically, FpA is cleaved at the AαArg16-Gly17 peptide and FpB is cleaved at the 
AαArg16-Gly17 peptide. After FpA cleavage, the α chains have new N-terminal sequences 
(Gly-Pro-Arg) called knobs “A” [62]. When the fibrin molecules interact, the knob “A” 
forms a complementary interaction with hole “A”, found on the γ-nodules within the side 
D domain; this is called an “A-a” interaction (Fig 2-1A) [63]. 
Fibrin polymerization begins when two fibrin molecules interact and the “A-a” 
interactions hold the two fibrin monomers together resulting in a fibrin dimer. An 
additional fibrin monomer is added to the fibrin dimer where the D domain of the new 
monomer interacts with the D domain and E domain of the fibrin dimer resulting in fibrin 
oligomers [61]. These monomers are added longitudinally and the process continues to 
form two-stranded protofibrils, which are then cross-linked by activated factor XIII (Fig 2-
1B) [35-37, 59].  
After FpB cleavage, the β chains have new N-terminal sequences (Gly-His-Arg-
Pro) called knobs “B” which binds to hole “b” located on the β-nodule [62]. Once fibrin 
protofibrils reach a certain length, they aggregate laterally through interactions of knob “B” 
and hole “b”, and the C-terminal part of the γ chains (Fig 2-1A) [64]. The lateral assembly 
results in a fibrin fiber which acts like a meshwork where other factors, like platelets, 
albumin, and red blood cells, are incorporated to grow and strengthen the fibrin clot that 
can withstand pressure in the blood vessel and prevent blood loss (Fig 2-1B) [65]. 
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2.2.3 Fibrinolysis by Plasmin 
Homeostasis is also maintained through clot resolution, which is defined as 
degradation and clearance of blood clots, to avoid occlusion of blood vessels. Fibrinolysis 
or fibrin degradation helps regulate coagulation and aids with wound healing [65]. Plasmin 
is the canonical enzyme that degrades fibrin and is controlled by the plasminogen activator 
(PA) system [35, 58]. Plasminogen, the inactive zymogen of plasmin, is cleaved by tissue-
type and urokinase PA (tPA and uPA) to form plasmin [66]. Plasmin hydrolyzes fibrin in 
the coiled-coiled region between the E and D domain [58] releasing fragment E from the 
central part of fibrin and two D fragments from the side regions [62]. Fibrinogen and its 
cleavage products have binding sites that facilitate tissue repair including vasoconstriction, 
angiogenesis, cell migration, and proliferation of various cells including fibroblasts, 


































Figure 2-1: Schematic of fibrin formation and degradation. 
(A) Top- Schematic of complimentary knob-hole interactions during fibrin polymerization. 
Bottom- Atomic resolution of knob-hole interactions. (B) Steps of fibrin polymerization, 
including longitudinal and lateral aggregation of fibrin and fibrin degradation by the 
canonical protease plasmin.  
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2.2.4 Fibrinolysis by Non-Plasmin Proteases 
 Although plasmin is the canonical enzyme for fibrin degradation, other proteases 
have been identified that hydrolyze fibrin at different sites generating different cleavage 
products.  Cysteine cathepsins are members of the papain-like cysteine protease family 
[46], a large group of proteases with structure similar to papain. Papain can cleave 
mammalian fibrinogens and cause fibrin gelation [67-69]. Papain and cysteine cathepsins 
have similar structures, suggesting cathepsin fibrinolytic potential.  An alternative 
fibrinolytic system was identified in peripheral blood leukocytes, where elastases and 
cathepsin G (serine proteases) are localized in leukocyte granules, which generate fibrin 
cleavage fragments that are distinct from the canonical plasmin system [70]. Other studies 
have shown that plasminogen activator-deficient transgenic mice have an alternative 
fibrinolytic pathway that does not use plasmin to clear thrombi [71, 72]. This led to 
studying a non-plasmin fibrinolytic pathway that uses integrin Mac-1 on monocytes which 
binds and internalizes fibrin [11]. Later, cathepsin D (aspartyl protease) was identified as 
the lysosomal fibrinolytic enzymes responsible for monocyte-mediated fibrinolysis [10]. 
These studies challenge that fibrinolysis could be perturbed by non-plasmin proteases via 
novel pathways and mechanisms. 
 Vasculogenesis 
Vasculogenesis is de novo formation of microvessels seen in embryogenesis, tumor 
growth, and following extensive vascular damage [73, 74]. This is different from 
angiogenesis where microvessels are formed from pre-existing vessels, usually in response 
to injury. Microvessel formation is a complex and coordinated process that includes ECM 
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remodeling, endothelial cell (EC) migration, cytokine secretion, lumen formation, and 
mural cell (i.e. pericyte) recruitment [22, 73, 74].  
In embryogenesis, precursor cells called angioblasts differentiate into ECs which 
form the inner most lining of vessels, called the tunica intima layer. ECs proliferate to form 
a neo-capillary network organized into a vascular tree with branches [75]. During postnatal 
vasculogenesis bone marrow-derived endothelial progenitor cells migrate to the site of 
damage and differentiate into mature ECs forming a neo-vascular network [73, 76].   
2.3.1 Cell matrix and protease interactions in angiogenesis  
Angiogenesis includes proteolytic remodeling of ECM during EC migration, 
invasion into perivascular tissue, and tubulogenesis (lumen formation). Dynamic 
regulation of enzymatic activity is critical to facilitating this process. During the beginning 
of angiogenesis, the basement membrane, which lies below the EC layer and interstitial 
connective tissue matrix, is degraded, and proteases are required to break down the ECM. 
[77]. Three groups of endopeptidases regulate angiogenesis: matrix metalloproteinases 
(MMPs), serine proteases, and cysteine cathepsins. Their activities are controlled by 
activation cascades and inhibitors, tissue inhibitors of metalloproteinases (TIMPs), serpins 
(serine inhibitors), and cystatins (cathepsin inhibitors) [20]. 
Similar to cathepsins, soluble MMPs are secreted as inactive pro-enzymes that 
become activated in the cellular environment [21]. MMP-1, -2, and -9, degrade ECM and 
basement membrane to aid in vascular remodeling, cell migration, and sprout formation 
[77]. Additionally, MMPs can release ECM-bound angiogenic growth factors (i.e.: VEGF 
and bFGF) in pericytes from vessels undergoing angiogenesis [20, 78]. Conversely, MMP-
7, -9, and -12 can generate an endogenous inhibitor for angiogenesis by converting 
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plasminogen into angiostatin [21, 77]. TIMPs are endogenous inhibitors of MMPs and 
function by binding to activated MMPs, and proteolytic activity is regulated based on the 
ratio of TIMPs bound to MMPs [19]. Some TIMPs can play a role in angiogenesis 
independent of MMP inhibition, such as TIMP-3 which can bind to VEGF receptor 
blocking VEGF which reduces angiogenesis [20].  
Serine proteases are a broad class of proteases involved in various functions, some 
of which might have indirect involvement in angiogenesis. However, more attention has 
been placed on the plasminogen activators, urokinase activators (uPA) and tissue-type 
plasminogen activators (tPA), and plasmin. uPA and plasmin are involved in cell migration 
and invasion by degrading ECM and regulating intracellular signaling upon binding to 
PARs (plasminogen activator receptor) [20, 79]. Both uPA and tPA can cleave 
plasminogen into activated plasmin, and are inhibited by plasminogen activator inhibitors 
[20]. Further, the pro-angiogenic effects of VEGF are mediated by a single chain variant 
of uPA. After uPA is endocytosed via uPAR and transported to the nucleus where uPA 
binds to a transcription factor (HHEX/PRH) that is a repressor of VEGF1 and VEGF2 gene 
promoters, thus inducing expression of VEGF receptors which helps regulate EC 
proliferation [80]. ECM proteins and MMPs can be activated by plasmin which aids 
remodeling during angiogenesis. Studies have shown plasminogen is involved in 
angiogenesis; aminocaproic acid, a plasmin inhibitor reduced formation of capillary 
structures in ECs treated with bFGF, and aortic ring assays using plasminogen deficient 
mice had reduced sprouting of capillaries [81, 82]. 
Mechanisms of cathepsins in angiogenesis have not been completely understood, 
but some studies have shown potential roles they could play in the process. CatK and catL 
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are secreted outside cells and localize around cell membranes, which can help contribute 
to endothelial progenitor cells (EPC) recruitment to the angiogenic area [20]. CatL 
deficient mice had impaired blood flow restoration in ischemic limbs, and when their bone 
marrow cells were transplanted in mice neovascularization was reduced [83], suggesting 
that catL could be implicated in EPC-induced neovascularization. Inhibition of catS 
impairs mouse EC invasion in assays using MatrigelTM and type I collagen. Further, despite 
normal VEGF and bFGF levels, during wound repair, catS deficient mice had impaired 
microvessel development as indicated by less number of microvessels forming, suggesting 
catS plays a role in angiogenesis [24]. Another study identified pro-angiogenic properties 
of catL. MDA-MD-231 (breast cancer cell line) were intradermally added to nude mice, 
then treated with catL inhibitor, and it was demonstrated that catL is implicated in 
angiogenesis including stimulating EC sprouting, promoting migration, invasion, and tube 
formation, and increasing EC proliferation [84]. 
Cathepsins, MMPs, and serine proteases are part of a complex proteolytic network 
that facilitate de novo vessel formation. By understanding the role of cathepsins in 
angiogenesis, researchers will be able to better control angiogenesis and vasculogenesis for 
wound healing and other regenerative medicine applications in tissue engineering.  
2.3.2 Vascularization in Regenerative Engineering 
 According to the US Government Information on Organ Donation and 
Transplantation, as of July 2019 there are over 113,000 people on the national transplant 
waiting list. Every 10 minutes another person is added to the list. This list continues to 
grow, and the gap between donors and transplants widens. Regenerative medicine could 
help address the issue of organ transplant shortages [85, 86]. The goal of tissue engineering 
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is to regenerate tissue and organs to replace, maintain, and improve damaged tissue and 
organs [87]. A main hurdle to translate tissue engineering to the clinic is vascularization 
[88-91]- a way to diffuse oxygen, nutrients, and remove waste (similar to how our 
vasculature works) in these constructs. 
 Vascular networks supply cells with nutrients to maintain viability, thus, cells need 
to be within 100-200µm of a capillary for diffusion of oxygen, nutrients, and waste [91-
93]. Diffusion of oxygen into tissue is a major limitation, and because of this, developing 
larger constructs is challenging [94].  Vascularization of thinner (hundreds of microns in 
size) constructs and avascular tissue have been more successful. This is likely because 
vascularization takes time (days to weeks) and cells in the middle of larger tissue constructs 
die during this time without proper diffusion [95]. To decrease vascularization time of 
constructs, one strategy is to add a network to the tissue or organ before implantation, this 
is termed pre-vascularization. Pre-vascularization approaches will allow the engineered 
networks to integrate with the patient’s vasculature and perfusion of the tissue construct 
will be faster [90, 91]; this is advantageous to ensure proper diffusion of oxygen and 
nutrients, and removal of waste [90, 91, 96]. Pre-vascularization techniques include 
scaffolds, cell-based, rotating and perfusion bioreactors, microfluidic devices, and modular 
assembly [13, 93, 97-99].  
2.3.3 A Microfluidic Device for Vascularization 
 Generating vascular constructs in 3D engineered tissue constructs in microfluidic 
devices provide an optimal, reproducible platform for developing vasculature allowing 
spatial and temporal control over the microenvironment including applying flow, addition 
of growth factors, and perturbing biomaterial mechanical properties [100]. Continuous 
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perfusion of culture media is advantageous, as it provides nutrients and oxygen, and waste 
removal in order to sustain long term culture. To recapitulate 3D microvessels both 
microphysical function and 3D microstructure must be replicated; including formation of 
lumen where cells are aligned luminal to basal axis, which induces hollowing or 
tubulogenesis [100, 101].  
 Microfluidic devices are advantageous for developing vasculature in vitro, allowing 
for control over the microenvironment with the ability to easily manipulate three major 
factors  that induce vasculogenesis: 1) biomechanical (i.e.: interstitial flow, shear stress, 
gel stiffness), 2) extracellular signaling molecules (paracrine signaling), and 3) cell 
type/cell-cell interactions (i.e.: co-culture with EC and mural cells to improve vessel 
stability or cell-cell contact of ECs via cadherins and tight junctions to form lumen) [89, 
100, 102]. To control network morphology, including vessel diameter, number of branches, 
and branch length, engineered microvessel design approaches have focused on 
manipulating proangiogenic factors, such as VEGF or FGF, or  scaffold/hydrogel 
parameters, such as collagen and fibrin(ogen) concentration [91-94, 103]. Additionally, 
applying interstitial flow helped direct vasculogenesis during microvessel formation, 
particularly in the formation of branching vessels [92, 94, 103]. 
 Microvascular networks are formed in vitro in a microfluidic device, made using 
polydimethylsiloxane (PDMS) and soft lithography, with separate channels for human 
umbilical vein endothelial cells (HUVECs) and normal human lung fibroblasts 
(fibroblasts) encapsulated in fibrin gel (Fig 2-2A). Various combinations of parameters 
including cell type, hydrogel density, and addition of growth factors altered the number of 
branches, average branch length, percent vascularized area, and average vessel diameter. 
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It was determined that using combining HUVECs and fibroblasts (stromal cells), was 
needed for microvascular networks to remain stable beyond 4 days. Also, networks made 
with HUVECs and fibroblasts had increased area of vascularization and perfusable 
segments compared to networks only made using HUVECs. Addition of growth factors, 
VEGF and sphingosine-1-phosphate (S1P), to ECs and fibroblasts added stimulatory 
signals, changing morphology where there was increased branching compared to EC only, 
EC and fibroblasts, and ECs and growth factors. There was a dose dependent relationship 
between microvessel stability and the fibroblast seeding density. Last, fibrin gel density 
was manipulated by increasing the fibrinogen concentration; as fibrinogen concentration 
increased, the number of branches increased, branch length and vessel diameter decreased, 
and percent vascularized area did not change. A table qualitatively demonstrates the effect 
of altering growth factors, fibroblast seeding density, and fibrin concentration is in Figure 
2-2C [15].  
 Another iteration of the microfluidic device is made with three channels for a gel 
scaffold, allowing for multiple matrix compositions to be tested simultaneously (Fig 2-2D). 
Various combinations of collagen only, fibrin only, and collagen and fibrin were tested, as 
well (Fig 2-2E); in the fibrin gel only conditions the fibrin did not retract, meaning the 
fibrin gel was not detached from the walls of the microfluidic channel during microvascular 
network development. Thus, fibrin was selected as the matrix for the development of 
microvessels over a 2-week period, where microvessels became patent by day 7 which 
































Figure 2-2: Design approaches using a microfluidic device for developing 
microvascular networks. (A) Schematic of microfluidic device; separate channels for 
human umbilical vein endothelial cells (ECs) encapsulated in fibrin gel and normal human 
lung fibroblasts (fibroblasts) encapsulated in fibrin gel. (B) Microvasculature networks 
made with ECs only compared to ECs and fibroblasts without or without growth factors 
(VEGF and S1P) to demonstrate differences in number of vessel branches, branch length, 
vessel diameter, and vessel area. (C) Table of microvascular network conditions including 
growth factors, fibroblast seeding density, and fibrin concentration, and whether there was 
increase, decrease, or no change in vessel branching, length, area, and diameter. (D) 
Schematic of microfluidic device; GS1, GS2, and GS3 are three sections for gel scaffolds 
to assess multiple matrix compositions in an experiment. (E) Microvascular networks made 
in different types of matrix: collagen only, collagen and fibrin, and fibrin only. Gel 
retraction was observed in collagen only and collagen and fibrin gel. 
 
Top Figure adapted from Whisler et al. Tissue Engineering: Part C 2014   
Bottom Figure adapted from Park et al. Cellular and Molecular Bioengineering 2014 
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 Sickle Cell Anemia 
 Sickle cell anemia (SCA) is the most commonly inherited blood disorder in the 
United States affecting 100,000 Americans [34]. According to the Center for Disease 
Control and Prevention (CDC), 1 in 365 African American babies are born with the disease 
and 1 in 13 African American babies are born with sickle trait. Globally, there is an increase 
in the burden of SCA where 300,000 children are affected each year, and it is estimated 
that by 2050 more than 400,000 children under the age of 5 will be born with SCA [104]. 
SCA is a lifelong and serious condition, where people are under long-term treatment and 
pain/symptom management, and the healthcare costs for SCA is approximately $1.1 billion 
USD, annually [105]. 
 Sickle cell disease (SCD) is the umbrella term for a group of inherited blood 
disorders that affect β-globin, a subunit on hemoglobin, a protein in red blood cells that 
aids in the transport of oxygen [106]. There are different types of hemoglobin; adult 
“normal” hemoglobin is defined as HbA and sickle mutated hemoglobin is defined as HbS. 
Sickle cell anemia (SCA) is inherited autosomal recessively, where both copies of the gene 
have the same sickle mutated hemoglobin; this is denoted as homozygous sickle (HbSS or 
SS) [34]. Another variation includes individuals who are heterozygous for HbS, but do not 
have SCA, which is termed sickle trait (HbAS) [107].  
2.4.1 Molecular Level 
 SCA is a multifactorial disease caused by a single point mutation in the nucleotide 
on the sixth position of β-globin, a subunit of hemoglobin, where glutamic acid, a 
hydrophilic molecule, is substituted for valine, a hydrophobic molecule [106]. Under 
oxygenated conditions, hemoglobin is soluble because valine is not exposed to the red 
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blood cell (RBC) cytoplasm. Under deoxygenated conditions, some of the HbS 
polymerizes due to valine being exposed to the aqueous environment, resulting in rigid 
fibers that contort the RBC membrane, giving RBCs their characteristic “sickle” shape [34, 
106, 108]. As the hemoglobin binds oxygen, the fibers “melt,” and the RBCs return to their 
normal circular shape. Repetitive sickling and unsickling damages the RBC membrane, 
and when the RBC membrane is damaged, this results in irreversibly sickled RBCs and, 
and reduces the RBCs lifespan from ~120 days to 9 to 10 days [106]. 
2.4.2 Sickle Pain Crisis and Other Complications 
 Vasculopathy occurs due to RBC membrane rupture, hemolysis, which releases 
byproducts causing increased inflammatory cytokines [109], mononuclear cells [40], and 
monocyte adhesion to the endothelium [110]. These proinflammatory conditions lead to 
vascular remodeling characterized by intimal thickening and lumen narrowing in larger 
cerebral vessels [111]. This includes infiltration of monocytes into sub-endothelial lining, 
elastic lamina degradation, and proliferation of smooth muscle which enhances lumen 
narrowing and lesion progression [110, 112]. Other complications include strokes,  acute 
chest syndrome, hemolytic anemia, venous thrombosis, vaso-occlusive crisis (VOC) which 
is blockage of small vessels, and ischemic organ damage [34, 106].  
 Acute pain, referred to as sickle pain crisis, is a common, frequent, unpredictable 
complication of SCA leading to recurrent hospitalization [34, 106]. Normally, RBCs are 
deformable and can easily pass through microcirculation. However, sickled RBCs are rigid 
and sickled reticulocytes (immature RBCs) are more adherent under SCA conditions [32, 
113]. Collectively, these properties result in RBCs getting stuck in post-capillary venules 
causing blockage of blood flow which can lead to complete vessel occlusion causing 
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ischemic injury to the organ and sudden sharp pain [114, 115]. Even though SCA is a 
hematological disorder, blocked blood flow deprives organs of blood and oxygen [106]. 
2.4.3 Chronic Coagulation Activation 
 People with SCA are said to be in a hypercoagulable state where they experience 
chronic coagulation activation, which is mediated by factors involved in the intrinsic and 
extrinsic coagulation pathways. The state of chronic coagulation activation is 
multifactorial; almost every part of the coagulation system is altered in SCA [31, 116]. 
Evidence of hypercoagulation in SCA includes increased platelet and tissue factor 
activation, depletion of natural anticoagulant proteins, protein C and protein S, and 
abnormal fibrinolytic activation [33]. Clinical and animal model studies are characterized 
by coagulation, chronic hemolysis, and inflammation which suggests that chronic 
coagulation activation could contribute to pathogenesis of SCA [117]. Although it is known 
that chronic coagulation activation is prevalent in SCA, researchers need to understand 
mechanisms of chronic coagulation activation and how it contributes to the 
hypercoagulable state in SCA pathophysiology and subsequent complications [30, 33]. 
This leaves a gap in knowledge for defining the role of hypercoagulability in SCA, 
including understanding its pathogenesis.  
 Thrombin generation is an indicator of a balanced effect of all coagulation cascade 
components [118]. Thrombin generation assays are used to measure thrombin generation 
rate and potential to generate thrombin ex vivo in plasma and whole blood [119-122]. An 
increase in thrombin generation is indicated by an increase in concentration of markers 
including, fibrinopeptide A, α-thrombin-antithrombin (αTAT) complexes, and D-dimers 
[30, 32, 123]. 
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 Studies from ex vivo thrombin generation assays have some inconsistent results 
when measuring parameters such as time to peak thrombin generation, thrombin peak 
height, and endogenous thrombin potential (ETP). There was a report of higher peaks [124] 
for thrombin generation time, while others have identified shorter peaks [119, 125, 126] in 
people with SCD compared to controls. Discrepancies in thrombin peak height 
(measurement of highest thrombin concentration) have also been identified between 
disease state and control; with some reports of higher peaks [124, 126] versus lower peaks 
[119]. ETP is the amount of thrombin generated in vitro after coagulation activation [127]. 
Decreased ETP has been reported in people with SCD at healthy state compared to healthy 
controls [125, 128], but another group has reported increased ETP [124]. The same studies 
also had inconsistent results when reporting time to peak thrombin generation and ETP 
when comparing values during steady state versus crisis state in people with SCD.  
 Although researchers acknowledge limitations with studies using thrombin 
generation assays, the inconsistencies leave a gap in knowledge. It has been suggested that 
sample preparation, timing of blood collection, and analytic conditions (i.e.: types and 
concentration of factors used to trigger ex vivo clotting need to be standardized) [33]. 
Correlating thrombotic complication from assays to disease state has proven challenging. 
Herein, lies an opportunity to look at other abnormal circulating biomarkers in plasma, 
such as cysteine cathepsins.  
2.4.4 Using Anticoagulants in Patients with SCD 
 Anticoagulant and antiplatelet therapies have not significantly helped prevent or 
treat VOC and thrombotic complications in SCA [129]. Although anticoagulants initially 
showed promise, hemorrhage and bleeding risks have limited studies [130].   Direct oral 
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anticoagulants, including rivaroxaban and dabigatran, have been given to people with SCD 
that had venous thromboembolisms (VTE), but there was no difference in recurrence or 
minor bleeding incidences compared to people treated with warfarin (blood 
thinner/anticoagulant) [131]. Sevuparin, derived from heparin, inhibits the conversion of 
prothrombin to thrombin, reduces anticoagulant activity and inhibits human SS RBCs from 
adhering to ECs in vitro. An “adoptive” mouse model was used where human SS RBCs 
were infused into mice; sevuparin prevented vaso-occlusion and normalized blood flow 
[132]. Findings like these made sevuparin a leading therapeutic agent, leading to one of the 
largest VOC studies to date. However, in 2019 sevuparin failed during phase II clinical 
trials, because there were no meaningful clinical benefits or improvements in patients and 
was not effective for improving resolution time of VOC [133].  
 Anticoagulant therapeutics have been used as a treatment option to reduce or 
prevent thrombotic complications in SCA, however they have risks for bleeding 
complications and hemorrhaging. This motivates the need to develop new therapies for 
novel anti-coagulant targets. I hypothesize that cysteine cathepsins can perturb the 
coagulation cascade and promote coagulation activation, but are not essential clotting 
factors such as thrombin or plasmin.  This introduces the idea of targeting proteases, like 
cathepsins, rather than clotting factors to prevent coagulation.  
2.4.5 SCD Mouse Models for Chronic Coagulation Activation Studies 
 Mouse models are useful for studying pathophysiology and underlying etiology of 
SCD by targeting specific parts of the coagulation cascade to understand the roles specific 
coagulation factors. Figure 2-3 is a simplified overview of the coagulation cascade that can 
be used for reference. Researchers have sought to understand the interplay between SCA 
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and coagulation. Techniques range from treating mice with inhibitors for specific 
coagulation cascade factors to generating new mouse models by cross breeding mice from 
sickle transgenic backgrounds and hemostasis models or using gene editing approaches. 
 To test the relationship between sickle cell pathology and hemostasis activation, 
studies have been done by cross breeding plasminogen or fibrinogen deficient mice with 
sickle cell disease transgenic (SAD) mice. The SAD mouse model has three combined 
mutations of human α-globin and human β-globin: β6Glu-Val (Hb S), βb23Val-Ile (Hb Antilles), 
and b121Glu-Gln (Hb D-Punjab). SAD mice resembles human SCA pathophysiology 
including in vivo erythrocyte sickling under deoxygenated conditions, vaso-occlusion, age-
dependent splenomegaly, vascular congestion with thrombi in lung, kidney, and liver 
[134]. SAD mice with fibrinogen deficiency had higher incidences of mortality and poorer 
survival profiles, likely due to bleeding related events leading to death, and hypoxic 
conditions [135]. Typically, fibrinogen deficient mice do not experience significant 
bleeding under normoxic conditions, suggesting that SCA conditions in double transgenic 
mice aggravated bleeding and mortality related outcomes. By contrast, SAD mice with 
plasminogen deficiency had similar deleterious effects to SAD and control mice, and did 
not worsen mortality [135]. In other words, SCA conditions in plasminogen deficient cross 
bred mice do not exacerbate conditions. Overall, this study concludes fibrinogen has 
beneficial effects to maintain vascular integrity, aid in tissue repair, and support hemostasis 
under SCA conditions [135]. 
 Tissue factor (TF), a high affinity receptor and co-factor for factor VII that initiates 
blood coagulation, was elevated in leukocytes from Berkeley SS mice [136]. Berkley SS 
mice express human sickle hemoglobin  and are generated from deletions of murine α and 
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β globins (α-/-, β-/-) with a transgene containing human α, βs, Aγ, Gγ, and β globins.  These 
mice have similarities to human SCA pathophysiology including erythrocyte sickling and 
intravascular hemolysis [137]. Treating Berkeley SS mice with anti-tissue factor antibody 
reduced coagulation activation, inflammation, and EC injury, but the antibody did not 
reduce RBC hemolysis rate or improve the anemic state. Berkeley SS mice with EC-
specific deletion of the TF gene had decreased levels of interlukin-6, a proinflammatory 
cytokine, but there was no effect on coagulation activation, as indicated by similar elevated 
α-thrombin-antithrombin (αTAT ) complexes compared to control Berkeley SS mice [136]. 
Follow up work assessed how factor X, a serine protease that cleaves prothrombin to active 
thrombin, and thrombin contributed to coagulation activation and vascular inflammation 
in SCA. To test this, Berkeley SS mice were given rivaroxaban (factor X inhibitor) or 
dabigatran (thrombin inhibitor). Additionally, protease active receptor (PAR) -1 and -2, 
thrombin receptors, deficient mice were transplanted with bone marrow from Berkeley SS 
mice. Overall, inhibiting factor X and thrombin reduced thrombotic complications and 
vascular inflammation in SCA, suggesting that factor X and thrombin contribute to 
vascular inflammation, and PAR-2 is a potential target for inhibition [138].  
 Thrombin has been another target in mouse model studies. Treating Berkeley SS 
mice with prothrombin (factor II) antisense oligonucleotide “gapmer” reduced circulating 
prothrombin, the precursor to thrombin, correlated with reduced early mortality. Genetic 
mutation was also used; hematopoietic stem cells from Berkeley SS mice were transplanted 
into prothrombin deficient mice. Genetically modified mice had reduced inflammation, 
reduced EC dysfunction, and improvement in end organ damage associated with SCD. 
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Together, these studies demonstrate prothrombin contributes to SCA-induced end organ 
damage, suggesting another therapeutic target [139].  
 Fibrinogen binds with leukocytes through the αMβ2 integrin receptor, which triggers 
leukocyte functions including phagocytosis and production of inflammatory cytokines 
[140]. To see if fibrinogen-mediated inflammation contributes to SCD pathophysiology, 
hematopoietic stem cells from Berkeley SS mice were transplanted into mice with a mutant 
form of fibrinogen, that does not bind to the αMβ2 integrin receptor on leukocytes [141]. 
The genetically modified SCD mice had a reduction in reactive oxygen species, circulating 
white blood cells, and inflammatory cytokines/chemokines. Although there was no 
improvement in heart, liver, and lung function, there was improvement in kidney function 
in the mice. Thus, fibrinogen-leukocyte signaling is activated in SCA and potential 
therapeutic target [141]. 
 These SCA mouse models demonstrate how targeting factors in the coagulation 
cascade including tissue factor, prothrombin/thrombin, factor X, and fibrinogen can help 
researchers understand the interactions between SCA and coagulation. The coagulation 
cascade includes serine proteases, however, I hypothesize that under SCA conditions when 
other proteases, like cysteine cathepsins are upregulated [40, 41], they can be involved in 
chronic coagulation activation, as well. Sickle cell mouse models with targeted cathepsin 



















Figure 2-3: Schematic to illustrate aspects of coagulation cascade targeted in mouse 
studies to understand the roles of specific coagulation factors. 
Mouse models have been used to study pathophysiology and underlying etiology of SCD 
by targeting specific parts of the coagulation cascade to understand the roles specific 
coagulation factors: (A) plasminogen deficient mice, (B) fibrinogen deficient mice, bone 
marrow transplant from Berkeley SS mice into mice with a mutant form of fibrinogen, (C) 
anti-tissue factor antibody, endothelial cell-specific deletion of tissue factor gene, (D) 
treatment with rivaroxaban (factor X inhibitor), (E) treatment with dabigatran (thrombin 
inhibitor), bone marrow transplant from Berkeley SS mice into mice with protease active 
receptor (PAR) -1 and -2 (thrombin receptors) deficient , and (F) prothrombin antisense 
oligonucleotide “gapmer” to reduce circulating prothrombin. 
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CHAPTER 3  HUMAN CATHEPSINS K, L, AND S: RELATED 
PROTEASES, BUT UNIQUE FIBRINOLYTIC ACTIVITY 
This chapter was adapted from Douglas, S.A. et al. (2018) “Human cathepsins K, L, and 
S: related proteases, but unique fibrinolytic activity.” Biochimica et Biophysica Acta 
1862(9)1925-1932. doi: 10.1016/j.bbagen.2018.06.015. 
 Introduction 
 Hemostasis and the clotting cascade have been defined by a series of proteolytic 
reactions usually dominated by serine proteases [35, 36, 61], eventually resulting in 
cleavage of fibrinogen which self-assembles into a fibrin meshwork that catches red blood 
cells to form a clot and prevent excess blood loss. Fibrin forms from the self-assembly of 
cleaved fibrinogen, a hexameric protein with quaternary structure of three pairs of 
symmetrical polypeptide chains (α, β, and γ) held together by multiple disulfide bonds [35, 
58]. Once a fibrin clot is formed, it can be resolved through the fibrinolytic action of 
plasmin, a serine protease, that itself is activated from the zymogen plasminogen by tissue 
plasminogen activator or urokinase plasminogen activator [142]. The action of plasmin on 
fibrin is well defined, but the action of other protease families on fibrin are still to be 
determined. 
 Cysteine cathepsins are powerful proteases known to be secreted by various cell 
types in tissue destructive diseases, including cancer [5], atherosclerosis [4, 6, 143]. These 
enzymes are known to degrade extracellular matrix (ECM) proteins and are some of the 
most powerful collagenases and elastases [7, 9]. The substrate redundancy of cysteine 
cathepsins has been documented [2], however few studies have identified cathepsin-
mediated fibrin degradation. Cysteine cathepsins are members of the papain-like cysteine 
protease family [46]. Papain cleaves mammalian fibrinogens and cause gelation [67-69]. 
Papain polymerizes fibrin that is insoluble in 5M urea, 1M sodium bromide, or 0.1 M 
 32 
monochloroacetic acid forming intermolecular cross-links, similar to how fibrin cross-links 
with factor XIII and Ca2+ [67]. Other studies demonstrated that cathepsin D, an aspartyl 
protease, has dose-dependent (100 nM – 10 μM) fibrinolytic activity, and can lyse fibrin, 
albumin-enriched and albumin/red cell-enriched fibrin clots [10].  
 Beyond fibrin's physiological and pathophysiological, native roles, fibrin is 
becoming more popular as a building tool for biomaterials and regenerative medicine 
applications with promise demonstrated for vascularized tissue engineered constructs [15], 
biological machines [144], micro and nanoscaffold applications [145], and vascularized 
organ-on-chip systems [13]. Fibrin-based constructs are favored materials to engineers, 
designing matrices, because of controlled gelation time, defined network architecture, and 
well characterized mechanical properties [16, 17, 37]. Degradation kinetics are required to 
control structural and biochemical properties in these fibrin-based constructs. Proper 
design and tuning fibrin degradation due to proteolytic cleavage is needed for optimal 
cellular signaling and matrix interactions [16, 17]. The aim of this work is to determine 
proteolytic susceptibility of fibrin by cysteine proteases. Our studies show that non-plasmin 
fibrinolytic proteases, cathepsins K, L, and S, have emerged as an alternative mechanism 
for fibrin destabilization in long term tissue cultivation. 
 Our lab has used molecular docking and bioinformatics sequence specificity 
analysis (PACMANS), to predict potential binding and cleavage sites of cathepsins K, L 
and S on fibrin [42]. It was determined that catK, L, and S are capable of binding to the α, 
β, and γ chains on fibrinogen at overlapping and different sites. Specifically, catK, L, and 
S have preferential binding sites in both the E (central) domain, an area prone to cleavage, 
which is also the known location of where thrombin cleaves, to initiate fibrin formation 
and where plasmin cleaves to break down and degrade the fibrin clot. The evidence of 
cleavage site redundancy in our model is representative of redundancy of cathepsins on 
other substrates, and this could be indicative of the conserved active sites of cathepsins. 
Understanding cathepsin-mediated fibrin(ogen) olysis has implications in fibrin-based 
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tissue engineered constructs as researchers understand environmental cues that influence 
network remodeling. 
 Materials and Methods 
3.2.1 Fibrin Gel Formation 
 Fibrin gels were formed in a 96 well plate. Human fibrinogen (FIB 3 Plasminogen, 
von Willebrand Factor and Fibronectin Depleted; Enzyme Research Laboratories) was co-
incubated with human alpha thrombin (Enzyme Research Laboratories) in 50mM Tris-
HCl/100mM NaCl, at a concentration of 2.5 mg/mL and 1 NIH U/mL in a final volume of 
100 µl, respectively, for 2 hours at 37oC. Fibrin gels were carefully washed with Tris-HCl 
to remove unpolymerized fibrinogen and thrombin. Before enzymes were added, plates 
were imaged using the ImageQuant LAS 4000 (GE Healthcare). 
3.2.2 Fibrin Gel Degradation 
Increasing amounts (0, 0.15, 0.375, 0.75, or 1.5 µg) of recombinant human 
cathepsins K, L, S (Enzo) in 50 µl assay buffer (0.1M sodium phosphate buffer, pH 6.0, 
1mM EDTA) with 2mM dithiothreitol (DTT) for 24 hours at 37oC. Fibrin gels were 
alternatively incubated with plasmin (5µg/µL; Enzyme Research Laboratories) or Tris-
HCl/NaCl. Plates were imaged after degradation. The samples were centrifuged at 8000 
rpm and the soluble fraction as collected and saved. The insoluble fraction was prepared in 
50mM Tris-HCl/100mM NaCl with 25% β-mercaptoethanol (OmniPur) and sonicated. 
insoluble fraction and soluble fraction samples were prepped for reduced SDS-PAGE and 
multiplex gelatin zymography. 
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3.2.3 Fibrin Fragment Degradation 
Fibrin gels were formed using the protocol described above. Gels were incubated 
with plasmin (5µg/µL) for 24 hours and the soluble fraction, containing released fibrin 
fragments, was collected. Recombinant human cathepsins K, L, and S (1.5µg) in assay 
buffer (0.1M sodium phosphate buffer, pH 6.0, 1mM EDTA) with 2mM dithiothreitol 
(DTT) was added to fibrin fragments for 24 hours at 37oC. Samples were prepared for 
reduced SDS-PAGE and multiplex gelatin zymography. 
3.2.4 SDS-PAGE 
Samples were prepared with reduced loading dye (5X - 0.05% bromophenol blue, 
10% SDS, 1.5 M Tris, 50% glycerol, 25% beta-mercaptoethanol) and run on 10% SDS-
PAGE gels. Gels were stained with Coomassie stain (10% acetic acid, 25% isopropanol, 
4.5% Coomassie blue), followed by destaining (10% isopropanol and 10% acetic acid) and 
imaged with an ImageQuant LAS 4000 (GE Healthcare), and densitometry performed with 
ImageJ (NIH) to quantify fibrin polypeptide chains. 
3.2.5 Multiplex Cathepsin Zymography 
Samples were resolved in multiplex cathepsin zymography using methods 
previously described [146]. Briefly, samples were prepared using a non-reducing loading 
buffer (5×-0.05% bromophenol blue, 10% sodium dodecyl sulfate (SDS), 1.5 M Tris, 50% 
glycerol. A 12.5% SDS-PAGE gel was used and embedded with 5 mg/ml gelatin substrate. 
Both gels were run at 200 V at 4 °C. Proteases were renatured in 65mM Tris buffer pH 7.4 
with 20% glycerol for 3 washes, 10 min each, then incubated in and pH 4 (acetate buffer, 
1mM EDTA with 2mM DTT, freshly added) or pH 6 (phosphate buffer, 1mM EDTA with 
2mM DTT, freshly added) activity assay buffer. After overnight incubation, gels were 
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stained with Coomassie Blue (4.5% Coomassie blue; Sigma-Aldrich, 10% acetic acid, and 
10% isopropanol) then destained (10% acetic acid and 10% isopropanol). 
3.2.6 Statistical Analysis  
 Statistical significance was determined using a two-way ANOVA between 
normalized no enzyme control and recombinant enzyme control, respectively, using 
GraphPad. All experiments were replicated at least three times and a p value of <0.05 was 
considered statistically significant. 
 Results 
3.3.1 Cathepsin L degrades fibrin gels, releasing degraded fibrin products into the 
supernatant. 
 To test if human cathepsin L (catL) has fibrinolytic activity, polymerized fibrin gels 
were incubated with increasing amounts of catL, or plasmin as a positive control, in 96-
well plates for 24 hours. Fibrin gels were imaged before and after degradation; areas of 
grey are intact fibrin and areas of black indicate regions where fibrin gel was degraded (Fig 
3-1A). Empty wells are all black. The mean value of grey areas was measured to quantify 
percent intact fibrin gel. As catL amount incubated with the gels increased, there was a loss 
of fibrin gel by 3%, 26%, and 48% for 0.15, 0.75, and 1.5 µg, respectively, with a 
significant decrease at 1.5µg of catL compared to the no enzyme control (n=4, *p<0.005) 
(Fig 3-1A). Next, it was determined if the fibrin molecule itself was degraded into 
fragments using reducing SDS-PAGE. After incubation, the supernatant was collected, 
containing solubilized fragments released from the fibrin gel (referred to as the soluble 
fraction), and the remaining fibrin gel (referred to as the insoluble fraction) was solubilized 
by breaking disulfide bonds between the fibrin α, β, and γ chains with 25% beta-
mercaptoethanol in Tris-HCl. Proteins were then resolved by reducing SDS-PAGE and 
stained with Coomassie blue to determine proteolysis of the α, β, and γ chains in both 
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supernatant (soluble) and fibrin gel (insoluble) fractions.  For the soluble fraction α, β, and 
γ chains were only identified in supernatant of gels incubated with 0.15µg catL, the lowest 
amount, suggested by hydrolysis of α band in other lanes. There was a significant loss of 
the α chain in the insoluble gel fraction as the amount of catL increased (n=3-5, *p<0.005; 
#p<0.0001) (Fig 3-1B), which corroborates the gel degradation images from Figure 3-1A.  
 Multiplex cathepsin zymography was used to identify active catL remaining in the 
soluble fractions, after incubations, which are visualized as cleared, white bands (Fig. 3-
1C). To determine if there was a correlation with the degraded fibrin in the insoluble 
fraction, visualized as Coomassie stained dark bands (Fig. 3-1D). It should be noted that 
catL was not expected to provide a zymography signal in the insoluble fraction due to gel 
dissolution with β-mercaptoethanol, which also breaks cathepsin disulfide bridges and 
diminishes activity. Soluble fractions contained active catL bands at the expected 
molecular size of 20 kDa, with increasing intensity as the incubated amount of active catL 
increased. With as little as 0.15 μg, the active catL band was visible at 100 kDa and 37 
kDa, but as the amount of catL incubated with the fibrin gels increased, active catL 
appeared at other molecular weights: between 100 and 75 kDa, and between 75 and 50 kDa 
(n=3–5, **p < .05; %p < .01; #p < .0001). The associations between fibrin and catL were 
even able to withstand the ionic detergent, SDS, denaturation as they migrated through the 
polyacrylamide gel. The cascading pattern of higher molecular weight active catL bands 
corresponded to the loss of α and β chains of fibrin protein. Active catL bands were 








Figure 3-1: Cathepsin L degrades fibrin gels, releasing fibrin degradation products 
into the supernatant. Fibrin gels (100 µl) were polymerized in 96 well plates then 
incubated with increasing amounts of cathepsin L (catL) in 50 µl assay buffer for 24hrs. 
(A) Fibrin gels were imaged in 96 well plates before (0 h) and after (24 h) incubation, where 
grey color indicates intact fibrin and black indicates areas of degraded fibrin gel, as shown 
by the black levels in the empty wells. Area of grey intensity were quantified to determine 
intact fibrin percentage. The fibrin gel was degraded by 3%, 26%, and 48% for 0.15, 0.75, 
and 1.5 µg, respectively, with a significant decrease at 1.5µg of catL compared to the no 
enzyme control. (B) After degradation, the fibrin fragments released into the supernatant 
(denoted to as the soluble fraction) were collected and the remaining fibrin gel (insoluble 
fraction), was collected and solubilized with β-mercaptoethanol to prepare it for SDS-
PAGE. Coomassie stained protein bands of α (63.5 kDa), β (56 kDa), and γ (47 kDa) chains 
of fibrin were visible in the insoluble fraction.  Densitometry of bands are quantified in the 
graph. As the amount of catL increased, there was a significant loss of the α chain from the 
insoluble gel fraction. (C) Cathepsin zymography was used to assess the amount of active 
catL. Active catL bands were identified in the soluble fraction at multiple molecular sizes. 
Unbound active catL appears at 20 kDa and the higher molecular weight (75 to 37kDa) 
bands of active catL appear in a cascading pattern that corresponds to the degraded α and 
β fibrin fragments. Bands are quantified in the graph at the right by densitometry for the 
insoluble α and β chains of fibrin, and 75 kDa, 50 kDa, 37 kDa, and 20 kDa bands. (n=3-
5, **p<0.05; %p<0.01; *p<0.005; # p<0.0001) 
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3.3.2 Cathepsin K degrades α and β fibrin polypeptide chains, and fibrin 
degradation products. 
 Cathepsin K (catK) was also investigated to determine if it could degrade fibrin. 
Fibrin gels were prepared as described above, incubated with increasing amounts of catK 
for 24 hours, and both supernatant and fibrin gel were assayed, as was done for catL. There 
was a significant decrease in fibrin gel with 1.5µg of catK compared to no enzyme controls 
(n=5, ^p<0.001) (Fig 3-2A). CatK degraded the α and β fibrin chains with as little as 
0.15µg, as shown in the SDS-PAGE of the insoluble fibrin gel (n=5, *p<0.005; #p<0.0001) 
(Fig 3-2B). As the amount of catK was increased, little to no solubilized fibrin was detected 
in the supernatant, suggesting that even the released fibrin was subject to further 
degradation by catK. From zymography, no active catK was detected in the soluble or 









































Figure 3-2: Cathepsin K degrades α and β fibrin polypeptide chains. Increasing 
amounts of cathepsin K (catK) were incubated with fibrin gels for 24 hours in 96-well 
plates. (A) Fibrin gels were imaged before and after incubation, with grey indicating intact 
fibrin. As the amount of catK increased, more fibrin degradation was observed with a 
significant decrease in fibrin with 1.5µg of catK. (B) Loss of fibrin α, β, and γ bands in the 
insoluble gel was determined using SDS-PAGE; densitometry below is for the α and β 
chain of remaining fibrin gel (insoluble). In the soluble fraction, little to no fibrin fragments 
were detected. (C) The zymogram showed no active catK remained in either the fibrin gel 
or in the supernatant with the released fibrin fragments. (n=5, *p<0.005; ^ p<0.001, # 
p<0.0001) 
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3.3.3 Cathepsin S degrades α, β, and γ fibrin polypeptide chains, and fibrin 
degradation products.   
 There was complete dissolution of the fibrin gel when incubated with either 0.75 or 
1.5 µg of catS after 24 hours (n=5, *p<0.05; #p<0.0001) (Fig 3-3A). SDS-PAGE confirmed 
that 0.15 µg of catS significantly hydrolyzed the α chain of fibrin, and both the α and β 
chains were completely degraded with 0.75µg of catS (n=5, *p<0.05; #p<0.0001) (Fig 3-
3B). Released fragments were not detected in the soluble fraction, except for after 
incubation with 0.75 µg catS, suggesting near complete degradation of released fragments. 
Zymography was used to quantify active catS. Active catS was detected only at 25kDa, the 
expected size for free catS, and not associated with any higher molecular weight fibrin 
fragments (n=5, #p<0.0001) (Fig 3-3C). As with catK, large macromolecules, unable to 
migrate through the gel, were also observed in the soluble fraction at the top of the gels 
(open arrow). The intensity of these large fragments is inversely related to the amount of 
catS during the incubation period, and smaller fragments were detectable in the supernatant 
















Figure 3-3: Cathepsin S degrades the α, β, and γ fibrin polypeptide chains, and fibrin 
fragments. Fibrin gels were formed and incubated with increasing amounts of cathepsin S 
(catS) for 24 hours. (A) 96-well plates were imaged pre- and post cathepsin incubation. As 
the catS amount increased, more fibrin degradation was observed and was quantified as 
shown with complete degradation of fibrin with 0.75 and 1.5µg of catL. (B) SDS-PAGE 
used to image loss of fibrin α, β, and γ polypeptides due to catS hydrolysis fibrin 
degradation; densitometry below is for the α and β chain of remaining fibrin gel (insoluble) 
normalized to the no enzyme control.  Increased catS amounts correlated with loss of the 
α and β fibrin chains in the fibrin gel (insoluble fraction) and little to no detection of fibrin 
fragments (soluble fraction). Densitometry is shown below for the α and β fibrin gel. (C) 
Zymography was used to quantify active catS. Unbound catS was detected in the soluble 
fraction with increasing intensity correlated to increasing catS amount. Large 
macromolecules that are unable to migrate through the gel were also observed in the 
soluble fraction (open arrow at top of gel image). (n=5, *p<0.05; #p<0.0001).   
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3.3.4 Time course of fibrin gel degradation by cathepsins K, L, and S. 
 Incubation of fibrin gels with either catK or catS led to minimal detection of 
released fibrin fragments from the supernatant, contrary to catL. It was hypothesized that 
cleaved fibrin fragments were initially released but not detected because they were 
completely degraded by the cathepsins over time. To test this hypothesis, fibrin gels were 
incubated with 1.5µg of catK, L, S, or plasmin for a time course of 4, 8, or 24 hours.  A 
statistically significant loss of fibrin gels was observed after 24 hours for catK, catL, and 
catS (n=5, %p<0.01, #p<0.0001) (Fig 3-4A). CatS, however, seemed to degrade the fibrin 
faster, reaching statistical significance after only 4 hours. After incubation with catK, the 
α chain of fibrin was not detected by as early as 4 hours from the fibrin gel fraction (Fig 3-
4B). Of the fibrin fragments released into the soluble fraction, α and β fibrin polypeptides 
were detected after both 4 hrs and 8 hrs (p<0.05), but then there was a loss of the α chain 
by 24 hrs, suggesting catK released the fragments and then degraded the fragments in the 
supernatant (Fig 3-4B- left). For catL, there was a steady loss of the α chain of fibrin from 
4hrs to 8 and 24hrs in the supernatant and fibrin gel (Fig 3-4B- center). CatS completely 
degraded the α and β chains of fibrin in the supernatant and fibrin gel after only 4hrs (Fig 
3-4B- right), with complete loss of all signal by 24 hrs, coinciding with the complete 






Figure 3-4: Cathepsin L degrades fibrin gels, releasing fibrin degradation products 
into the supernatant. Fibrin gels (100 µl) were polymerized in 96 well plates then 
incubated with increasing amounts of cathepsin L (catL) in 50 µl assay buffer for 24hrs. 
(A) Fibrin gels were imaged in 96 well plates before (0 h) and after (24 h) incubation, 
where grey color indicates intact fibrin and black indicates areas of degraded fibrin gel, as 
shown by the black levels in the empty wells. Area of grey intensity were quantified to 
determine intact fibrin percentage. The fibrin gel was degraded by 3%, 26%, and 48% for 
0.15, 0.75, and 1.5 µg, respectively, with a significant decrease at 1.5µg of catL compared 
to the no enzyme control. (B) After degradation, the fibrin fragments released into the 
supernatant (denoted to as the soluble fraction) were collected and the remaining fibrin gel 
(insoluble fraction), was collected and solubilized with β-mercaptoethanol to prepare it for 
SDS-PAGE. Coomassie stained protein bands of α (63.5 kDa), β (56 kDa), and γ (47 kDa) 
chains of fibrin are visible in the insoluble fraction.  Densitometry of bands are quantified 
in the graph. As the amount of catL increased, there was a significant loss of the α chain 
from the insoluble gel fraction. (C) Cathepsin zymography was used to assess the amount 
of active catL. Active catL bands were identified in the soluble fraction at multiple 
molecular sizes. Unbound active catL appears at 20 kDa and the higher molecular weight 
(75 to 37kDa) bands of active catL appear in a cascading pattern that corresponds to the 
degraded α and β fibrin fragments. Bands are quantified in the graph at the right by 
densitometry for the insoluble α and β chains of fibrin, and 75 kDa, 50 kDa, 37 kDa, and 





3.3.5 Cathepsins L and S remain active over longer periods in the presence of fibrin. 
Mature cathepsins can lose their proteolytic activity in vitro over short periods of time 
(within a few hours), but the presence of specific macromolecular substrates, such as 
collagen and elastin, can stabilize and extend cathepsin activity [50, 147]. To test if fibrin 
was one such substrate, cathepsin zymography was used to determine the amounts of active 
cathepsins K, L, and S that were present after increasing incubation times with fibrin gels. 
No active catK was detected in the released fibrin fragments at any of the time periods 
(n=4) (Fig. 3-5A). However, active catL was observed at all time points tested (Fig. 3-5B). 
As the incubation period extended from 4 to 24 hours, there was a significant cascading 
loss of active catL signal at higher molecular weight bands (100, 75, 50, and 37kDa) 
progressively, with the 50kDa band remaining relatively constant, as quantified in the 
densitometry (n=4, #p<0.0001). CatS was different from both catK and catL, in that active 
catS was detected only at 25 kDa, unbound catS, its expected size, and the signal was 
diminishing from 4 to 24hrs concomitant with loss of Coomassie stained fibrin fragment 



























Figure 3-5: Cathepsins L and S remain active over longer periods of time in the 
presence of fibrin. Zymography was used to determine the ability for fibrin to extend the 
activity time of cathepsins K, L, and S. (A) No active catK was detected in the supernatant 
after 4, 8, or 24 hours. (B) Bands of active catL appear with a cascading loss of higher 
molecular weight bands (100, 75, 50, and 37kDa) between 4 and 24 hours. (C) Active catS 
was only detected at 25kDa, its expected molecular weight, with the amount of active catS 
decreasing over 24 hours. (n=4, #p<0.0001) 
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3.3.6 Cathepsins K, L, and S degrade plasmin-generated fibrin fragments. 
 To specifically demonstrate if cathepsins are capable of successively proteolyzing 
released fibrin fragments from the bulk fibrin gel into undetectable fragments, catK, L, and 
S were incubated with fibrin fragments. To generate these fragments, polymerized fibrin 
gels were first incubated with plasmin for 24 hours, and the soluble fraction was collected, 
then separately incubated with 1.5µg of either catK, catL, or catS for an additional 24hrs. 
All samples were resolved in SDS-PAGE, alongside aliquots of the plasmin-generated 
fragments sample that was not subject to cathepsin proteolysis as a control (n=4). 
Compared to control, there was a loss of the 55kDa fibrin fragment after incubation with 
catK and catL (Fig 3-6A). CatS also completely degraded the 55kDa fibrin fragment in 
addition to the 50kDa and 45kDa fibrin fragments (Fig 3-6A). Cathepsins K, L, and S 
successively processed the plasmin-generated fibrin fragments into lower molecular 
weight fragments (25 kDa to 37kDa), supporting our hypothesis that cathepsins cleave 
fragments from fibrin gel, but can also successively proteolyze released fibrin fragments 
generated by plasmin.  
 Zymography was used to assess the amount of active cathepsins present after 
incubation with plasmin-generated fibrin fragments (Fig 3-6B). Zymograms were 
incubated at pH4 for optimal catL activity and pH6 for optimal catK activity [148]. In 
contrast to catK co-incubation with fibrin gels (Fig 3-2C), when catK was co-incubated 
with fibrin fragments (Fig 3-6B), active catK was detected at 75kDa, a size where active 
catK has been detected when bound to ECM [149], different from its usual expected 
electrophoretic migration distance of 37 kDa. Active catL and catS were observed at their 
expected molecular sizes, 20kDa and 25kDa, respectively. When catL was co-incubated 
with fibrin (Fig 3-1C) or fibrin fragments (Fig 3-5B), active catL was detected at higher 
molecular weights, ~50kDa and 37kDa. This demonstrates catL can successively cleave 
fibrin fragments and remain bound to fibrin fragments during successive proteolytic 


















Figure 3-6: Cathepsins K, L, and S degrade plasmin-generated fibrin fragments.To 
identify if cathepsins K, L, or S could successively degrade the released fibrin fragments 
into smaller molecular weight fibrin fragments, fibrin gels were first incubated with 
plasmin for 24 hours, then the fibrin fragments released into the supernatant were collected 
then incubated with catK, L, or S for 24 hours. (A) Compared to the no enzyme control, 
catK, L, and S successively degraded the fibrin fragments into lower molecular weight 
fragments. CatS completely degraded the 55kDa, 50kDa, and 45kDa fragments while catK 
and L only degraded the 55kDa fibrin fragments. (B) From zymography, active catL was 
at its expected molecular size (20kDa), as well as the higher molecular weights (~50kDa 
and faintly at 37kDa), corresponding to the results from the dosing and time course fibrin 
degradation experiments. Active catK is observed at 75kDa. Unbound active catS was 
observed at 25kDa in the zymograms incubated at pH 6. Active catL appears in the 
zymograms incubated at pH 4. 
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 Discussion and Conclusions 
 Taken together, these results demonstrate that human cysteine cathepsins K, L, and 
S are fibrinolytic proteases. This has not been demonstrated for the human cathepsins 
previously, although parasitic orthologues have indicated they had fibrinolytic potential 
[12, 150]. From these data, catK, L, and S can hydrolyze the α and β chains of fibrin as 
indicated by the loss of these chains in SDS-PAGE after incubation with the proteases of 
interest. Further, it was demonstrated that although cat K, L, and S share 60% sequence 
homology; cleavage patterns after fibrinolysis are unique to each cathepsin (Fig 3-7), plus 
their rates of fibrinolysis differed, which was shown by the degradation and loss of the 
fibrin gels with increasing amounts of enzyme and when they were incubated for different 
periods of time. CatS was the most fibrinolytic, followed by catK and L, yet catK and L 
differed in a number of ways. CatL was bound to multiple cleavage fragments of fibrin, 
and this mechanism of association, still to be determined, was sufficient to retain its binding 
even in the presence of SDS, a strong ionic detergent. CatK, however, did not show this 
property and the amount of active catK was not detected by zymography after the 
incubation periods.  This is relevant in that certain substrates have been shown to extend 
the active life of cysteine cathepsins, and from these studies, fibrin should be added to this 
list for cathepsin L. Finally, catK, L, and S appear not to hydrolyze the fibrin in one event, 
but successively process it into smaller fragments, and can also bind and cleave fragments 
produced after plasmin-mediated fibrinolysis suggesting multiple sites of cleavage along 
the molecule. Again, the patterns of degradation differ among the cathepsins studied here, 
corroborating the finding that though they are closely related, they still retain unique 
































Figure 3-7: Cleavage patterns after fibrinolysis are unique for cathepsins K, L, and S 
compared to plasmin.  (A-C) Increasing amounts of cathepsins K, L or S (catK, L or S) 
were incubated with fibrin gels for 24 h. After degradation, the fibrin fragments released 
into the supernatant (denoted as the soluble fraction) were collected and the remaining 
fibrin gel (insoluble fraction), was collected and solubilized with β-mercaptoethanol to 
prepare it for SDS-PAGE. Coomassie stained bands denote the different patterns when 
cleaved by each of the cathepsin. (D-F) 1.5 μg of cathepsins K, L or S (catK, L or S) were 
incubated with fibrin gels for 4, 8, or 24 h. (0 h control time points for insoluble and soluble 
fractions shown in catK gel). After degradation, the fibrin fragments released into the 
supernatant (denoted as the soluble fraction) were collected and the remaining fibrin gel 
(insoluble fraction), was collected and solubilized with β-mercaptoethanol to prepare it for 
SDS-PAGE. Coomassie stained bands denote the different patterns when cleaved by each 
of the cathepsin. 
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 There is clinical relevance to these findings as fibrin is involved in the coagulation 
cascade after vessel injury. The proteases thrombin and plasmin are considered responsible 
for the initiation and degradation of fibrin [35, 36, 58], respectively, and the possibility of 
other enzymes being involved is understudied. Cysteine cathepsins are known to be 
involved in vascular related injuries [27, 151] and vascular remodeling [6, 152], and 
identified in atherosclerotic plaques [6, 153]. Cathepsins have been shown to be produced 
and secreted by endothelial cells that line the blood vessel wall [6, 152], and even catB and 
catD shown to play some role in cleaving other factors in the fibrinolytic system [154]. 
With such access to the clot, the roles of cysteine cathepsins and their putative activity to 
resolve these clots should be considered in physiological, and perhaps pathophysiological 
scenarios. As an example, elevated cysteine cathepsins are elevated in sickle cell disease 
[40], which is a disease that is also associated with a hypercoagulable state [155]. Cathepsin 
partial or complete fibrinolysis may prevent full solid clots from forming or staying in a 
protective way. However, our recent study also shows that cathepsins potentially can be 
involved in fibrin gel formation as they can hydrolyze fibrinogen as well [42]. This putative 
conflict will need to be resolved to understand the participation of this additional class of 
proteases in hemostasis. 
 There are specific details to highlight regarding the differences among cathepsins 
K, L, and S. CatS appeared to degrade the fibrin gel faster than the other proteases in this 
in vitro study, but it may not necessarily be a better fibrinolytic enzyme than plasmin in 
vivo; there are pH dependent and environmental cofactors that must be considered, but this 
deserves further investigation since catS is unique among cysteine cathepsins in that it 
retains its activity at neutral pH [7, 54]. Additionally, cathepsin S was shown to be elevated 
in the plasma of patients with diabetes [156, 157], associated with wound healing and 
hemostatic abnormalities, and other cardiovascular diseases, which may be a biomarker for 
these diseases [152, 158, 159]. Adsorption of active cathepsins to substrates and extension 
of their active lifetimes has been described for elastin [50] and collagen [147], and these 
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data presented here suggest fibrin be added to this list for catL. CatL and catK have had 
exosites identified that improve their catalysis of matrix proteins by binding them at these 
allosteric sites [158]. It was not identified if the fibrin binding site for catL is the same as 
its exosite for elastin, but the mechanism may exist. CatL adsorbs to fibrin as it was cleaved 
from the bulk fibrin gel, and the fibrin could be serving as a pool for active catL, thus 
stabilizing and sustaining its activity. As catL cleaves fibrin, it remains active and provides 
further hydrolysis of fibrin fragments which can prolong proteolysis within the system. 
These implications for fibrin acting as a reservoir for catL, to extend catL-mediated 
degradation in native tissue or in engineered tissue constructs, could be a design issue for 
tissue engineers using fibrin constructs in regenerative medicine and therapeutics research. 
 There is already evidence of unexplained proteolytic breakdown of fibrin-based 
tissue engineered constructs. Cysteine cathepsins were shown to be upregulated in 
engineered living systems such as a walking biological machine, composed of a skeletal 
muscle strip made with fibrin as part of its scaffold. Studies used aminocaproic acid (ACA), 
which inhibits conversion of plasminogen to plasmin, slowed degradation of the muscle 
strips at earlier time points, but catL was still active and a contributing factor to the 
breakdown of the walking biological machine [144]. Microvascular networks formed in a 
microfluidic device using a co-culture of endothelial cells and fibroblasts encapsulated in 
fibrin, formed a patent lumen. However, within days to weeks the networks collapse in an 
unpredictable, uncontrolled manner [15] and cathepsin mediated degradation may be 
involved. During vasculogenesis, proteolytic activity is required for matrix remodeling [20, 
160] and uncontrolled proteases could lead to scaffold destabilization. Fibrin-based 
constructs for the nervous system have been developed and reviewed here [161]. Fibrin 
nanoparticles have also been proposed for drug delivery [162], and their degradation by 
cysteine proteases can affect release profiles.  
 To conclude, this work introduced human cysteine cathepsins as a new class of 
proteases for the biomaterial community to consider when developing fibrin-based 
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constructs. It is possible that fibrin-based constructs can sustain active cathepsins which 
will degrade them, causing constructs to fail. This motivates our future studies to identify 
the cleavage sites of cathepsin on fibrin to better understand the mechanism and develop 
novel cathepsin inhibition strategies to control proteolysis and meet design criteria for 
proper engineering. There is also clinical relevance and potential research avenues for 
cathepsin based mechanisms underlying aberrant clot resolution, especially since 
cathepsins are secreted by endothelial cells which line the blood vessel walls providing 



















CHAPTER 4  BIOMECHANICAL AND BIOCHEMICAL 
REGULATION OF CYSTEINE CATHEPSINS IN MATRIX-
REMODELING OF FIBRIN-BASED ENGINEERED 
MICROVASCULAR NETWORKS                            
 Introduction 
 Vasculogenesis is the formation of de novo microvessels, which is usually observed 
in embryogenesis, tumor growth, and after extensive vascular damage [73, 74]; this differs 
from angiogenesis where microvessels are formed from pre-existing vessels, usually after 
injury [22]. These processes are complex and coordinated, involving ECM remodeling, 
endothelial cell (EC) migration, cytokine secretion, lumen formation, and mural cell (i.e.: 
pericyte) recruitment [22, 73, 74]. The mechanisms that drive vasculogenesis and 
angiogenesis need to be better understood, as it can help engineers develop better strategies 
for microvascular networks in regenerative medicine. 
 Cell microenvironments, which include extracellular matrix (ECM), various cell 
types, and factors (i.e.: signaling molecules or proteases), change cellular behavior. The 
ECM could act as a reservoir for bound growth factors and proteases which could indirectly 
regulate ECs; thus, controlling availability of biochemical signals [22]. Capillary 
morphogenesis requires proteolytic remodeling of ECM during EC migration, invasion 
into perivascular tissue, and tubulogenesis or lumen formation [22, 23, 163]. This is 
mediated by various cell types secreting angiogenic factors and extracellular proteases, 
such as matrix metalloproteinases (MMPs) [21-23].  
 The role of MMPs in vasculogenesis have been well studied and characterized. 
Following induction by pro-angiogenic factors, such as VEFG [164] and FGF [165], 
MMPs, secreted by ECs, degrade the surrounding ECM [21, 22]. In vitro and in vivo 
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models  have demonstrated that MMPs are important for migration and invasion of 
endothelial cells (ECs) [19, 166]. MMP-1, -2, and -9, degrade ECM and basement 
membrane to aid in vascular remodeling, cell migration, and sprout formation [77]. They 
can also release ECM-bound angiogenic growth factors in pericytes from vessels 
undergoing angiogenesis [20].  As such, MMPs have been a common focus of study [20, 
21, 77] and primary target of inhibition during the development of engineered microvessels 
as a strategy to enhance their development [14, 167]. However, other proteases, like 
cysteine cathepsins, could contribute to active ECM remodeling in the vascular niche. 
 Cathepsins have been implicated in angiogenesis [24-28] and in the pathogenesis 
of vascular diseases, including atherosclerosis and the formation of abdominal aortic 
aneurysms [6, 26, 143, 168]. Studies have shown that specifically, cathepsins K and S (catK 
and S)  are involved in neovascularization, where their inhibition has impaired formation 
of vessels [27, 28]. Stimulation of ECs with inflammatory cytokines and angiogenic factors 
induced catS expression, but when catS was inhibited, cell invasion was impaired and EC 
tube formation was reduced [24]. Increased cathepsin L (catL) has been linked to cell 
invasion and neovascularization [3, 83], and catL has been identified in tip/stalk-like and 
phalanx-like ECs, types of invasive/migratory ECs [169]- this is discussed more in Chapter 
7. Thus, cathepsins potentially play pivotal roles in angiogenesis/vasculogenesis, and they 
are likely to be involved in remodeling of matrix in microvascular network formation. 
 Here, the role of cathepsins in proteolysis during microvascular network 
development was determined by using a microfluidic model to perturb the network using 
flow and cathepsin inhibitors. ECM and vascular remodeling are dependent on 
biomechanical and biochemical cues within the microenvironment [21-23], and it is 
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important for engineers to consider the role of matrix remodeling proteases during 
microvessel formation. Studying these complex interactions can improve understanding 
their role in vasculogenesis, which can help improve design constraints for future 
microvascular networks. Our work demonstrates that active cathepsins decrease under 
fluid flow conditions while increasing their endogenous inhibitor, cystatin C. Adding 
cathepsin inhibitors to microvessels cultured under static conditions reduces the amount of 
active cathepsins. These findings suggest that cathepsin inhibitor interventions could aid 
in prolonging network stability, demonstrating the need for us to consider cathepsins as 
contributors to ECM remodeling in microvasculature network. 
 Materials and Methods 
4.2.1 Cell Culture and Generation of Microvascular Networks 
 Human umbilical vein endothelial cells (ECs) were transduced by standard 
Lentivirus procedures to label the cytoplasm by red or blue fluorescent protein expression 
(RFP or BFP) and normal human lung fibroblasts (fibroblasts) which are non-fluorescent 
in all experiments, except for Figure 2 (cytoplasmic GFP). Both cell types were purchased 
from Lonza and were cultured until confluency in T150 and T75 flasks coated with rat tail 
collagen 1 (50mg/mL, Corning). HUVEC were cultured in VascuLife media (LL-0003) 
and normal human lung fibroblasts (fibroblasts) were cultured in FibroLife (LL-0011) 
media (Lifeline Cell Technology) that was changed every 2 days.  
 Once confluent, cells were dissociated using TrypLE (ThermoFisher) at 
concentrations of 24x106 cells/mL ECs and 4.8x106 cells/mL fibroblasts, which results in 
final cell concentrations of 6 and 1.2 x106 cells, respectively. Thus, a 5:1 ratio of 
EC:fibroblasts were cultured in a (fibrin gel 3mg/mL), as previously reported [170]. The 
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cell-gel solution was injected within a macro-scale (~100L total gel volume) PDMS (10:1 
ratio, Ellsworth adhesives) single-gel channel platform. Microvascular networks formed 
via a vasculogenesis-like process over ~7days, following which half of the` devices were 
exposed to continuous flow, inducing a low shear stress (~2Pa  =  2 dynes/cm2 – average 
value across vessels, as determined previously [171]) for 48hrs. Flow was maintained by a 
pressure head (~0.5mm H2O) generated across the gel using an in-house built chamber 
fitted to the PDMS device, which was driven by a positive displacement (solenoid-driven) 
air pump. For sample collection for immunoblot and zymography, the hydrogel component 
of the PDMS devices containing microvascular networks were extracted (for both static 
and flow conditions) on day 9 and flash-frozen in the vapor phase using liquid nitrogen, 
and then stored at -80°C until further sample preparation as indicated below.  
4.2.2 Cathepsin Inhibitor Experiments 
 Microvascular networks were grown in a scaled-down version (same as prior use 
[170, 172]) of the microfluidic chip (~35µL cell/gel volume). These microvascular 
networks were all cultured until day 7 prior to addition of 10µM E-64, or 1µM cystatin C 
(Molecular Innovations), or a control volume of diluent in the media. These samples were 
cultured until day 10 and flash-frozen in the vapor phase using liquid nitrogen, and then 
stored at -80°C until further sample preparation as indicated below. 
4.2.3 EC and Fibroblast 2D Culture on Fibrin Gels 
 Fibrin gel (3mg/mL) was prepared by mixing at 1:1 ratio 6mg/mL fibrinogen (from 
bovine plasma, Sigma) with 4U thrombin (from bovine plasma, Sigma). A total volume of 
100µL was added to the center of each well of a 12-well plate and rotated for complete 
coating. Fibrin was gelled for several minutes prior to addition of complete media and 
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incubation at 37°C overnight in a standard incubator. The following day ECs and 
fibroblasts were seeded onto either non-coated or fibrin coated wells, at a concentration of 
5x104 cells/well. HUVECs and fibroblasts were cultured for 2 days in VascuLife or 
FibroLife, respectively. Following that media was collected into a separate tube. The 
remaining cells and fibrin gel (homogenate), were collected and homogenized in 
zymography lysis buffer. 
4.2.4 Immunofluorescence Staining and Confocal Microscopy Imaging 
 Microvascular networks in microfluidic devices were fixed at day 7 using 4% 
paraformaldehyde (PFA, 8% Electron Microscopy Science, diluted with Dulbecco’s 
phosphate buffered saline (DPBS), VWR) for 30mins. Well-plates were fixed on day 2. 
Following several washes with DPBS, samples were subsequently permeabilized with 
Triton-x 100 (0.1% v/v in DPBS) for 10mins and incubation in blocking buffer (5% w/v 
BSA (Sigma), 3% v/v goat (or horse) serum in DPBS) for several hours. Primary anti-
human antibodies were used at 2µg/mL in wash buffer (0.5% w/v BSA in DPBS) as 
follows: rabbit polyclonal anti-cathepsin K (ProteinTech), goat polyclonal anti-cathepsin 
L (R&D systems), goat polyclonal anti-cathepsin S (R&D systems), anti-collagen 1 
(Abcam, ab34710), monoclonal mouse anti-FSP1 (Novus). Appropriate secondary 
antibodies (ThermoFisher) were used at dilutions of 1:200. DAPI (Invitrogen) was used at 
1:1000 for 10mins. Samples were imaged on a confocal microscope (Olympus IX81) with 
Fluoview v4.1. Z-stack images were captured using 5µm slices (~20-30 total number) and 
presented as maximum z-projections, unless otherwise specified. Co-localization of 
antibodies was performed using the NIH ImageJ analysis tool. 
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4.2.5 Multiplex Cathepsin Zymography 
 Multiplex cathepsin zymography was used to assess active cathepsins, as 
previously described [148]. Samples were prepared using a non-reducing loading buffer 
(5×-0.05% bromophenol blue, 10% sodium dodecyl sulfate (SDS), 1.5M Tris, 50% 
glycerol. A 12.5% SDS-PAGE gel was used and embedded with 5 mg/ml gelatin substrate. 
Gels were run at 200 V at 4 °C. Proteases were renatured in 65mM Tris buffer pH 7.4 with 
20% glycerol for 3 washes, 10 min each, then incubated in pH 6 (phosphate buffer, 1mM 
EDTA with 2mM DTT, freshly added) activity assay buffer overnight. Next, gels were 
stained with Coomassie Blue (4.5% Coomassie blue; Sigma-Aldrich, 10% acetic acid, and 
10% isopropanol) then destained (10% acetic acid and 10% isopropanol). For inhibitor 
assays, 1µM of cathepsin K II inhibitor (1-(N-benzyloxycarbonyl-leucyl)-5-(N-Boc-
phenylalanyl- leucyl) carbohydrazide [Z-L-NHNHCONHNH-LF-Boc], 
Calbiochem/Millipore Sigma) or 1µM of cathepsin L inhibitor (Z-FY-CHO, 
Calbiochem/Millipore Sigma) was added to the pH6 assay buffer prior to overnight 
incubation. 
4.2.6 Immunoblotting 
 Samples were prepared with reduced loading dye (5× - 0.05% bromophenol blue, 
10% SDS, 1.5M Tris, 50% glycerol, 25% beta-mercaptoethanol) and run on 12.5% SDS-
PAGE gels. Proteins were transferred onto a nitrocellulose membrane, and then 
immunoblotted using the following antibodies: rabbit polyclonal anti-cathepsin K 
(ProteinTech), goat polyclonal anti- cathepsin L (R&D Systems), goat polyclonal anti-
cathepsin S (R&D Systems), rabbit polyclonal anti-cystatin C (EMD Millipore), or goat 
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polyclonal anti-GAPDH (R&D Systems). Immunoblots were imaged using Odyssey CLx, 
LI-COR. Densitometry was performed with ImageJ (NIH). 
4.2.7 Statistical Analysis 
 Statistical significance was determined using a two-way ANOVA (unless noted 
otherwise) between normalized RAW264.7 macrophage control or recombinant enzyme 
control, using GraphPad. All experiments were replicated at least three times and a p value 
< 0.05 was considered statistically significant. 
 Results 
4.3.1 Shear, induced by flow, decreased amount of active cathepsins in 
microvascular networks 
 Generating vasculature within microfluidic devices allows for control over 
mechanical cues such as shear stress [23, 173, 174]. Considering the significant influence 
of fluid flow on vasculature [173, 175], and that mechanical cues are tied to remodeling of 
the vascular niche [176, 177], it is important to investigate how these mechanisms alter 
cathepsin activity during ECM remodeling.  It has been previously reported that cathepsins 
are mechanosensitive [28]; catL activity is inhibited when ECs are exposed to laminar shear 
stress [6]. It was hypothesized that applying luminal flow through vessels would reduce 
active cathepsins in microvascular networks. To test this hypothesis, microvascular 
networks were developed in a large-scaled version of a single-gel channel PDMS device 
using a co-culture of human umbilical vein endothelial cells (ECs) and normal human lung 
fibroblasts in a fibrin gel, as previously described [170, 172]. Following microvessel 
formation, pressure driven recirculating fluid flow was applied from day 7 to day 9 (48hrs) 
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on half of the devices, with the others cultured under static conditions as controls. A  pump 
was used to impose a shear stress averaging ~2Pa = 2 dynes/cm2 [171]. The 
microvessels/networks were collected and homogenized, then samples were prepared for 
cathepsin zymography. Multiple active cathepsins bands were detected (37kDa, ~27kDa, 
and ~23kDa), which were determined to be cathepsins K and L based on known 
electrophoretic distances [148]. Flow significantly reduced the amount of active catK (37 
kDa) by 42% ±2.3%, catK/L (27 kDa) by 52% ±4.5%, and catL (23 kDa) by 55% ±04.6 
(Fig 4-1A).  
 Zymograms were repeated, in the presence of either a catK inhibitor (Figure Fig 4-
1B) or a catL inhibitor (Fig 4-1C) to confirm the bands seen in Figure 1A. Incubation with 
the catK inhibitor blocked the appearance of the 37kDa, 27kDa, and 23kDa active bands. 
In the presence of the inhibitor, the 37kDa and 23kDa active bands no longer appeared; 
however, microvascular networks subjected to flow retained some active cathepsin bands 
at 27kDa, compared to static conditions (p = 0.0134). Thus, the 37kDa, 27kDa, and 25kDa 























Figure 4-1: Shear flow through microvessels decreases amount of active cathepsins in 
microvascular networks. 
ECs and fibroblasts were cultured at a 5:1 ratio in a 3mg/mL fibrin gel within a macro-scale 
(~100uL gel volume) PDMS platform. Microvessels (MVNs) formed via a vasculogenesis-
like process over ~7days. Some devices were exposed to continuous flow, inducing a low 
shear stress (~2Pa) for 48hrs.  Flow was maintained by a pressure drop generated across the 
gel using an in-house pum p. Gels containing MVNs were extracted from devices (static 
and shear) on day 9. Zymography was run to assess the amount of active cathepsins, as 
indicated by white clear bands, and western blots were done to assess for presence of 
cathepsins and cystatin C. (A) Multiple active cathepsin bands were observed in the 
zymogram. There was a significantly less amount of active cathepsins in MVNs formed 
under shear stress compared to static devices (p < 0.05). To identify the cathepsins in the 
zymogram, (B) cathepsin L inhibitor and (C) cathepsin K inhibitor was added to the assay 
buffer. In the zymogram with Cathepsin L inhibitor added, an active cathepsin band was 
identified at 25kDa, while the other bands were blocked. However, more active cathepsin 
is observed in MVNs made under shear compared to static suggesting that different 
cathepsins are affected by flow. Cathepsin K inhibitor in the assay buffer blocked all active 
cathepsins.  
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4.3.2 Flow increases cathepsin L protein levels and expression of cystatin C 
 Zymography is used to detect active cathepsins, but immunoblots are needed to 
detect the total amount of protein. It is possible that the procathepsin and mature forms of 
cathepsin could be present but not in an active conformation that would yield a 
zymographically detected signal. To assess how flow affects cathepsin expression and 
maturation in microvascular networks, total protein was determined by immunoblot.  Flow 
caused a 44% ±0.14% increase in pro catL level and 53% ±2.57% increase in levels of 
mature catL compared to static controls (Fig 4-2A); this result was counter to the amounts 
of active cathepsin detected in zymography (Figure 1A). To potentially resolve this 
discrepancy, immunoblots were done for cystatin C, the tight binding, endogenous 
inhibitor of cysteine cathepsins, expressed by most nucleated cells, and previously shown 
to be upregulated by endothelial cells under flow conditions [178]. Consistent with these 
results, microvascular networks subjected to flow demonstrated a 64% ±13% increase in 
cystatin C compared to those cultured under static conditions (p = 0.0219, Fig 4-2B). This 
suggests that flow induced upregulated cystatin C can bind to cathepsins and reduce the 






























Figure 4-2: Shear flow through microvessels increased the total amount of cathepsin 
L and cystatin C in microvascular networks. 
(A) There was significantly more pro (p = 0.0049) and mature cathepsin L (p = 0.0332) in 
networks formed under flow compared to static conditions. No cathepsin K or cathepsin S 
were detected by western blot. To understand the increase in cathepsin L present, networks 
were assessed for cystatin C, endogenous cysteine cathepsin inhibitor. (B) Cystatin C was 
significantly increased in MVNs formed under shear stress (p = 0.0219). This increase in 
cystatin C corroborates the decrease in active cathepsins.  
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4.3.3 Cathepsins K, L, and S were present in stromal and luminal regions of 
microvascular networks  
 Next immunofluorescence was used to determine locations of cat K, L, and S in the 
microvascular networks, and if they were associated with one cell type more than the other. 
Microvascular networks were fixed and labeled with antibodies against fibroblast specific 
protein (FSP-1) and collagen I (Fig 4-3A) to demonstrate the cell associations and 
organization in the formed microvascular network.  Images were reconstructed using NIH 
ImageJ (Fig 4-3B). The left side is a maximum z-projection with orthogonal projections 
demonstrating open vascular lumen, and the right side is the corresponding x-y plane for 
the projects, demonstrating remodeling by fibroblasts (green) of ECM by reflectance 
imaging. This was done to see where cathepsins localized with the lumen (open circles) or 
stroma (surrounding area), and visualize matrix remodeling (grey) (Fig 4-3B). Cat K, L, 
and S were localized in the apical (arrow with ‘A’) and basal (arrow with ‘B’) side of the 
ECs, and in the stroma (arrow with ‘S’), where fibroblasts are located (Fig 4-3C). CatK 
and catS were seen more on the apical side of the lumen and stroma. CatL was on both the 
apical and basal side of the lumen, as well as the stroma.  A co-localization plugin (NIH 
ImageJ) was used to identify the overlapping intensity between ECs or fibroblasts and cat 
K, L, or S. Briefly, mean co-localization R values (acquired from z projections of n=3 
images each) showed that cathepsins localize predominantly with fibroblasts, in 
comparison to ECs (Fig 4-3C). This result corresponds with the fact that fibroblasts are 
mostly responsible for degradation and remodeling of the ECM, which is seen by confocal 

























Figure 4-3: Cathepsins localize in lumen and stroma of microvascular networks.  
(A) Confocal images of RFP-labelled HUVECs, FSP-1 labelled fibroblasts, and identified 
collagen I, and cathepsins K, L, or S. Mean co-localization of cathepsins with HUVEC (via 
RFP) or fibroblasts (via FSP-1). (B) Live confocal image showing open vascular lumen in 
orthogonal projections. Images were reconstructed into 3D z-stacks using to see where 
cathepsins localized with the lumen (open circles) or stroma (surrounding area), and 
visualize matrix remodeling (areas of white are reflectance of matrix). (C) CatK, L, and S 
were localized in the apical (arrow with ‘A’) and basal (arrow with ‘B’) side of the ECs, 
and in the stroma (arrow with ‘S’), where fibroblasts are located. A co-localization plugin 
(NIH ImageJ) was used to identify the overlapping intensity between ECs or fibroblasts 
and cat K, L, or S. Cathepsins co-localize significantly more with fibroblasts compared to 
ECs. Significance is indicated by *p < 0.05 using a t-test. 
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4.3.4  Small molecule inhibition of cathepsins is more effective than cystatin C 
 To test if exogenously applied inhibitors could further reduce the active cathepsin 
signal in microvascular networks, biochemical inhibition strategies were done using 
cysteine cathepsin inhibitors: cystatin C, endogenous 13 kDa protein that is a broad 
cathepsin inhibitor, and E-64, a 357Da broad-spectrum inhibitor of cysteine cathepsin 
family members [179]. On day 8, after microvascular networks were formed, either cystatin 
C (1µM) or E-64 (10µM) was added to microvascular network cultures that were cultured 
under static conditions for 48 hours to allow time for the inhibitors to equilibrate and bind 
to any cathepsins already present, plus any newly synthesized. Homogenates and 
supernatants were collected to quantify the amounts of cell-associated and secreted active 
cathepsins, respectively, in the presence of these inhibitors (Fig 4-4A). Adding E-64 
significantly reduced the top active band (75kDa, p=0.0004), active catK (37kDa, 68% 
±9.7% decrease, p=0.0271), catK/L (27kDa, 61% ±8.7% decrease, p=0.0155), and catL 
(23kDa, 73% ±10.4% decrease, p=0.0012) compared to microvascular networks with no 
inhibitor added. However, cystatin C did not significantly reduce the amount of active 
cathepsins detected.  
 In the supernatant, there was nearly a complete reduction in the amount of active 
cathepsins between 0 hours (top, Fig 4-4B) and 48 hours (bottom, Fig 4-4B) in 
microvascular networks that had E-64 added (p = 0.0448). After 48 hours of inhibiting the 
cathepsins, there was significantly less active catK/L in E-64 samples compared to cystatin 
C group (p=0.0326) and no inhibitor group (p = 0.0442). Zymography also detected active 
cathepsin bands at 75kDa, which was reduced by 32% ±3.9% after addition of E-64, but 
there was little difference in amount of active cathepsins between the microvascular 
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networks that had no inhibitor and those with exogenous cystatin C. Previously the 75 kDa 
bands have been identified as active cathepsins bound to released ECM and/or tissue 




















Figure 4-4: Cathepsin inhibitor, E-64, reduced active cathepsins in microvessels.  
Cathepsin inhibitors, cystatin C or E-64, was added to microvascular networks for 48 hours. 
Lysate, containing microcascular networks, and supernatant, containing media was collected 
from devices. Cathepsin zymography was used to measure the amount of active cathepsins in 
the microvessel. (A) Microvascular networks with E-64, compared to vehicle, had significantly 
reduced active top band (75kDa, p=0.0004), catK (37kDa, p=0.0271), catK/L (25kDa, 
p=0.0155), and catL (20kDa, p=0.0012) in lysate, which contains microvessels. There were no 
significant differences between cystatin C and vehicle networks, however there was a decrease 
in active cathepsins in microvascular networks made with cystatin C versus E-64, except for 
top band (p=0.0003) and catL (p= 0.0009). (B) In the supernatant, there was a significant 
decrease in the amount of active cathepsins between day 8 and 10 in the microvessels treated 
with E-64 (p = 0.0448). At day 10 there was significantly less active K/L in samples with E-64 
compared to vehicle (p = 0.0442) and cystatin C (p=0.0326).  Zymography also detected 
cathepsin bound to tissue (75kDa). 
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 Immunoblots were run on these samples to quantify the total protein amounts of 
catK, L, and S after adding cathepsin inhibitor to microvascular networks to assess cell 
feedback loops or responses to cathepsin inhibition. CatK and catS were not detected by 
immunoblot. From lysates, E-64 significantly reduced the amount of mature catL in 
microvascular networks compared to cystatin C (p=0.0021), or no inhibitor control 
(p=0.0026) groups. There was no significant difference in pro catL between the three 
groups (Fig 4-5A). There was significantly more cystatin C in homogenates of 
microvascular networks that had cystatin C added compared to no inhibitor (86% ±12.3%, 
p<0.0001) and E-64 (71% ±10.1%, p<0.0001) networks (Fig 4-5A). The supernatant of 
microvascular networks with cystatin C had 3-fold higher cystatin C, compared to no 
inhibitor (p<0.0001) and E-64 (p<0.0001) (Fig 4-5B), clearly indicating the exogenously 
added cystatin C was still circulating and not all taken up by the cells. Despite there being 
significantly more cystatin C present in microvessels with cystatin C added, there was no 




























Figure 4-5: Cathepsin inhibitor, E64, reduced cathepsin L in microvessels. 
(A) In lysate, there was no significant difference in pro catL between the three groups, 
however, microvascular networks with E-64 had significantly less mature catL compared 
to vehicle (p=0.0026) and cystatin C (p=0.0021) microvascular networks. At day 10, there 
was significantly more cystatin C in microvascular networks made with cystatin C 
compared to vehicle (p<0.0001) and E-64 (p<0.0001) networks. (B) In supernatant, no 
mature cathepsin L was detected, however, there was a decrease in pro catL from day 8 to 
day 10 in E-64 (p=0.0161) networks. There was significantly less pro catL in D10 E-64 
networks compared to vehicle (p=0.0053) and cystatin C (p=0.0002). Between day 8 and 
day 10, the supernatant of cystatin C treated microvascular networks had a significant 
increase in cystatin C (p < 0.0001). There was significantly less cystatin C in vehicle 
(p<0.0001) and E-64 (p<0.0001) microvascular networks compared to cystatin C.  
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4.3.5 Fibroblasts are a dominant source of cathepsins, sustained by fibrin culture 
 Engineered microvessels are significantly influenced by cell types, their ratio and 
densities in culture, and by the containing gel, which influences vessel geometry and 
permeability [15, 170]. ECs (HUVECs) and fibroblasts have both been shown to produce 
cathepsins [28, 181].  Cathepsins localized mostly with fibroblasts in Fig 4-3C, suggesting 
more cathepsins were produced by them. In vitro, ECs and fibroblasts might increase 
cathepsin production in the presence of fibrin, which could be facilitate by cell integrin 
binding to fibrin which could stimulates cathepsin gene expression [182] or promote 
localization of the cathepsins to the cell surface [183].  To understand their individual 
contributions of HUVECs and fibroblasts, each cell was separately cultured on fibrin gels 
or tissue culture polystyrene (TCPS) for 24 hours. CatK and catS were not detectable by 
immunoblot, however, catL was identified. Fibroblasts produced more pre catL and mature 
catL compared to ECs (Fig 4-6), which corroborates our findings in Fig 4-3 that cathepsins 
mostly co-localize with fibroblasts. Interestingly, the homogenate, which contains the cell 
lysate, fibrin gel, and any proteins associated/bound to them, contained less pre catL and 
mature catL in fibroblasts cultured on fibrin gels compared to no fibrin (Fig 4-6A). The 
opposite was found in the supernatant; fibroblasts cultured on fibrin gel had more pro catL 






























Figure 4-6: Fibroblasts contribute more cathepsins to microvascular networks.  
HUVECs (ECs) and normal human lung fibroblasts (fibroblasts) were separately cultured 
on fibrin or no gel (TCP); homogenate, containing cells and fibrin gel, and media, 
containing secreted proteins, were collected and prepared in reducing loading dye. Western 
blots were used to identify presence of cathepsins. (A) In homogenate, fibroblasts had 
significantly more pro cathepsin L compared to ECs in no fibrin (p < 0.0001) and on fibrin 
gels (p = 0.011). More pro cathepsin L was present in fibroblasts cultured on no fibrin 
compared to fibroblasts cultured on fibrin gels (p=0.0141). Fibroblasts had significantly 
more mature cathepsin L in no fibrin conditions (p=0.0011) compared to ECs. More mature 
cathepsin L was present in fibroblasts (p<0.001) and ECs (p=0.0155) on no fibrin gels 
conditions compared to culturing on fibrin gels. (B) In media, ECs and fibroblasts had 
significantly more pro (p=0.0370, p =0.0204) and mature (p=0.0203, p=0.0003) cathepsin 
L when cultured on fibroblasts. 
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 The extracellular matrix (ECM) of microvascular networks are initially composed 
mostly of fibrin, but then the fibroblasts and ECs deposit other matrix proteins (i.e.: 
collagen, Figure 4-3A). Studies have shown that ECM substrates, including collagen and 
elastin, can sustain and extend cathepsin activity after they adsorb or bind upon release 
from cells [50, 147]. Based on our previous studies, fibrin is a substrate that can sustain 
active cathepsins for 24 hours [180]. It was hypothesized that ECM in the microvascular 
networks could serve as a bioactive reservoir to sustain cathepsin activity over longer 
durations. Therefore, ECs and fibroblasts were separately cultured on fibrin gels for 24 
hours (in 2D well plates) to test the hypothesis that fibrin can amplify cathepsin activity. 
Homogenate, containing both cells and fibrin gel, and supernatants media were collected, 
and prepared for zymography. Multiplex cathepsin zymography was used to identify active 
cathepsins in the supernatant and homogenate of the individually cultured cell types. ECs 
and fibroblasts cultured on fibrin had significantly more active cathepsins compared to 
those cultured on TCPS (Fig 4-7A & 4-7B). This was observed in both homogenate and 
media. Based on the ratio of cells cultured on fibrin gels to cells cultured on no fibrin 




Figure 4-7: Separately culturing endothelial cells and fibroblasts on fibrin gels to 
identify if fibrin sustains active cathepsins in vitro.  
(A) ECs and (B) fibroblasts were separately cultured on fibrin gels or tissue culture plates 
(TCP); homogenate, containing cells and fibrin gel, and media, containing secreted 
proteins, were collected and prepared in non-reducing loading dye. Multiplex cathepsin 
zymography was run to assess the amount of active cathepsins. When ECs or fibroblasts 
are cultured on fibrin gel, there are increased amounts of active cathepsins in media 
(p=0.0023, p<0.0001) and homogenate (p<0.0001, p<0.0001).  In the presence of fibrin 
there is more active cathepsins; suggesting that fibrin helps maintains active cathepsins 
and enhances their activity in vitro. Sustaining cathepsin activity for longer periods of time 
makes them available to degrade matrix substrates in more complex systems, like the 
microvascular networks (C) Based on ratio quantification from zymograms in A and B, 
fibroblasts produce more active cathepsins compared to ECs. 
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 Discussion and Conclusions 
 Here, investigated cathepsin activity during microvascular network formation was 
investigated. Microvessels formed in a fibrin matrix had a significant amount of active 
catK and catL, predominantly produced by fibroblasts. CatK, L, and S localized with ECs, 
associated with lumen on the apical and basal sides, as well as the fibroblasts which are 
associated with the stroma. When cell types were separately analyzed, fibroblasts produced 
more cathepsins compared to ECs, corroborating increased co-localization in stroma of 
microvascular networks. Defining the role of cathepsin-mediated fibrin degradation in 
microvascular networks suggests that cathepsin inhibitory strategies might be necessitated 
to improve matrix stability over long durations in culture.  
 Proteolytic activity is needed for matrix remodeling during 
vasculogenesis/angiogenesis. When developing microvasculature, researchers typically 
consider MMPs [14, 90, 103, 167, 184] as proteases to facilitate these processes. However, 
another class of proteases, cysteine cathepsins need to be considered as they have been 
implicated in vascular remodeling [24-28]. MMPs and cathepsins can be secreted by the 
same cell types involved in vascular formation including ECs [48, 169, 185] and fibroblasts 
[48, 186]. Both proteases interact in a proteolytic network, a coordinated cascade of events 
and interactions between different types of proteases connects proteases from different 
families into the same network [187]. While MMPs regulate the fate of ECM remodeling 
during microvascular network development, our data demonstrated that cysteine cathepsins 
do, as well. Understanding proteolytic interactions could help us uncover the roles 
cathepsins play in vasculogenesis and identify approaches to improve engineered 
microvessel design. Understanding cathepsin-mediated ECM remodeling in microvessels, 
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could help identify if cathepsins are a target for implanting novel microvascular network 
design strategies.   
 Microfluidic devices are advantageous for developing vasculature in vitro, allowing 
for control over the microenvironment with the ability to easily manipulate growth factors 
and mechanical cues; various strategies have been used to create perfusable 
microvasculature-on a-chip [188]. It is important for engineers to consider that as the 
environment is perturbed, cells will sense, adapt, and respond; and thus, other properties 
will emerge. Flow decreased the amount of active cathepsins and increased total amount 
of cystatin C in microvascular networks. This provides an example of biomechanical cues 
changing the properties of the proteases. Cathepsins are shear-sensitive proteases. In ECs, 
laminar shear stress inhibits catL activity [152]. Types and rate of flow can affect cathepsin 
activity. It was demonstrated that ECs under proatherogenic oscillatory 5 dynes/cm2 with 
directional changes in flow) shear stress had higher amounts of cathepsin K compared to 
atheroprotective, unidirectional shear stress (15 dynes/cm2) [6]. This was done in vitro 
using confluent layers of ECs with a Teflon cone to induce shear stress, and our work is 
done in microfluidic devices with microvascular networks that had unidirectional laminar 
flow (~2 dynes/cm2). Flow also affects cystatin C; in ECs, oscillatory flow increases 
cathepsin expression and reduces cystatin C [178]. Flow in microvessels that increased 
total cathepsin present, however, cystatin C was also increased which aligned with a 
reduction in active cathepsins. Future directions could include assessing different types of 
flow or flow rates, and based on previous observations [6, 28, 152], changing these 
parameters could alter the amount of active cathepsins in microvascular networks. 
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Two different types of broad cathepsin inhibitors, cystatin C or E-64, were 
exogenously added to study how biochemical cues affect proteases. Cystatin C is the 
endogenous enzyme that reversibly binds to active sites of cathepsins to prevent substrate 
degradation [57]. E-64 is a small molecule inhibitor that irreversibly binds to the cathepsin 
active site [179].  Adding E-64 to microvascular networks significantly reduced active 
cathepsins, but cystatin C did not. Cystatin C was mostly in the supernatant (Fig 4-5B), 
suggesting that it did not cross the EC barrier. Also, there was no flow applied to these 
devices, so cystatin C was likely not swept away in a current. Although cystatin C is an 
extracellular cathepsin inhibitor; this poses a question about how permeable the EC barriers 
are in these microvascular networks. It is possible that transport varies due to the size 
differences of the inhibitors; E-64 is smaller compared to cystatin C- 0.347kDa compared 
to 13kDa, respectively. I hypothesize that because of the smaller size of E-64, it can pass 
through ECs via transcytosis, where E-64 is taken up by ECs with bulk volume during 
pinocytosis and exocytosis to the stroma. Conversely, cystatin C is not transported 
efficiently; it is likely too large for pinocytosis and could be transported to ECs via general 
uptake or receptor mediated endocytosis. This would limit the amount of cystatin C 
transported and likely why more cystatin C was found in the media the networks were 
cultured in (Fig 4-5B). This is worth further exploring as our lab has previously reported 
interesting cathepsin inhibitor behavior with E-64 [189], where breast cancer cells treated 
with E-64 had reduced active catL, but an increase in active catS. Also, our lab has 
previously observed upregulated active cathepsins in biological machines (bio-bots), 
another type of multi-cellular engineered living system that contains fibrin as a key matrix 
component.  Active catL was identified in bio-bots, even when bio-bots were treated using 
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a serine protease inhibitor aminocaproic acid (ACA) [144], however, treatment of bio-bolts 
with E-64 could extend their lifetime [190]. This demonstrates that cathepsin inhibition can 
improve longevity of an engineered construct; an approach that can be used in the future 
to improve design of microvascular networks. It also should be noted that cathepsin 
inhibitors were added at the end of microvascular network development and there were 
still differences in remodeling. Perhaps earlier addition of inhibitors could lead to improved 
longevity of microvessels. 
 Microvascular networks are formed in a dynamic and complex environment, with 
mechanical and signaling cues from the ECM, including the production and secretion of 
cysteine cathepsins. Engineered microvessels form with complex interactions including 
cues from the surrounding ECM matrix [19, 93, 94, 166].  It is known that cell-cell 
interactions with matrix, cytokines, and shear stress can regulate protease expression and 
activity [6, 152]. A key observation is that fibroblasts produce more cathepsins compared 
to ECs, and their activity was increased with fibrin, suggesting that the fibrin in 
microvascular networks matrix could serve as a bioactive reservoir for cathepsins to 
maintain activity for longer periods of time. Stromal cells, such as fibroblasts,  are essential 
for aiding the sprouting microvessels to improve development of patent microvascular 
networks [13, 15, 176, 191]. Eliminating fibroblasts to reduce active cathepsins may not 
be conducive for maintaining long term vessel viability, however, as demonstrated, the 
addition of flow and inhibitors can decrease active cathepsins to prevent proteolysis. This 
could make fibroblasts or other stromal cells an ideal cell type to target for creating an 
inducible cell line to control endogenous cathepsin production, which can be done by 
creating a “switch” to turn on cathepsins to facilitate remodeling with the ability to turn off 
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cathepsin production when activity is too much and causes destruction. Also, one could 
consider using nanoparticle microcarriers for timed delivery of E-64, seeing that this was 
the optimal inhibitor for cathepsins in MVNs. 
 Researchers have used various techniques for creating microvasculature that have 
varying cell sources, matrices, culturing conditions, and application of interstitial flow. 
One group used a 3D microfluidic device to apply interstitial flow using HUVECs. Their 
approach differs in that they utilized a collagen gel and increasing amounts of VEGF. They 
identified there is a balance between flow magnitude and VEGF concentration [103]. 
Similarly, manipulating flow and adding different cathepsin inhibitors can affect network 
formation and proteolytic activity. Studies were also done experimenting with the timing 
of adding broad spectrum MMP inhibitors during microvascular network formation. When 
added at the beginning of the angiogenic growth phase microvessel formation was blocked, 
however, addition after the angiogenic growth phase (day 7), helped prevent vessel 
regression [192]. A key difference with their approach is that a rat aortic angiogenesis 
model was used. Considering this, our data suggests that vascular regression is due to 
unbalanced proteolysis where there is continuous proteolytic activity that degrades the 
ECM and reduces the lifespan of the causing microvessels to fail. Another group used 
HUVECs or ECs derived from induced pluripotent stem cells (iPSC-ECs) and nhLFs 
coated on dextran microcarrier beads embedded in a fibrin matrix to examine capillary 
morphogenesis. Adding broad spectrum MMP inhibitor or serine inhibitor, to inhibit 
plasmin, the endogenous enzyme that degrades fibrin, did not eliminate sprouting of 
microvessels, however with both inhibitors combined, sprouting was completely blocked. 
The researchers suggested that these observations could be due to proteolytic interactions 
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between plasmin and MMP, or a third type protease involved in vasculogenesis [184]. Our 
experiments are similar in terms of cell source and matrix, although ours utilized a 
microfluidic device while the authors use a microcarrier system. Taking both studies 
together, this furthers the argument that cysteine cathepsins are part of the proteolytic 
network in regulating morphogenesis in these engineered systems.  
 Our work demonstrates how biomechanics, particularly fluid shear stress, control 
cathepsin presence and activity during microvessel formation, suggesting an approach to 
reduce extended proteolysis by cathepsins, which could subsequently extend microvascular 
network lifespan. Addition of catK or catL inhibitors during the overnight zymography 
assay wash demonstrated that not only are active catK and catL are present in the system, 
but also suggests that both cathepsins are regulated differently by flow; something to 
consider when identifying which cathepsin to target with inhibitors during microvessel 
development. This data confirms microvascular networks contain cathepsins in 
ECM/stroma, which could act as a bioactive reservoir to sustain proteases and making them 
available to degrade matrix substrate, fibrin, causing microvessel regression (i.e.: decrease 
in vessel diameter and vessel density). Our work demonstrates the need to consider novel 
cathepsin inhibition strategies to control proteolysis and meet design criteria for fibrin-
based engineered tissues. 
 Together, these results provide insight into the role cathepsins play in ECM 
remodeling of microvascular networks. Cathepsins were localized, and their activity and 
expression were quantified in engineered microvasculature. Flow through microvascular 
networks not only upregulates the amount of cathepsins, but also the amount of their 
endogenous inhibitor, resulting in a net effect of a decreased amount of active proteases in 
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the system. Also, small molecular inhibitors can get through ECM barrier to block activity. 
Further, our work identifies an increase in active cathepsins from ECs and fibroblasts 
cultured on fibrin gels demonstrating, in vitro, a mechanism between cathepsins and fibrin, 
a follow up to our previous work using recombinant proteases and fibrin gels [180]. 
Cathepsins could bind to fibrin and it serves as a reservoir sustaining functional time of 
active cathepsins over longer periods of time in vitro and in multi-cellular engineered living 
systems. The long-term goal is to prevent microvessel regression, and characterizing 
cathepsins biomechanical and biochemical properties in microvascular networks provides 
insight for promising future studies. 
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CHAPTER 5  INCREASED FIBRINOPEPTIDE A IN A 
HUMANIZED SICKLE CELL MOUSE MODEL IS CAUSED BY 
CATHEPSIN-MEDIATED FIBRINOGENOLYSIS 
 Introduction 
Sickle cell anemia (SCA) , red blood cell disorder, facilitates a state of chronic 
coagulation activation, also known as hypercoagulation, where most parts of the 
coagulation cascade are altered [31, 116]. Evidence of this includes increased activation of 
platelets and tissue factor, decreased levels of anticoagulant proteins, and abnormal 
fibrinolysis [33]. The cause of SCA-mediated hypercoagulation is not well understood, 
although there are hypotheses that it may be caused by vaso-occlusive crisis (VOC) or a 
secondary effect due to SCA [33, 106, 116]. Studies using anticoagulants and antiplatelet 
therapeutics have not helped prevent or treat hypercoagulation and vaso-occlusive 
conditions in SCD patients [31, 129-133, 193] and researchers need to better understand 
how abnormalities in coagulation activation contributes chronic coagulation activation in 
SCD pathophysiology and complications. Understanding underlying mechanisms of 
hypercoagulation in SCD could lead to the development of effective anticoagulant 
therapies specific to the SCD population.  
In the coagulation signaling cascade, thrombin - a serine protease - cleaves 
fibrinopeptide A and B from fibrinogen, promoting fibrin polymerization and coagulation 
(Fig 2-1). It has been reported that people with SCA have increased plasma concentrations 
of fibrinopeptide A (FpA) [33, 39, 193] , a marker of coagulation activation, and studies 
suggest it is not only due to thrombin activity [39], suggesting the potential involvement 
of another protease.  
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Our lab has shown that there is an increase in cathepsin K (catK) in sickle cell 
anemia [40, 41]. People with SCA have increased numbers of circulating peripheral blood 
monocytes (PBMCs) and under the disease state, PBMCs induce catK activity in 
endothelial cells [40]. Also, cathepsin K-dependent arterial remodeling occurs via elastin 
and collagen degradation in the SCD Townes mice model [41]. Based on the increased 
amount of cathepsin K in SCA and increased plasma concentration of FpA in people with 
SCA, the connection between cat K and FpA was questioned. From computational docking 
algorithms, cathepsins (cat), K, L and S have putative binding and cleavage sites on 
fibrinogen in the central E domain, where FpA is located [42]. Furthermore, there is 
evidence that catK (and catS) have a unique preference to cleave proline and glycine at the 
P2 and P3 position [194]. Taken together, it is hypothesized that increased plasma levels 
of FpA in SCD is due to cysteine cathepsin activity, specifically catK, contributing to SCD 
hypercoagulation, and inhibiting cathepsin activity can reduce elevated FpA levels.  
 Materials and Methods 
5.2.1 Mouse Model Experiments 
Townes sickle transgenic mouse model (B6;129-Hba tm1(HBA) Tow Hbbtm2 
(HBG1,HBB*) Tow/Hbbtm3 (HBG1, HBB) Tow/J) were obtained from The Jackson 
Laboratory. Animals were housed following a 12-hour light-dark cycle and fed Lab Diet 
5001 ad lib. Pups were weaned, separated by sex at 21 days old, and their hemoglobin was 
genotyped using Native SDS-PAGE. All experiments were approved by Georgia Institute 
of Technology Institutional Animal Care and Use Committee (IACUC) with supervision 
of veterinarians in the Physiology Research Laboratory.  
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 Mice were selected for daily injection with small molecule cathepsin inhibitor, E-
64 (9mg/kg, Sigma-Aldrich), or vehicle (DMSO in saline) based on genotype. Mice were 
injected daily beginning at 1 month of age for 2 months, until age 3 month. Blood was 
collected from mice into heparinized tubes, at 1, 2, and 3 months of age. Samples were 
centrifuged at 2,000xg for 20 minutes to separate plasma. 
5.2.2 Cathepsin K Deficient Mouse with Sickle Cell Anemia 
Cathepsin K deficient mice B6.129X1-Ctsktm1Psa were crossed with the Townes 
sickle mice described above.  AA K-/-, AS K-/-, and SS K-/- genotypes for mice were 
confirmed using PCR for presence of human hemoglobin and absence of mouse 













Figure 5-1: PCR confirming generation of a cathepsin K deficient mouse with sickle 
cell anemia 
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5.2.3 Multiplex Gelatin Cathepsin Zymography 
 Multiplex cathepsin zymography was used to assess active cathepsins, as 
previously described [148]. Samples were prepared using a non-reducing loading buffer 
(5×-0.05% bromophenol blue, 10% sodium dodecyl sulfate (SDS), 1.5M Tris, 50% 
glycerol. A 12.5% SDS-PAGE gel was used and embedded with 5 mg/ml gelatin substrate. 
Gels were run at 200 V at 4 °C. Proteases were renatured in 65mM Tris buffer pH 7.4 with 
20% glycerol for 3 washes, 10 min each, then incubated in pH 6 (phosphate buffer, 1mM 
EDTA with 2mM DTT, freshly added) activity assay buffer overnight. Next, gels were 
stained with Coomassie Blue (4.5% Coomassie blue; Sigma-Aldrich, 10% acetic acid, and 
10% isopropanol) then destained (10% acetic acid and 10% isopropanol). For inhibitor 
assays, 1µM of cathepsin K II (1-(N-benzyloxycarbonyl-leucyl)-5-(N-Boc-phenylalanyl- 
leucyl) carbohydrazide [Z-L-NHNHCONHNH-LF-Boc], Calbiochem/Millipore Sigma) 
was added to the pH6 assay buffer prior to overnight incubation. Zymograms were imaged 
using Odyssey CLx, LI-COR. Densitometry was performed with ImageJ (NIH) to quantify 
active cathepsins.  
5.2.4 Multiplex Fibrinogen Cathepsin Zymography 
Recombinant cathepsin K, L, or S (10ng; Enzo), or plasmin (0.5µg; Enzyme 
Research Laboratories) was prepped in a non-reducing loading buffer. A 12.5% SDS-
PAGE gel was embedded with 5mg/mL fibrinogen (FIB 3 Plasminogen, von Willebrand 
Factor and Fibronectin Depleted; Enzyme Research Laboratories) substrate. Cathepsins 
were renatured in the buffer and incubated in pH4 or pH6 assay buffer overnight, as 
described above. Plasmin was renatured in 2.5% Triton-X 100 for 2 washes, and placed in 
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a pH modified MMP assay buffer (0.05% Triton X 100, pH 8.58). Gels were stained, 
destained, and imaged as previously described. 
5.2.5 Turbidity Analysis 
Fibrinogen (2.5 mg/mL; FIB 3 Plasminogen, von Willebrand Factor and 
Fibronectin Depleted; Enzyme Research Laboratories) and cathepsins K, L, or S (1ng/µL; 
Enzo) or human alpha thrombin (1 NIH U/mL; Enzyme Research Laboratories) were 
combined in 50mM Tris-HCl/100mM NaCl. The course of gelation was assessed over the 
course of 2 hours using a plate reader (BioTek) with absorbance readings set to 350nm and 
420nm, based on previous protocols [195].  
5.2.6 SDS-PAGE 
Fibrinogen and cathepsins K, L, or S, or thrombin were combined as described 
above. Cleavage was stopped at 0, 5, 10, 15, 30, 60, and 120 minutes. The supernatant, 
which contains soluble fibrinogen and cleaved fibrinogen fragments, was collected and 
saved. Samples were prepared with reduced loading dye (5X - 0.05% bromophenol blue, 
10% SDS, 1.5 M Tris, 50% glycerol, 25% beta-mercaptoethanol) and run on 10% SDS-
PAGE gels. Gels were stained with Coomassie stain (10% acetic acid, 25% isopropanol, 
4.5% Coomassie blue), followed by destaining (10% isopropanol and 10% acetic acid) and 
imaged with an ImageQuant LAS 4000 (GE Healthcare), and densitometry performed with 
ImageJ (NIH) to quantify fibrin(ogen) polypeptide chains. 
5.2.7 Immunoblot 
For immunoblotting, samples were prepared with reduced loading dye (5X - 0.05% 
bromophenol blue, 10% SDS, 1.5M Tris, 50% glycerol, 25% beta-mercaptoethanol) and 
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run on 12.5% SDS-PAGE gel. Proteins were transferred onto a nitrocellulose membrane, 
and then immunoblotted using rabbit polyclonal anti-fibrinopeptide A (Abcam, for mouse 
plasma studies) or mouse anti-fibrinopeptide A (HyTest, for human recombinant protein 
studies). Immunoblots were imaged using Odyssey CLx, LI-COR. Densitometry was 
performed with ImageJ (NIH) to quantify cleaved fibrinopeptide A. 
5.2.8 Statistical Analysis 
Statistical significance was determined using a two-way ANOVA between no 
enzyme control or normalized 1 month AS plasma, unless indicated otherwise using 
GraphPad. All experiments were replicated at least three times and a p value of <0.05 was 
















5.3.1 Fibrinopeptide A was increased in plasma of 3-month old male mice with 
sickle cell anemia 
 To examine whether the Townes Mouse model had increased fibrinopeptide A 
(FpA), as observed in human plasma [33, 39, 193], ELISA was used to quantify FpA in 
non-sickle (AA), sickle trait (AS), and sickle cell anemia (SS) mice. There was no 
significant increase in FpA in 1-month old SS mice compared to AA and AS mice (Fig 5-
2A). At 3 months of age, the majority of mice had low FpA levels, although there was an 
outlier. When the data was divided by sex, it was determined that mice with low levels of 
FpA were all female mice.  This suggested that male mice had more FpA compared to 
female mice, however a greater number of mice are needed to provide significance. 
Immunoblots were performed to quantify FpA in AA, AS, and SS mice. At 1 month, there 














Figure 5-2: Quantifying fibrinopeptide A in Townes Sickle Mouse model.  
Immunoblots and ELISA were used to identify and quantify fibrinopeptide A (FpA) in plasma 
of AA, AS, and SS mice. (A) There was no difference in FpA quantified in 1-month AA, AS, 
and SS mice. Interestingly, with plasma from 3-month-old mice, there are clustering of data, 
where the higher FpA concentration were identified as male mice (circled) and lower 
concentration as female mice (brackets). (n=3-6, one-way ANOVA). (B) Immunoblots were 
done on 1 month AA, AS, and SS mice. Little difference was observed between FpA in AS 
and SS mice. This preliminary data suggests that male mice have more FpA than female mice.  
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5.3.2 Mice with sickle cell anemia have increased active cathepsins in plasma 
compared to non-sickle and sickle cell trait mice. 
Next, multiplex cathepsin zymography was used to test the hypothesis that active 
cathepsins in Townes mice plasma and hypothesized that mice with sickle cell anemia have 
more active cathepsins circulating in their plasma compared to non-sickle and sickle trait 
mice, and the amount of active cathepsins would increase as the mice aged. Plasma was 
isolated from blood collected from AA, AS, and SS mice at ages 1 and 3 months. Multiplex 
gelatin cathepsin zymography was used to measure amounts of active cathepsins in plasma. 
There was a single ~50kDa band, and 1 month and 3-month SS mice had significantly more 
active cathepsins compared to 1 month and 3-month AA and AS mice (Fig 5-3A). Age was 
a factor in SS-mediated active cathepsins, where there were elevated levels of cathepsins 
in plasma of 3-month SS mice compared to 1-month SS mice, and there was no significant 
difference in cathepsins in AA and AS mice between 1 and 3 months.  
5.3.3 Male mice with sickle cell anemia have more active cathepsins compared to 
female mice. 
As noted earlier, there was variability in the amount of active cathepsins within the 
mice with sickle cell anemia. To better parse this observation, AA, AS, and SS plasma 
samples were divided based on sex. At 1 month of age, male SS mice have more active 
cathepsins compared to female SS mice (Fig 5-3B).  This difference in the amount of active 
cathepsins between sexes was sustained as the mice age. SS male mice at 3 months of age 
have more active cathepsins compared to 1-month old male mice (Fig 5-3C), however there 
was no significant difference in the amount of active cathepsins of female mice between 1 










Figure 5-3: Mice with sickle cell anemia have increased active cathepsins compared 
to non-sickle and sickle cell trait mice, and SS male mice have more active cathepsins 
compared to SS female mice  
Blood from AA, AS, and SS mice were collected at 1 and 3 months of age, and plasma was 
isolated and zymography was used to assess for active cathepsins. (A) There was 
significantly more active cathepsins in SS mice compared to AA and AS at 1 month 
(p=0.0143, p=0.008) and 3 months of age (p<0.0001, p=0.002). In SS mice, there was an 
age-related increase (p=0.008) in active cathepsins between 1 and 3 months. This data 
suggests that elevated cathepsins in plasma is abnormal and likely have some 
pathophysiological contribution in sickle cell anemia. (B) There was variability in the 
amount of active cathepsins detected in SS genotype mice plasma; to investigate mice were 
separated based on sex. At 1-month, Male SS mice plasma have significantly (p=0.0023) 
increased active cathepsins compared to female SS mice plasma. (C) 3-month-old male SS 
mice have significantly more (p=0.0029) active cathepsins in plasma compared to 1 month. 
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5.3.4 Active cathepsins in AA, AS, and SS plasma were identified as cathepsin K 
and L. 
Based on previous work from our lab showing that cathepsin K is elevated in SCA 
[40, 41, 196], it was hypothesized that the active cathepsin detected in zymograms was 
cathepsin K. Our lab has also developed a novel cathepsin K deficient mouse model with 
sickle cell anemia to study how cathepsins contribute to SCA pathophysiology. Blood was 
collected and plasma was isolated from the cathepsin K deficient mice with SCA (AA K-/-
, AS K-/-, and SS K-/-) as well as control cathepsin K deficient mouse (K-/-) and Townes 
mice (AA, AS, and SS genotypes). Preliminary data showed that active cathepsins were 
still detected in SS K-/- mice, however the amount of active cathepsins was less than the SS 
mice, suggesting that another cathepsin may also be present in the plasma (n=1, Fig 5-4A). 
To determine the identity of the active cathepsin in plasma, zymography was done on AA, 
AS, and SS mouse plasma, then zymograms were incubated with an inhibitor of cathepsin 
K (1µM) or L (1µM) in the assay buffer overnight. The ~50kDa band was not detected in 
either zymogram (n=1, Fig 5-3B), suggesting that the elevated cathepsin in plasma was 





















Figure 5-4: Active cathepsins in AA, AS, and SS plasma are identified as cathepsins 
K and L. 
A novel cathepsin K deficient (K-/-) mouse with sickle cell disease was bred to identify 
the role of cathepsin K in disease progression, particularly in sickle cell mediated FpA 
generation. (A) Zymography was done on cathepsin K deficient AA, AS, or SS (AA K-/-, 
AS K-/-, and SS K-/-) mouse plasma and AA, AS, or SS mouse plasma or cathepsin K-/- 
mouse plasma as controls. SS K-/- still had active cathepsins present, but it was less than 
SS mice (n=1). Cathepsin K deficient mice had no active cathepsins. Collectively, this 
suggests that active cathepsins were not only cathepsin K. (B) To determine which 
cathepsins were present, zymograms were incubated overnight with catK or catL inhibitor 
in the assay buffer (n=1). No active cathepsins were determined in either zymogram, 
suggesting the active cathepsin band was catK and catL.  
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5.3.5 Multiplex cathepsin fibrinogen zymography detected active cathepsin K, L, 
and S  
 Molecular docking and bioinformatics sequence specificity analysis can predict 
potential binding interactions and hydrolysis sites of cathepsin K on fibrinogen, including 
the central E domain where FpA is located [42]. Further, after co-incubation of purified 
fibrinogen and recombinant cathepsin K, cathepsin K can hydrolyze the Aα chain of 
fibrinogen where FpA is located [42]. To directly test the fibrinogenolytic activity of 
cathepsins, the multiplex cathepsin zymography assay [148] was modified to include a 
fibrinogen substrate and tested it with recombinant cathepsin K, L, or S. Using pH4 assay 
buffer, a pH that has selectivity for detecting catL [148], CatL was observed at its expected 
molecular size, 20kDa (n=3, Fig 5-4A-top). CatS was identified with the pH4 and pH6 
assay buffer at ~25-37kDa. However, at pH6 catK was observed at 150kDa, nearly 3x 
higher than its expected molecular size (n=3, Fig 5-4A-middle). It is hypothesized that 
cathepsin K can act as a matricellular protease when cathepsin interacts with the surface of 
fibrinogen or, so the cathepsins K does not migrate during electrophoresis. Plasmin, a 
serine protease and canonical enzyme that degrades fibrin [66, 142], was used as a control. 
By manipulating the MMP assay buffer (Triton-X based) to pH 8.48, optimal conditions 
for plasma [66] there was a white band at ~86kDa, the expected molecular size of cathepsin 










Figure 5-5: Cathepsins are fibrinogenolytic, but do not cause gelation of fibrin. 
Recombinant catK, L, and S were used to test fibrinogen zymography (n=3). (A) Active catL 
was observed at its expected molecular size 20kDa and catS at its expected molecular size 
25kDa. CatK was found active at pH6, it is observed at 150kDa, nearly 3x higher than its 
expected molecular weight.  Plasmin, endogenous enzyme that degrades fibrin is a serine 
protease with optimal activity at pH 8.5, and by manipulating the MMP assay buffer to pH 
8.48, active plasmin was detected. (B) Turbidity analysis, a technique using absorbance to 
determine the turbidity or cloudiness of a solution, was performed to assess cathepsin-
mediated fibrin formation using recombinant human fibrinogen and catK, L, or S. Turbidity 
measurements show that cathepsin K and L have no change in absorbance, indicating that 
both enzymes do not produce a cloudy solution, indicating catK and catL are cleaving FpA 
and causing fibrin gelation. However, the slight increase in absorbance with catS, suggests 
the initiation of fibrin gelation, which means catS could have the potential to form fibrin 
before degrading it.  
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5.3.6 Cathepsins K, L and S cleaves fibrinopeptide A on fibrinogen, however it does 
not cause gelation of fibrin. 
With the finding that cathepsins K, L, and S are fibrinogenolytic, their role in 
cleaving fibrinogen to initiate fibrin polymerization was assessed. Papain causes gelation 
of fibrinogen [195] and since cysteine cathepsins are part of the papain-like family of 
peptidases, it was hypothesized that cathepsins K, L, or S could cleave fibrinogen and cause 
gelation. To do this, absorbance was measured to quantify the turbidity of cathepsin-
mediated fibrin gels over a 2-hour time period; more absorbance would indicate fibrin gel 
formation. There was no change in absorbance when fibrinogen was combined with catK 
or catL, suggesting that neither enzyme can cleave fibrinogen to form a fibrin gel (Fig. 5-
5B). With catS, there was a slight increase in turbidity starting around 70 minutes, 
suggesting the initiation of fibrin polymerization. However, turbidity peaked around 90-
100 minutes then decreased, suggesting that a gel started to form then was likely degraded 
by catS.  
Release of FpA from fibrinogen initiates the process to form fibrin, and after 
observing that cathepsins do not lead to the gelation of fibrin, the Aα, Bβ, and γ fibrinogen 
polypeptide chains were assessed using reducing SDS-PAGE. CatK degraded the Aα and 
Bβ polypeptide chains, and smaller molecular weight fragments were detected (Fig 5-6A- 
left). There was little to no degradation or cleavage of fibrinogen by catL (Fig 5-6A- 
middle). CatS degraded the Aα and part of the Bβ polypeptide chain, and smaller molecular 
weight fragments (Fig 5-6A- right). These experiments differ from Chapter 3, in that 
isolated fibrinogen was co-incubated with cathepsins K, L, or S to see if it cleaved FpA. 
Previous work cathepsins were co-incubated with fibrin where FpA was already cleaved 
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by thrombin. Overall, catK and catS produced distinct banding patterns compared to each 
other, suggesting they cleaved fibrinogen at different polypeptide sites. 
Protein samples were separated by SDS-PAGE and transferred to a nitrocellulose 
membrane, then immunoblotted for fibrinopeptide A (FpA). CatL released little to no FpA 
(Fig 5-6B- middle), which corroborates SDS-PAGE (Fig 5-6A-middle) where a little 
amount of Aα chain was degraded. CatK and catS cleaved FpA. As time increased, more 
FpA was released by catK, but after 60 minutes there was a decrease in the amount of FpA 
(Fig 5-6B- left). By contrast, catS released the same amount of FpA over 2 hours (Fig 5-







































Figure 5-6: Cathepsins K, L, and S degrade the Aα and Bβ fibrinogen polypeptide 
chains, but only cathepsins K and S cleave fibrinopeptide A. 
(A) Samples were resolved in reduced SDS-PAGE. Cathepsin K degraded the Aα and Bβ 
polypeptide chains, and smaller molecular weight fragments were detected. Cathepsin L 
degraded the Aα polypeptide chain. Cathepsin S degraded the Aα and some of the Bβ 
polypeptide chain, and smaller molecular weight fragments. Overall, cathepsins K and S 
produced distinct banding patterns compared to each other, suggesting each cleaves 
fibrinogen at different polypeptide sites. (B) As time increased catK released more FpA, as 
determined by immunoblots. However, after an hour there was a decrease in FpA 
suggesting it was degraded by catK. CatL released FpA consistently as time increased.  
CatS released FpA, but had a consistent concentration of released FpA. Overall, cathepsin 
K, L, and S cleaved fibrinopeptide A. 
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5.3.7 E-64 reduced the amount of active cathepsins and fibrinopeptide A in plasma 
of mice with sickle cell anemia.  
 To determine if cysteine cathepsins were responsible for increased FpA, mice were 
injected daily with E-64, a small molecule, broad cathepsin inhibitor, from 1 month to 3 
months of age, to test the hypothesis that E-64 will inhibit catK, preventing its cleavage of 
fibrinogen to release FpA. Mice were treated with vehicle or E-64 from 1 to 3 months of 
age, and blood was collected and plasma was isolated 1 and 2 months post treatment. 
Multiplex cathepsin zymography was used to assess amounts of active cathepsins in 
plasma, and ELISA was used to quantify plasma concentrations of FpA. As early as 1 
month of E-64 treatment, there was a reduction in the amount of active cathepsins in SS 
mice, and 2 months post treatment, there was a significant decrease in active cathepsins 
(Fig 5-7A). There was no significant decrease in plasma FpA levels of E-64 treated SS 
mice (Fig 5-7B). However, when separated by sex, there was less FpA was in the male SS 
















Figure 5-7: E-64 reduced the amount of active cathepsins and fibrinopeptide A in mice 
with sickle cell anemia.  
AA, AS, and SS mice were injected daily with small molecule cathepsins inhibitor, E-64, 
from 1 month to 3 months of age. Blood was collected and plasma was isolated; multiplex 
cathepsin zymography and ELISA was used to assess the amount of active cathepsins and 
quantify fibrinopeptide A (FpA) in plasma. (A) There was significantly less (p=0.0003) 
active cathepsin in SS mice after 2 months of treatment. (B) Preliminary data suggested 
FpA in male (dashed-circle) SS mice is reduced with E-64. 
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5.3.8 People with sickle cell anemia have increased active cathepsins in their plasma 
People with SCA have 3x higher the amount of FpA compared to people without 
SCA; and FpA levels can be 5x as higher when people with SCA experience VOC [33, 39, 
193], however, to see if the cathepsin plasma levels the Townes mouse model was also 
observed in humans, zymography was done on AA and SS human plasma. There was more 
active cathepsin in SS human plasma compared to AA human plasma (Fig 5-8), which 














Figure 5-8: Plasma from people with sickle cell anemia had active cathepsins.  
Blood was collected from AA or SS donors, and plasma was isolated. Zymography was 
done to assess the amount of active cathepsins. (A) SS human plasma has more active 
cathepsins compared to AA human plasma. This corroborates data from the Townes mouse 
model. 
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 Discussion and Conclusions 
People with sickle cell anemia (SCA) experience chronic coagulation activation, 
evidenced by an increase in circulating FpA in plasma. The aim was to investigate if 
cathepsins were casual agents of this. Results showed that SCA mediates increased levels 
of active cathepsins in plasma of humanized mouse model and humans. Circulating plasma 
FpA in Townes humanized sickle transgenic mouse model was quantified, and there was 
elevated FpA in plasma of SS male mice at 3 months of age. Treatment with E-64 reduced 
the amount of active cathepsins in the plasma, accompanied by a reduction in FpA 
concentrations. Cleaving FpA from fibrinogen is the first step in fibrin polymerization; 
even though catK and catS released FpA, it did not include fibrin polymerization. This 
demonstrates the potential role upregulated cathepsins can play in coagulation where they 
have access to cleave fibrinogen. Collectively, our data implicates cathepsin-mediated 
fibrinogenolysis in SCA. 
Researchers are trying to identify how chronic coagulation activation in SCA 
contributes to pathophysiology and complications of the disease [33, 193]. It is unknown 
if chronic coagulation activation directly causes VOC or if it is an effect due to SCA [197]. 
Anticoagulant therapeutic approaches have not significantly helped prevent or treat VOC, 
further these types of treatments have hemorrhage and bleeding risks, which have limited 
their studies clinically [130]. People with SCA have increased plasma levels of FpA, which 
is considered a marker of increased thrombin generation and hypercoagulation. This 
increase in FpA is not solely due to thrombin cleaving fibrinogen, suggesting involvement 
of another protease [39]. Our lab has shown that inflammation of SCA causes increased 
amounts of catK, which has been implicated in SCA disease progression [40, 41]. 
Combined with our computational docking models of cathepsins on fibrinogen [42], it was 
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hypothesized that increased plasma levels of FpA in SCA is due to cysteine cathepsin 
activity, specifically catK, contributing to SCA hypercoagulation. 
Amounts of active cathepsins and FpA in plasma of Townes humanized sickle cell 
mouse model were quantified using wildtype (AA), sickle trait (AS), and sickle cell anemia 
(SS) genotypes. Mice were injected daily with E-64, cathepsin inhibitor, for 2 months to 
determine if cysteine cathepsins were the cause of increased FpA. Blood from mice was 
collected from untreated and E-64 treated mice after 1 and 2 months of treatment, and 
plasma was isolated. Multiplex cathepsin zymography was used to assess amounts of active 
cathepsins in plasma, and an ELISA was used to quantify the concentrations of FpA in the 
plasma. To determine cathepsin-mediated fibrinogenolysis mechanisms, experiments were 
done with recombinant fibrinogen and recombinant cathepsins K, L, and S. Turbidity 
analysis was conducted to see if cathepsins could polymerize fibrin, along with SDS-PAGE 
and immunoblots to see if the fibrin polypeptide chains were cleaved and if FpA was 
released.  
Mice with SCA had more active cathepsins in plasma than wild type and sickle. As 
SS mice age, there was an increase in active cathepsins from 1 to 3 months of age, 
demonstrating positive correlation between cathepsin upregulation and age. Collectively, 
this data suggests that elevated cathepsins in plasma is a manifestation of SCA 
pathophysiology, and the age-related increase in cathepsins could be biomarkers of disease 
progression. Interestingly, male SS mice have more active cathepsins compared to female 
SS mice, which may be associated with differences in how the disease presents itself in 
males compared to females, clinically. Specifically, it may be associated with females 
having less frequent and less severe sickle crisis episodes, as well as longer life spans [198]. 
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Active cathepsins in SS human plasma were increased, corroborating data from our 
humanized mouse model. The age and sex of human samples are unknown; however, this 
information can be requested when more samples are acquired in the future. Preliminary 
data suggests that there was no difference in FpA plasma amount in mice at 1 month in 
AA, AS, and SS mice, but there was an increase in FpA plasma of male SS mice at 3 
months. Not seeing a difference in FpA compared to zymography results suggests that it 
could take time for cathepsins, among other proteases, to start cleaving fibrinogen to 
release FpA.  Inhibiting cathepsins with E-64 not only reduced the active cathepsins in 
plasma, but also reduced cleaved circulating FpA that was seen previously elevated in SS 
male mice plasma.  Together, this demonstrated cathepsin-mediated fibrinogenolysis in 
SCA. 
Mouse models have been used to understand the etiology of coagulation in SCA. 
Approaches include treating mice with coagulation cascade factor inhibitors to generating 
mice with genetic modifications in their coagulation factors.  To test the relationship 
between sickle cell pathology and coagulation activation, plasminogen or fibrinogen 
deficient mice were crossed with sickle cell disease transgenic (SAD) mice; fibrin(ogen) 
helps maintain vascular integrity, tissue repair, and supports hemostasis under SCA 
conditions. However, the study focused on mortality; where fibrinogen deficient SAD mice 
had poorer survival outcomes likely due to bleeding related events [135]. Tissue factor, 
which triggers the extrinsic coagulation pathway, was targeted using TF-antibodies in the 
Berkley SCD mouse model. There was no effect on the anemic state, but coagulation 
activation and inflammation was reduced [136]. Mice treated with  a factor II antisense 
“gapmer” to reduce prothrombin, died early, and genetically modified prothrombin 
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deficient mice saw improvements in SCA-associated end organ damage and reduced 
coagulation activation, as evidenced by a decrease in D-dimers [139]. While this is a 
significant finding in a mouse model, a clinical trial using sevuparin, which inhibits 
prothrombin, failed clinical trials in 2019 after failing to improve vaso-occlusive crisis 
resolution time with no clinical benefits or improvements in patients [133]. The results 
presented in this current study differ from the aforementioned models in two key ways: (1) 
amount of active cathepsin plasma levels were quantified and (2) genetic modifications 
targeted the cathepsins in a sickle cell mouse model. Aside from quantifying active 
cathepsins in plasma, circulating FpA was also quantified, an approach yet to be seen in 
mouse models. This approach targets a protease, cysteine cathepsins, which are not the 
central proteases for blood clotting. 
The novel cathepsin K deficient mouse with sickle cell anemia provided more 
insight for identifying the cathepsin in the SS (Townes) mice. Previous results from our 
lab [40, 41] suggested that it was catK. However, there was still presence of active 
cathepsins in the SS catK-/- mice and little to none in the catK-/- control, meaning another 
cathepsin was present. Using inhibitors in the overnight assay buffers helped us identify 
that the active cathepsin was likely catK and catL. Normally, catL appears ~20kDa, 
however, as demonstrated in Chapter 3, catL can bind to fibrin and fibrin fragments. Seeing 
the active cathepsin band appearing at ~50kDa in SS plasma, suggests that catL could be 
bound to fibrin or some other plasma/coagulation protein, thus it would appear at a higher 
molecular weight. Perhaps this could be elucidated by injecting mice to target specific 
cathepsins, rather than a broad-spectrum inhibitor like E-64. 
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Co-incubating isolated fibrinogen and recombinant cat K, L, or S demonstrated that 
cathepsins do not cleave fibrinogen to polymerize fibrin. Thrombin and cat K, L, and S are 
all endopeptidases, meaning that their catalytic triad hydrolyzes peptides at internal peptide 
bonds. The main difference is the nucleophile group in the triad- serine for thrombin and 
cysteine for cathepsin [199, 200]. This supports the idea that cathepsins could cleave 
fibrinogen, and release FpA like thrombin can. In addition, our molecular docking models 
show that cat K, L, and S can bind to the central E domain where FpA is located [42]. 
However, catK and catS degrade the Aα and Bβ polypeptide chains of fibrinogen, and FpA 
was released and degraded over time. This suggests that cathepsins can cleave FpA, but 
eventually became destructive and degraded fibrinogen. Other proteases have been 
reported to only cleave FpA from fibrinogen. There is evidence of different types of snake 
venom that can cleave FpA from fibrinogen including, batroxobin (a serine protease from 
Bathrops atrox venom), arvin (snake venom isolated from Agkistrodon rhodostoma), and 
a coagulant serine proteinase from T. flavoroviridis venom [12]. This further supports that 
cat K, L, and S may only cleave FpA from fibrinogen and not result in fibrin 
polymerization. 
Mechanisms and kinetics of fibrin formation have been identified. When thrombin 
cleaves fibrinogen, FpA is released faster than FpB to initiate protofibril formation and 
longitudinal aggregation. Lateral aggregation of fibrin is mediated by FpB release, which 
occurs more slowly compared to FpA [201]. There is an opposite rate of release with 
okinaxobin, a serine protease, which cleaves FpA and FpB; okinaxobin releases FpB at a 
faster rate than FpA [12]. This demonstrates that proteases might differ in the mechanisms 
and kinetics of fibrinogen cleavage and subsequent fibrin formation. Although cat K, L, 
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and S did not cleave FpA and cause fibrin gelation, our data supports that catK and catS 
could generate more FpA. This is possible as cathepsin L from Fasciola hepatica, a type 
of snake, created a fibrin clot with different cleavage sites on the polypeptide chains 
fibrinogen compared to thrombin [12]. When fibrin is formed by FpA cleavage only, 
thinner fibrin networks are formed compared to fibrin networks formed by cleavage of both 
FpA and FpB [62]. These observations demonstrate mechanisms and kinetics for 
fibrinogen cleavage and release of FpA, supporting the hypothesis that cathepsin cleave 
and release FpA. Perhaps, this is what occurred with experiments where isolated fibrinogen 
was co-incubated with recombinant human cathepsin K, L, or S; a different type of fibrin 












CHAPTER 6   FIBRINOLYSIS MECHANISMS IN MONOCYTES 
AND SIMULATED SICKLE FIBRIN CLOT DEGRADATION 
 Introduction 
 People with sickle cell anemia (SCA) are in a chronic inflammatory state as 
evidenced by an increase in elevated leukocytes, pro-inflammatory cytokines such as TNF-
α, IL-8, and IL-17, endothelial damage, hemolysis (RBC rupture), increased reactive 
oxygen species production [202, 203]. Vaso-occlusive crisis (VOC) and hemolysis-
dependent endothelial cell (EC) activation and inflammation increase tissue factor 
expression which leads to coagulation activation. It was proposed that activation of 
coagulation creates a loop that enhances VOC, EC activation, and inflammation via 
thrombosis [203]. In other words, abnormal blood clots in SCA causes vessels and tissues 
around the clots to become inflamed, which trigger the presence of increased levels of 
circulating monocytes. There is interplay between coagulation and vascular inflammation 
in SCA, where RBC sickling results in vaso-occlusion mediated ischemia-reperfusion 
injury and hemolytic anemia, which can result in increased vascular inflammation and 
activation of coagulation [203].  
 SCA is also characterized by monocytosis, where there is an increase in monocytes 
and circulating polymorphonuclear neutrophils (PMNs) [110, 204]. Monocytes from 
people with SCA are more activated and express interleukin (IL)-1β and TNF-α [110]. 
Production of IL-1β and TNF-α increases endothelial surface receptors and facilitates 
monocyte and sickle RBC adherence to endothelium, which can lead to vascular damage 
[106, 110, 205]. When monocytes are cultured with ECs, E-selectin, (intracellular adhesion 
molecule) ICAM and vascular adhesion molecule (VCAM) expression are also induced 
[206], another mechanism that can facilitate RBCs binding to endothelium [207].  
 Microvascular thrombosis, which is also associated with inflammation, is another 
complication in SCA that contributes to pulmonary hypertension, osteonecrosis, and stroke 
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[208]. Although thrombosis and inflammation have been viewed as separate systems that 
complement each other, cross-talk between the two systems need to be taken into 
consideration, especially because inflammation can stimulate thrombosis and thrombosis 
can promote inflammation [209]. Thrombosis with associated inflammation 
(thromboinflammation) is defined as a pathophysiological response in vasculature after 
blood vessel injury followed by a non-infectious inflammatory response; it includes 
activation of the coagulation system and innate immunity response [210].  It is suggested 
that developing thrombotic vaso-occlusion is due to sickled erythrocytes getting stuck in 
vessels leading to EC damage and vascular injury triggering a thrombotic response [211, 
212].  Others also have hypothesized that mechanisms such as RBC adhesion, endothelial 
dysfunction, and leukocyte activation are contributors [208-210].  
 Our lab has demonstrated that SCA activates peripheral blood mononuclear cells 
(PBMCs), which includes mostly monocytes and lymphocytes, to induce cathepsin K 
activity in ECs. However, when PBMCs from AA controls were stimulated with TNF-α, 
catK activity was increased. Inflammation and activated circulating PBMCs upregulate 
cathepsin activity in SCA [40]. In Chapter 5, I demonstrated there is increased circulating 
cathepsins in SS mice and human plasma. Collectively, this data suggests elevated 
cathepsins can be a pathophysiological manifestation of SCA. This chapter contains 
preliminary work that investigates monocyte-mediated fibrinolysis, where I hypothesize 
that cathepsins secreted by monocytes are fibrin(ogen)olytic and can resolve fibrin gels. 
This work connects the coagulation pathway and inflammation, as potential mechanism 
that contributes to abhorrent clot resolution and thrombosis. 
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 Materials and Methods 
6.2.1 Multiplex Cathepsin Fibrinogen Zymography 
 THP-1 monocytes were lysed in zymography lysis buffer and BCA was used to 
quantify protein. Samples were prepared in non-reducing loading buffer. The same 
protocol from Section 5.2.4 was used.  
6.2.2 THP-1 Monocyte 2D Culture on Fibrin Gels 
 Fibrin gels were formed in 12 well plates by combining fibrinogen (2.5mg/mL) and 
thrombin (1U/mL), for 2 hours at 37oC. GFP-tagged THP-1 monocytes were seeded onto 
the fibrin gels at 200,000 cells per well, completely covering the gel, and incubated for 24 
hours. Before and after cells were added, plates were imaged using the ImageQuant LAS 
4000 to visualize fibrin gel degradation. Plates were also imaged using immunofluorescent 
imaging before and after incubation. Following a 24-hour incubation, the homogenate, 
containing remaining fibrin gel and monocytes, and supernatant, containing fragments 
released from fibrin gels insoluble fragments were saved and collected, and reduced SDS-
PAGE was used to quantify fibrin degradation following the protocol described in section 
3.2.4. 
6.2.3 Degradation of Fibrin Clots Embedded with RBCs from AS and SS Mice 
 Simulated sickle fibrin clots were made with fibrinogen (5 mg/mL), thrombin 
(1U/mL), and RBCs from AS and SS mice (1% or 10%) in 50mM Tris-HCl/100mM NaCl, 
at a concentration of 2.5 mg/mL and 1 NIH U/mL in a final volume of 100 µl, then 
incubated for 2 hours at 37°C. Cathepsins K or S (0.15ng) were added and degraded RBC-
fibrin clots overnight. The supernatant, which should contain any released fibrin fragments, 
was collected and saved, and the homogenate, which contains fibrin gel and monocytes, 
was resuspended in Tris-HCl with 25% beta-mercaptoethanol and sonicated to solubilize 
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it. Both supernatant and pellet were prepped for reduced SDS-PAGE, to assess fibrin 
degradation using the protocols described in section 3.2.4. 
 Results 
6.3.1 Monocytes secrete cathepsins with fibrinogenolytic properties 
To test if monocytes secrete cathepsins with fibrin(ogen)olytic potential, multiplex 
cathepsin fibrinogen zymography was used to assess the amount of active cathepsin in 
THP-1 monocytes. Increasing amounts of THP-1 monocytes were resolved in fibrinogen 
zymography and gelatin zymography was used as a control, as gelatin is the baseline 
substrate for the cathepsins (Fig. 6-1). Cathepsins from the THP-1 monocytes, degraded 
the fibrinogen substrate. The amount of active cathepsins in the zymograms increased in a 
dose-dependent manner and was quantified using densitometry. In the fibrinogen 
zymogram, active cathepsins were observed between 50 and 75 kDa, however, in the 
gelatin zymogram, active cathepsins were observed at ~25kDa. This indicates that the 


































Figure 6-1: Fibrinogenolytic activity of cathepsins secreted by THP-1 monocytes 
Multiplex cathepsin zymography assessed proteolytic activity of cathepsins secreted by 
monocytes using (A) fibrinogen substrate and (B) gelatin substrate. As the amount of 
monocytes added increases, the amount of active cathepsins increases as quantified using 
densitometry. The active cathepsin in the fibrinogen zymogram appeared at a higher 
molecular size compared to the gelatin control zymogram. This suggests a binding 
interaction between cathepsins and fibrinogen that prevents the cathepsins from migrating 
further through the gel. 
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6.3.2 Monocytes migrate into and degrade fibrin gels in 24 hours. 
 To test the hypothesis that monocytes could degrade fibrin gels, THP-1 monocytes 
transduced to express GFP were co-cultured with fibrin gels overnight. Plates were imaged 
using fluorescence imaging before and after to assess monocyte migration into the fibrin 
gel. In plates with fibrin gel and monocytes there was less fluorescence at 24 hours, as 
indicated by a decrease in fluorescence (Fig 6-2A). However, there was little to no change 
in fluorescence in plates with monocytes only (Fig 6-2B). This suggests that the monocytes 
co-cultured on fibrin gels migrated into the fibrin. Fibrin gels were imaged before and after 
degradation to visualize bulk fibrin degradation, similar to what was described in Chapter 
3. In the co-culture of monocytes and fibrin gel, fibrin was degraded compared to the fibrin 
only control group (Fig 6-2D). Together, this suggests that as monocytes degraded the 















Figure 6-2: Monocytes migrate into and degrade fibrin gels 
Fibrin gels were made using fibrinogen and thrombin in 12 well plates, and GFP tagged  
THP-1 monocytes were seeded on top of the gels for 24 hours. (A) Less fluorescence was 
observed in the THP-1s seeded on fibrin gels, compared (B) to the monocyte only (no fibrin 
gel) control.  This suggests migration of the monocytes into the fibrin gels. Bulk fibrin 
degradation was also visualized. (C) At 24 hours, fibrin gel degradation (white arrows) was 
seen in the monocyte-fibrin gel co-culture, which could be compared (D) to the monocyte 
only (no fibrin gel) conditions.  
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6.3.3 Monocytes degrade the α and β fibrin polypeptide chains 
 To assess degradation of fibrin polypeptide chains, the homogenate, which 
contained monocytes and any remaining fibrin gel, was resolved in reducing SDS-PAGE. 
There was significantly less α polypeptide chain in monocytes seeded on a fibrin gel 
compared to fibrin only (p=0.001, n=3, Fig 6-3). However, there was significantly more β 
polypeptide chain present (Fig 6-3), suggesting that higher molecular size α polypeptide 
chains were degraded, giving more insight into possible cleavage sites. Proteins were also 
detected in the supernatant, and based on their molecular size (ranging from 50 to 75kDa) 

























Figure 6-3: Monocytes degrade the alpha chain of fibrin gels within 24 hours. 
As described in methods, fibrinogen and thrombin were combined to form fibrin gels and 
GFP tagged monocytes were seeded on top of the gels. Reduced SDS-PAGE was run to 
assess for fibrin degradation, and the α, β and γ polypeptide chains show partial fibrin 
degradation. Within 24 hours, monocytes degraded the alpha chain of fibrin, initializing 
fibrin degradation, but did not progress to degrade the beta and gamma bands of fibrin. 
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6.3.4 Degradation of RBC-fibrin clots with recombinant cathepsins   
 In vitro fibrin clots and thrombi also contain red blood cells (RBCs), which alter 
fibrin network structure and mechanical properties. RBCs incorporate into spaces between 
fibrin fibers which disrupt the network increasing the pore size and increases blood 
viscosity [213]. Clot mechanical properties are influenced by RBCs due to high 
deformability of RBCs [214, 215]. When fibrin clots had a RBC concentration of 10%, 
elastic and viscous moduli peaked, but then as more RBCs were added viscoelastic 
properties of RBCs dominate. One must also consider differences in SS RBCs mechanics; 
SS RBCs are less deformable [216] and the Young’s modulus is stiffer compared to AA 
RBCs [217].   
 The effect of RBCs on fibrin structure should be considered in future cathepsin-
mediated fibrinolysis studies. This would suggest that incorporation of SS RBCs alters 
fibrin network structure and mechanics which could impact fibrinolysis. I have done some 
preliminary work creating fibrin clots embedded with 1% or 10% of AS or SS RBCs, which 
were then degraded with recombinant cathepsin K or S (Fig 6-4A). Cathepsins K and S 
degraded AS RBC- fibrin clots (Fig 6-4B, Fig 6-4D) and SS RBC fibrin-clots (Fig 6-4C, 
Fig 6-4E) producing lower molecular size fragments in the pellet. There is degradation of 
α  polypeptide chain, however proteins appear in the supernatant, which are hypothesized 
to be fibrin fragments that were released from the fibrin gel by proteolytic cleavage. As the 
amount of AS or SS RBC increased from 0% to 10% there was an increase in the amount 
of fibrin fragments at lower molecular sizes. The banding patterns of the lower molecular 
size fibrin fragments differ between cathepsin K and S, but also there is a difference in 
banding patterns between AS and SS clots, indicating cathepsins cleaving fibrin at different 




Figure 6-4: Cathepsins K and S degrade fibrin gels embedded with AS and SS, with 
distinct banding patterns. 
(A) Stimulated clots were made with fibrin gel embedded with 1% or 10% AS or SS red 
blood cells (n=1). (B,C) Cathepsin K or (D,E) cathepsin S degraded stimulated AS or SS 
clots and produce different banding patterns, suggesting that each cathepsins cleave fibrin 
at different sites.  
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 Discussion and Conclusions 
 Monocytes secrete cathepsins with fibrinolytic properties, demonstrating a 
potential mechanism in fibrinolysis. Using modified multiplex cathepsin zymography, I 
demonstrated fibrinogenolytic activity of cathepsins. Next, THP-1 monocytes were co-
cultured on fibrin gels for 24 hours, where I demonstrated that monocytes migrate through 
and degrade fibrin gels. Further investigation using reducing SDS-PAGE, identified that 
the polypeptide chains of fibrin were degraded and released products into supernatant. 
Overall, this demonstrates cathepsin-mediated fibrin(ogen)olysis in vitro and suggests that 
monocytes could play a role in aberrant blood clot resolution.   
 Noticeably, there was a difference in the electrophoretic migration distance of 
active cathepsins in fibrinogen zymogram compared to gelatin zymogram; 50-75kDa and 
25kDa, respectively. This is similar to what was observed in Chapter 5 (Fig 5-4) with 
recombinant catK in a fibrinogen zymogram appearing at a higher molecular size than 
expected. In Chapter 3, I demonstrated that catL adsorbs to fibrin (Fig 3-1C and Fig 3-5B). 
Interestingly, the cathepsin electrophoretic migration distance in the fibrinogen zymogram 
is the same molecular size that catL adsorbed to fibrin. This suggests the cathepsins are 
binding to the fibrinogen substrate in the zymogram. Together, this led me to consider that 
cysteine cathepsins can act in a similar manner to matricellular proteins on fibrin(ogen). 
Matricellular proteins are non-structural proteins that are secreted into the extracellular 
environment, interacting with cell-surface receptors, proteases, and cytokines [218]. The 
CCN (Cyr-61, connective tissue growth factor, and Nov) family of cysteine-rich 
matricellular proteins, is an ECM protein involved in intercellular signaling by modulating 
growth factors such as TNFα. TGF-β, and VEGF; specifically, CCN1 engages cell surface 
receptors, with emerging roles in wound healing, inflammation, and vascular disease [219]. 
ADAMTs (A disintegrin-like and metalloprotease with thrombospondin motif), are another 
family of matricellular proteases that play roles in cell migration, tissue organization, 
coagulation, inflammation, and angiogenesis where they are proteolytically active on cell-
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surfaces [220]. I hypothesize that cathepsins bind to fibrinogen as they migrate through the 
gel, and the electrophoretic force cannot overcome the strong interaction between 
cathepsins and fibrinogen, thus the cathepsins do not migrate through the gel to its expected 
molecular size. Collectively, this evidence suggests cysteine cathepsins could act as 
matricellular proteases.  
 There was accumulation of the β polypeptide chain, as well as degradation of the α 
chain, which could suggest cathepsins degraded the α polypeptide chain into fragments that 
are approximately the same size as the β polypeptide chain (Fig 6-3). These results can be 
compared to work from Chapter 3 with the recombinant cat K, L, and S. The α chain is 
degraded by all three cathepsins, however only catK and catS degraded both α and β chain. 
Compared to recombinant studies, little to no fibrin fragments were observed in the 
supernatant. Also, there were no fibrin fragments below 50kDa in the PAGE for the 
homogenate compared to what was observed in Fig 3-7. Future work could consider doing 
a time course, where degradation is stopped a different time points, to see if fragments are 
generated at earlier time points and degraded over time.  
 Plasmin is the canonical protease that degrades fibrin, however, evidence suggests 
fibrinolysis in plasminogen activator-deficient transgenic mice occur via non-plasmin 
pathway [71, 72]. Cathepsins, secreted by monocytes, are in close proximity to fibrinogen, 
providing easy access for cathepsins to cleave fibrinogen in vasculature. This leads to the 
hypothesis that monocytes could play a supporting role in degrading fibrin. Even in the 
absence of plasmin, monocytes can internalize fibrin via Mac-1 integrin and degrade fibrin, 
resulting in a fibrin degradation pattern unique from plasmin [11]. Using chloroquine, 
which prevents endosomal acidification inhibiting lysosomal enzymes, it was concluded 
that fibrin degradation occurs in lysosomes of macrophages. Later, using protease 
inhibitors, including serine inhibitors and lysosomal cysteine inhibitors (including E-64d) 
determined that fibrin degradation was not blocked. However, with pepstatin A, an aspartyl 
protease inhibitor, inhibited fibrin degradation, leading to the identification of cathepsin D 
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as a fibrin(ogen)olytic protease [10].  I should note that this work was done in 1993 and 
1994, when cysteine cathepsins were mostly thought of as lysosomal proteases.  However, 
now extracellular function of cathepsins are being explored and more cathepsin-specific 
inhibitors have been identified, which could help us uncover mechanisms of non-plasmin 
fibrin degradation via monocytes. Our work demonstrated that active cysteine cathepsins 
are fibrin(ogen)olytic (Fig 6-1 and Fig 6-2) and future work should repeat these 
experiments using E-64 to target non-lysosomal cysteine proteases to further elucidate the 
role of cysteine cathepsins in degrading fibrin via monocytes. Monocytes would be seeded 
on fibrin gels, with E-64 added to the media, and fibrin degradation would be quantified 
using the methods described above.  
 This work demonstrates how two factors involved in the coagulation cascade and 
inflammatory pathway, fibrin and monocytes, could interact with each other.  
Thromboinflammation (thrombosis with associated inflammation) and microvascular 
thrombosis and their mechanisms warrant further studies in SCA. The interplay between 
coagulation and inflammation in SCA needs to be characterized, which could help provide 
better treatment for patients to prevent complications.  Work in this chapter demonstrates 
that monocytes could secrete cysteine cathepsins with fibrin(ogen)olytic properties. Future 
studies should make the in vitro system more physiologically relevant by seeding an EC 
monolayer on top of fibrin gels, with the addition of PBMCs on top.  
 One must also consider using fibrin clots that are more physiologically relevant by 
adding RBCs to fibrin gels. Fibrin clots with RBCs from people with SCA are denser where 
RBCs aggregate and agglomerate fibrin networks. and displayed aggregation of the RBCs 
and agglomerated fibrin clusters [221]. Preliminary work simulated clots by embedding 
RBCs from AS or SS mice in fibrin gels that were degraded with cathepsin K or S (Fig 6-
4). Distinct banding patterns of fibrin fragments corroborated findings in Chapter 3 where 
it was demonstrated that cathepsins K and S have unique fibrinolytic properties, suggesting 
that each cathepsin cleaves fibrin at unique cleavage sites. Our work identified fibrin 
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degradation products, however, future work could quantify fibrinolysis rate to see if 
cathepsins lyse fibrin faster and identify if fibrin clots with SS RBCs degrade at different 
rates compared to fibrin clots with AA RBCs. I hypothesize that given the altered structure 
of SS RBCS, lysis rates would be slower. Studies have identified that clot lysis rates are 
significantly lower in glycated clots from diabetic patients compared to controls [222, 223]. 
Future work could use similar methods with confocal microscopy [223] not only to 
measure fibrinolysis rates, but also to image fibrin clots with RBCs from people with SCA. 
Collectively, techniques presented in this chapter could be leveraged and combined to 

















CHAPTER 7  QUANTIFYING PROTEOLYTIC ACTIVITY OF 
SPECIALIZED ENDOTHELIAL CELLS FROM EMBRYONIC 
STEM CELLS                                               
Data from this chapter was published: Madfis, Lin, Kuma, Douglas SA. et al. (2018) “Co-
Emergence of Specialized Endothelial Cells from Embryonic Stem Cells.” Stem Cells and 
Development. 27(5)326-335 doi: 10.1089/scd.2017.0205. 
 Introduction 
 The endothelium layer forms the innermost layer of vessels and has a number of 
functions including regulation of vascular tone and structure integrity of vessels, immune 
cell responses, and blood clotting factors [224]. There is EC heterogeneity, where ECs can 
be distinguished based on phenotype, morphology, and function which vary based on their 
anatomical location in different tissue types and organs [225]. For example, ECs lining 
arteries are oriented longitudinally aligned in the direction of blood flow [226]. ECs of 
arteries and veins are continuous with tight junctions, whereas discontinuous layers are 
present in organs involved in filtration and secretion such as gastric and intestinal mucosa 
or glomeruli in kidneys [225]. Differences in EC function can be observed with EC 
permeability; constitutive flow between blood and tissue occurs via capillaries, and 
macromolecules can be transferred through the cells via endocytosis and exocytosis, or 
smaller solutes and fluids can transfer between cell-cell junctions [225, 226].  
 Structural and functional EC heterogeneity is also observed within a sprouting 
blood vessel during angiogenesis [226]. The leading edge of the sprouting vessel or “tip” 
ECs have more probing filopodia, and migrate toward the angiogenic stimulus [227], 
however they tip ECs do not proliferate of form lumen [227-229]. “Stalk” ECs are behind 
the tip ECs and more proliferative, form lumen, produce more ECM, and have shorter 
filopodia [230]. Another EC subphenotype, “phalanx EC” are non-sprouting, and less 
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migratory and proliferative Initially it was thought during sprouting there is plasticity and 
reversibility between the tip, stalk, and phalanx phenotypes. However, using staged 
differentiation and chemically specific media, distinct tip/stalk (Fig 7-1A) and phalanx (Fig 
7-1B) cell types have been cultured and expanded for up to 9-10 passages, where the 
tip/stalk ECs are more migratory and proliferative, with increased angiogenic-like 
sprouting on MatrigelTM compared to phalanx [231]. 
 As discussed in Chapter 4, proteolytic activity facilitates angiogenesis aiding in EC 
migration and ECM remodeling. Matrix metalloproteinases (MMPs) aid in vascular 
remodeling by degrading ECM and basement membrane which facilitates EC migration 
and invasion, and sprout formation [19, 166, 232]. Cathepsins (cat) K, L, and S have been 
identified in ECs and are upregulated by ECs in areas of disturbed flow [28]. To further 
characterize the migratory ability of the sub-populations, we wanted to know what enzymes 
were responsible for differences in sprouting activity within the ECs. Here the amount of 
active proteolytic enzymes of tip/stalk and phalanx ECs was quantified, with the hypothesis 
that the more migratory tip/stalk ECs would have increased proteolytic activity compared 




Figure 7-1: Tip/stalk and phalanx endothelial cells 
Endothelial cell (EC) subtypes have heterogeneity with differences between phenotype 
and morphology. (A) Tip/stalk phalanx ECs are more migratory and proliferative, 
characterized by an elongated appearance. (B) Phalanx ECs have a “cobblestone” like 
morphology are less migratory and proliferative. 
 
Adapted from Madfis et al. Stem Cells and Development 2018 
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 Materials and Methods 
7.2.1 Multiplex Gelatin Cathepsin and MMP Zymography 
 Tip/stalk and phalanx EC were lysed in zymography lysis buffer and total protein 
concentrations were quantified. Equal amounts of lysate were loaded for matrix 
metalloproteinase (MMP) or cathepsin zymography, as previously described [148, 233]. 
Zymograms were imaged using an ImageQuant LAS 4000 (GE Healthcare), and 
densitometry was performed with ImageJ (NIH) to quantify cleared white bands, indicative 
of proteolytic activity. 
 Results 
7.3.1 MMP2 activity was significantly increased in tip/stalk ECs compared to 
phalanx ECs 
 MMP zymography was done on cell lysates from tip/stalk and phalanx ECs, to 
determine differences in active amounts of proteolytic enzymes between the two EC 
subphenotypes (Fig 7-2). There was significantly more active mature MMP2 in the 
sprouting tip/stalk-containing EC compared with phalanx EC. However, the phalanx ECs 
contained significantly more pro-MMP2, the inactive zymogen form that must be cleaved 
to be active. This shows differences in proteolytic activity, where more mature MMP which 

































Figure 7-2: MMP proteolytic activity in tip/stalk and phalanx endothelial cells 
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7.3.2 Active cathepsin L was identified in tip/stalk and phalanx ECs 
 Both EC subtypes have increased amounts of active cathepsins. In the zymogram 
incubated at pH4, more catL activity was quantified in tip/stalk ECs (Fig 7-3A). This was 
corroborated in the zymograms incubated at pH 6 by the 20 kDa cathepsin band being 
significantly higher in the tip/stalk EC, while the 15 and 22 kDa fragments were only found 
in the phalanx EC (Fig 7-3B). Thus, increased active cathepsins are associated with 
























 Discussion and Conclusions 
 These results show distinct proteolytic activity in sprouting (tip/stalk) and non-
sprouting (phalanx) EC subtypes. The more invasive and migratory EC subphenotype, 
tip/stalk ECs had increased MMP2 activity and catL which corroborates the sprouting 
characteristic. The invasive behaviors of sprouting ECs is thought to be regulated by 
different pathways.  For example, MMP2 is activated by ADAM17 during angiogenesis 
[234], and overexpression of ADAM17 reduces antiangiogenic molecular expression 
[235], which could contribute to the invasiveness of sprouting ECs [236]. Guanylate 
binding protein-1 GTPase inhibits MMP1expression, which reduces the invasiveness and 
tube formation of ECs [237], suggesting a role for MMP1 in angiogenesis. CatL is more 
upregulated in endothelial progenitor cells compared to mature ECs, and has been 
associated with invasion and neovascularization [3, 83]. In humans, an increase in 
angiogenic EC behaviors has been associated with catL but the mechanism yet to be 
determined [84]. 
 Tip/stalk and phalanx ECs are derived from mice, which means the cathepsins 
identified in the tip/stalk and phalanx ECs is specifically mouse catL, which is the ortholog 
for human catV; they share 75% sequence identity yet have different levels of expression 
and functions[3]. When incubated at pH4, mouse catL was higher in phalanx ECs 
compared to tip/stalk ECs, which could suggest mouse catL is multifunctional depending 
on the EC subphenotype. However, this angiogenic shift controlling catL activity in ECs 
is not clear and warrants further studies. I think this is a good opportunity to use these 
specialized ECs in the microvascular networks, where ECs could form via a vasculogenic-
like process and cathepsin inhibitors could be added to identify the role of cathepsins 
during formation. Further, using tip/stalk and phalanx ECs is more physiologically accurate 
compared to HUVECs for studying angiogenesis, due to the more invasive and migratory 
phenotypes. It has been suggested that HUVECs would be better suited for studying 
atherosclerosis and lining small diameter vascular grafts.  
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 Overall, cathepsins and MMPs are involved in the sprouting behavior of tip/stalk 
ECs, which could be associated with its migratory and invasive characteristics, likely 
contributing to the angiogenic pathway. Distinct proteolytic activity profiles for sprouting 
versus non-sprouting ECs supports the EC subpopulations are regulated differently which 
motivates future work to understand how proteases contribute to the invasiveness and 



















CHAPTER 8  PACMANS ANALYSIS OF CATHEPSINS               
K, L, AND S ON PLASMINOGEN  
 Introduction 
 Cysteine cathepsins are elevated in the plasma of SS mice, where they have access 
to the coagulation factors that could become substrates for the cathepsins. This mechanism 
could contribute to chronic coagulation activation where the cysteine cathepsins compete 
and interfere with the natural coagulation factors, such as plasminogen- the inactive, 
zymogen form of the serine protease, plasmin. The structure of plasminogen includes five 
kringle domains (denoted as K1, K2, etc.). Although the exact role of kringle domains is 
not clear, they are present in blood plasma, specifically in coagulation factors, proteases, 
apolipoprotein, and growth factors [238]. Kringle domain sequences differ, yet structures 
are highly conserved. They  contain surface-exposed loops, comprised of ~80 amino acids 
stabilized by three disulfide bonds (Fig 8-1) [239, 240]. Single or multiple kringle domains 
of plasminogen bind to membranes and other proteins, which inhibit endothelial cell 
proliferation, tube formation, and angiogenesis [240].  
 Plasminogen contains a disulfide bond, C558–C566, surrounding the activation site 
at R561–V562 [241] . Tissue plasminogen activator (tPA) is the canonical enzyme that 
cleaves plasminogen at the R561 and V562 bond generating a two chain-plasmin, a heavy 
chain that contains the five kringle domains, and a light chain that contains the catalytic 
domain [241, 242]. Angiostatin, the fragment of plasminogen that contains the first 4 
kringle domains, are potent inhibitors of angiogenesis by inhibits endothelial cell (EC) 
proliferation and migration. Plasminogen is cleaved to form angiostatin by numerous 
proposed mechanisms, including cleavage by MMPs- 2, 3, 7, and 9, [240, 243]. Cleavage 
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by different proteases suggests that there are several angiostatin isoforms or angiostatin-
related proteins formed under different physiological conditions. There is evidence of 
cysteine cathepsins hydrolyzing plasminogen. Plasminogen cleavage by cathepsin V 
(catV), releases angiostatin-like products which inhibit angiogenesis. However, cathepsins 
K and L (catK and catL), did not generate angiostatin-like products [244], and although 
cathepsin S (catS) can cleave plasminogen, the released fragments do not inhibit 
angiogenesis on ECs [245]. 
 Here, I analyzed the likelihood of cathepsins K, L, or S binding to plasmin(ogen) 
with bioinformatics site sequence specificity analysis. To do this, I used the lab’s 
previously published PACMANS: Protease‐Ase Cleavages from MEROPS ANalyzed 
Specificities program [246], which identifies putative sites on substrates highly susceptible 
to cleavage by proteases using a sliding‐window approach to score amino acid sequences 
based on preference in the active site of the protease taken from the MEROPS database. 
These sequences were then mapped to kringle domains, light chain, and near known 
proteolytic cleavage sites on a plasminogen sequence. 
 Materials and Methods 
8.2.1 PACMANs Analysis  
 PACMANs program accessed from: https://platt.gatech.edu/PACMANSuse/form 
and previously published [246]. The substrate input was plasminogen, which was accessed 
from UniProt, and protease-ase input was cathepsins K, L, or S, which were each accessed 
from the MEROPS database, with a pocket size upper bound 1 and lower bound 8. The 
higher the cumulative score, the greater the likelihood cleavage occurs; normalized scores 
are used to compare among the analyzed cathepsins on plasminogen. 
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8.2.2 Determining Kringle Domain and Known Protease Cleavage Site Sequences 
on Plasminogen 
 The kringle domains (K1, K2, K3, K4, and K5) amino acid sequences were 
determined based on the structure of plasminogen previously published [247], where 
sequences are from cysteine residues (C-C) at the base of the loop (denoted by the colored 
lines and circles in Fig 8-1).  Known cleavage sites for elastase, aureus V8 protease, and 
R561-V562 (site that gets cleaved to generate plasmin) were also determined from the 
plasminogen figure (circled in black in Fig 8-1). It should be noted that the structure is 
missing the first 20 amino acid sequences, and the sequence numbers used in PACMANS 
align with the sites/numbers for the plasminogen site sequence in UniProt. These 
differences had to be taken into consideration to identify sequences from PACMANS on 






























Figure 8-1: Kringle Domain and Known Protease Cleavage Sites on Plasminogen 
 
Figure adapted from Soff et al. Cancer and Metastasis Review. 2000. 
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 Results 
8.3.1 Likelihood of plasminogen cleavage by cathepsin K 
 There were 12 top ranked PACMANS sequences in the kringle domains and 3 top 
ranked sequences in the light chain (Fig 8-2, Table 8-1). Based on the score, the sequences 
in the K3 domain at #274-281 QCLK/GTGE was the most likely location for cleavage by 
catK (scored at 0.934). The next top scored sequences were in the K1 domain at #177-184 
DILE/CEEE (scored at 0.922), which was four residues shifted from the known cleavage 
site for aureus V8 protease (CEEE/CMHC). There were other top scores of catK on 
plasminogen where cleavage sites were located in the light chain of plasmin: #667-674 
(ALLK/LSSP) scored at 0.901, #747-754 (GHLA/GGTD), and #713-720 (AGLL/KEAQ). 
Closer analysis of other top scored likely cleavage sites revealed there were possible 
cleavage sites near known elastase sites: #360-367 (EQLA/PTAP) was six residues away 
from elastase 2 (SSPV/STEQ) with a score of 0.771, #91-98 (VVLF/EKKV) was four 
residues away from elastase 1 (ESLY/VKKE) with a score of 0.763, #368-375 
(PELT/PVVQ) was three residues away from elastase 3 (LTPV/VQDC) with a score of 
0.735, and #98-105 (VYLS/ECKT) was two residues away from elastase 1 (ESLY/VKKE) 

















Figure 8-2: Top scored likely locations for cathepsin K cleaving plasminogen 
Sites identified on plasminogen within kringle domains and near known protease cleavage 
sites (elastase, aureus V8 protease, pepsin, or cleavage site that generates plasmin).  
 
Figure adapted from Soff et al. Cancer and Metastasis Review. 2000. 
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8.3.2 Likelihood of plasminogen cleavage by cathepsin L 
 There were 7 top ranked PACMANS sequences in the kringle domains and 3 on 
the light chains for catL on plasminogen (Fig 8-3, Table 8-2). The highest score (0.96) of 
catL on plasminogen was at #667-674 (ALLK/LSSP), which is located in the light chain 
of plasmin. Two other high scores were located in the light chain, as well #669-676 
(LKLS/SPAV) and #635-642 (VILG/AHQE) with scores of 0.891 and 0.862, respectively. 
Similar to catK, catL also had a top scored sequence in the K1 domain at #177-184 
DILE/CEEE, however it scored lower at 0.776. CatL was also the only cathepsin that had 
a top score (0.709) at #580-587 RVVG/GCVA and is within 3 residue shifts of the Arg-
Val site that is cleaved to generate plasmin.  Sequence #362-369 (LAPT/APPE) with a 
score of 0.728 was unique in that it is between elastase 2 and elastase 3. Other top scored 
likely cleavage sites, revealed close residue shifts near other elastases; #459-466 
(ASVV/APPP) was two residues away from elastase 4 (GTEA/SVVA) with a score of 
0.923, #360-367 (EQLA/PTAP) was six residues away from elastase 2 (SSPV/STEQ) with 
a score of 0.812, and #460-467 (SVVA/PPPV) was four residues away from elastase 4 

















Figure 8-3: Top scored likely locations for cathepsin L cleaving plasminogen 
Sites identified on plasminogen within kringle domains and near known protease cleavage 
sites (elastase, aureus V8 protease, pepsin, or cleavage site that generates plasmin). 
 
Figure adapted from Soff et al. Cancer and Metastasis Review. 2000. 
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8.3.3 Likelihood of plasminogen cleavage by cathepsin S 
 There were 6 top ranked PACMANS sequences in the kringle domains and 4 on 
the light chains for catS on plasminogen (Fig 8-4). Similar to catL, the highest score (0.996) 
of catS on plasminogen was at #667-674 ALLK/LSSP, located in the light chain of 
plasmin.  Other light chain sequences included #714-721 GLLK/EAQL, #635-642 
VILG/AHQE, and #669-676 LKLS/SPAV with scores of 0.924, 0.917, and 0.912, 
respectively. CatS also had a top scored sequence in the K1 domain at #177-184 
DILE/CEEE, however it scored lower at 0.836. Similar to catK and catL, there were also 
top scores for catS cleavage on plasminogen near known elastase cleave sites. There was a 
top score at #360-367 (EQLA/PTAP) that was six residues away from elastase 2 
(SSPV/STEQ) with a score of 0.844. Like catK, catS had a top score at #368-375 
(PELT/PVVQ) that was three residues away from elastase 3 (LTPV/VQDC) with a score 
of 0.759. There was overlap of sequences near elastase 4: #459-466 (ASVV/APPP), #465-



















Figure 8-4: Top scored likely locations for cathepsin S cleaving plasminogen 
Sites identified on plasminogen within kringle domains and near known protease cleavage 
sites (elastase, aureus V8 protease, pepsin, or cleavage site that generates plasmin).  
 
Figure adapted from Soff et al. Cancer and Metastasis Review. 2000. 
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8.3.4 Comparing plasminogen cleavage by cathepsins K, L, and S to cathepsin V 
 It has been previously reported that catV cleaves plasminogen and produces 
angiostatin-like products, unlike catK, L, and S [244, 245]. PACMANS identifies the 
putative site of a protease on a substrate, scoring the likelihood of a protease cleaving at a 
specific amino acid sequence. The higher the score, the more likely the cleavage event, and 
normalized scores allows for comparison between the different cathepsins on the same 
substrate [42, 246]. I hypothesized that the top score cleavage sites for catV on 
plasminogen would be higher than that of catK, L, and S on plasminogen. To test this, I 
ran PACMANS analysis with catV as the protease-ase and plasminogen as the substrate 
(Fig 8-5, Table 8-4) and compared it to the results for catK, L, or S (Appendix Table A-6). 
Interestingly, the highest score for catV was 0.914 at #667-674 ALLK/LSSP in the light 
chain; this sequence also overlapped with catK, L, and S with scores of 0.902, 0.96, and 
0.996, respectively. Thus, catL and catS had higher scores than catV for this sequence. 
Another sequence that overlapped was #274-281 QCLK/GTGE where some of the scores 
were higher than catV; scores included 0.934 for catK, 0.864 for catL, 0.934 for catS, and 
0.884 for catV. These scores are normalized so they could be compared between different 
cathepsins; the higher the score the higher the likelihood of cleavage at that site. The 
highest scores for catK, L, and S were 0.934, 0.96, and 0.996, respectively and all of these 
high scores overlapped with the highest scores for catV. These computational predictions 
suggest that further experiments are warranted to study the mechanisms behind 






Figure 8-5: Top scored likely locations for cathepsin V cleaving plasminogen 
Sites identified on plasminogen within kringle domains and near known protease cleavage 
sites (elastase, aureus V8 protease, pepsin, or cleavage site that generates plasmin).  
 
Figure adapted from Soff et al. Cancer and Metastasis Review. 2000. 
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 Discussion and Conclusion 
 Cleavage of plasminogen at various sites can generate angiostatin isoforms or 
angiostatin-related proteins forms. Plasmin is cleaved into two chains; the heavy chain that 
contains the kringle domains and light chain with catalytic domain that degrades fibrin. 
Here, I computationally analyzed the likelihood of cathepsins K, L, and S cleavage sites 
on plasminogen using bioinformatics cleavage site predictions. The sequences from the 
PACMANS analysis were then identified on plasminogen sequences with respect to the 
locations within kringle domains, light chains, and known cleavage sites for elastase. 
 Cysteine cathepsins showed preference for cleaving sequences within the kringle 
domains and had potential cleavage sites within two to six residues of known elastase 
cleavage sites on plasminogen. Cleavage at various sites within the kringle domain of 
plasminogen could release angiostatin-like products or isoforms [240, 243], and elastase 
cleaves plasminogen is an alternative pathway to generate angiostatin and inhibit 
fibrinolysis [248, 249]. I hypothesize that cathepsins could also cleave plasminogen and 
generate angiostatin-like products in a similar manner. It has been shown previously that 
catV does not produce active plasmin, rather it cleaves plasminogen producing fragments 
with anti-angiogenic properties, however, catK and catL do not degrade plasminogen 
[244]. The protocol co-incubated plasminogen and catK, L, or V for 1 hour using 30nM of 
catK or catL with 4.5µM of plasminogen. However, based on computational predictions, I 
would not completely rule out that catK, L, and S cannot hydrolyze plasminogen, 
especially considering catK, L, and S had higher top scores compared to catV (Appendix 
Table A-6). Future experiments could use isolated plasminogen and recombinant 
cathepsins in increasing concentrations and varying degradation time, to see if there is a 
threshold amount of cysteine cathepsins and time to degrade plasminogen. I propose this, 
because of evidence where low concentrations of papain can generate fibrin clots from 
fibrinogen, but higher concentrations degrade fibrin [195]. I hypothesize that catK, L, or S 
could cleave plasminogen within kringle domains, which could generate isoforms or 
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“kringle-like” domains, and new properties could emerge which could interfere with the 
naturally occurring coagulation factors.   
 CatK, L, and S also showed preferential cleavage in the light chain of plasminogen. 
The light chain of plasmin contains the catalytic domain that hydrolyzes fibrin. If cysteine 
cathepsins could degrade the light chain of plasmin, then plasmin would lose its fibrinolytic 
potential. This could be a problem as plasmin degrades fibrin into fibrin degradation 
products (FDP) which aid in angiogenesis, including pro-angiogenic factors that stimulate 
angiogenesis, such as fibrin E fragment. I hypothesize if plasmin is degraded by cysteine 
cathepsins, then plasmin-generated pro-angiogenic fibrin fragments are not produced; in 
other words, cathepsins can act indirectly to inhibit angiogenesis. 
There were some overlapping sites with top scores where cathepsins K, L, or S 
could bind to plasminogen: DILE/CEEE (catK score 0.922, catL score 0.776, catS score 
0.836), QCLK/GTGE (catK score 0.934, catL score 0.864, catS score 0.934), and 
EQLA/PTAP (catK score 0.771, catL score 0.812, catS score 0.844). There were also some 
overlapping sites between two cathepsins. These overlapping sites can be seen in the same 
image in Appendix A (Figure A-1 and Figure A-2). Overlapping sequences or redundancy 
in hydrolysis sites, highlights a property of cathepsins K, L, and , as they are known to 
have substrate specificity redundancies [2].  
 Future directions should include a more robust modeling approach using 3D 
molecular docking instead of the “manual” approach I used. Not only would there be more 
accuracy with identifying cleavage sites/sequences on plasminogen, but this would provide 
a better visualization of binding interactions, which could be cross analyzed with the 
PACMANS analysis. Further, molecular modeling could identify areas on plasminogen 
that are more difficult to access. However, I hypothesize that because the large kringle 
domains are loop structures protruding on the outside of plasminogen [241], cathepsins are 
more likely to bind to these sites, as predicted by PACMANS. Eventually work can move 
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into the wet lab, where cathepsins can degrade plasminogen, and their degradation products 
can be added to endothelial cell proliferation assays to see if generated sequences impair 
endothelial cell sprouting. This preliminary modeling work provides a foundation to 




















CHAPTER 9  CONCLUSIONS AND FUTURE DIRECTIONS  
 Major Findings 
 The objective of this thesis was to study cathepsin-mediated fibrin(ogen)olysis to 
identify the roles cathepsins play in polymerization and degradation of fibrin. Cysteine 
cathepsins are collagenases and elastases [9, 50, 250], and for the first time I am showing 
that human cathepsin (cat) K, L, and S are fibrin (ogen)olytic proteases. Thrombin and 
plasmin, are the canonical proteases that cleave fibrinogen and degrade fibrin, respectively. 
Here, I studied the enzymology of cathepsins hydrolyzing fibrin(ogen) and placed it in the 
context of fibrin-based microvascular networks and abhorrent blood clotting mechanisms. 
 I questioned if cathepsins could degrade fibrin, driven by evidence that novel non-
plasmin proteases could be involved in destabilization of fibrin-based constructs including 
biological robots [144] and microvascular networks [14, 15, 184]. My work provides 
insight into why these types of fibrin-based constructs collapse and fail, by proposing that 
cathepsin-mediated fibrinolysis mechanisms could be involved in degrading the fibrin in 
the matrix. For the first time, I have shown that human cat K, L, and S were fibrinolytic 
proteases and successively hydrolyze fibrin into smaller fragments, suggesting cathepsins 
had multiple cleavage sites on fibrin. Although the cathepsins are closely related, they had 
unique cleavage patterns and varying rates of fibrinolysis. CatS was the most fibrinolytic, 
compared to catK and catL. Interestingly, catL was bound to fibrin, demonstrating that 
fibrin is another substrate that can sustain the active life of cathepsins. These findings 
helped introduce a new class of proteases to the biomaterial community. Hydrolysis of 
fibrin by cathepsins and their mode of action properties must be considered when 
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developing fibrin-based constructs. Furthermore, this work has clinical implications for 
cathepsin based mechanisms underlying aberrant clotting mechanisms. 
 To understand the role of cathepsins in proteolysis and matrix remodeling during 
microvascular network development, I used a microfluidic model to perturb the network 
using flow and cathepsin inhibitors as a potential target to prolong vessel stability. 
Microvessels formed in a fibrin matrix with ECs and fibroblasts have a significant amount 
of catK and catL activity. These upregulated active cathepsins destabilize microvascular 
networks causing vessels to regress. Applying luminal unidirectional flow induces low 
shear which decreases active cathepsins and increases endogenous cystatin C inhibitor; a 
potential mechanism to help reduce upregulation proteolysis.  Cat K, L, and S localized 
with ECs, associated with lumen on the apical and basal sides, as well as the fibroblasts 
which were present in the stromal area. Next, parts of the microfluidic network were 
assessed separately using an in vitro model through culturing ECs or fibroblasts on fibrin 
gels. Here, I identified that fibroblasts produced more cathepsins compared to ECs, 
corroborating increased co-localization of cathepsins with fibroblasts in stroma of 
microvascular networks. Further, this showed that fibrin is another substrate that can 
extend the activity of cathepsins over longer periods of time. In microvascular networks, 
fibrin in the matrix can serve as a bioactive reservoir sustaining activity of cathepsins over 
longer periods. If the cathepsins remain adsorbed to fibrin and continue to degrade fibrin, 
the cycle will continue. Fibrinolysis of the matrix cause destabilization and eventual 
construct failure. This observation has implications in other multi-cellular engineered 
living systems, such as the biological robots. 
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 To determine the role cysteine cathepsins play in abnormal blood clotting, active 
cathepsins were quantified in the Townes humanized transgenic mouse model of wild type 
(AA), sickle trait (AS), and sickle cell anemic (SS) mice. I identified a significant increase 
in the amount of active cathepsins in SS mice as early as 1 month of age compared to AA 
and AS mice. Active cathepsins increased in plasma of SS mice from 1 to 3 months of age. 
This shows there was an age-related increase in cathepsins, which could contribute to 
accelerated damage in SCA. Male SS mice had increased active cathepsins compared to 
female mice. Seeing these sex-related differences mirrors what is seen clinically, where 
men have a higher severity of clinical complications compared to women; men have more 
episodes of sickle pain crisis and lower life expectancies compared to women [198, 251]. 
Perhaps different cathepsins activity levels can contribute to these sex-related differences 
in SCA.  
 The amount of circulating FpA, a marker of coagulation, was also quantified in AA, 
AS, and SS mice. Preliminary data showed that male mice at 3 months of age could have 
more FpA compared to female mice, however no differences in FpA were observed at 1 
month. Cathepsins were fibrinogenolytic and released FpA, however, they cannot cleave 
FpA from fibrinogen and cause gelation of fibrin. Mice were injected with E-64 to inhibit 
cathepsins from cleaving circulating fibrinogen. After 2 months of treatment, active 
cathepsin levels were reduced, as well as circulating FpA in male mice. Together, this 
showed implications for SCA-induced cathepsin-mediated fibrinogenolysis. 
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 Future Directions 
9.2.1 Elucidate cathepsin-mediated fibrin(ogen)olysis mechanisms 
Cathepsins K, L, and S degrade fibrin in unique ways compared to each other and 
plasmin. Future work could include sequencing sites of fibrin degraded by cathepsins 
compared to cathepsins cleaving fibrinogen to identify if there are any overlapping 
hydrolysis sites. Studies can also be done to assess dissociation and association constants 
of cathepsins with fibrin(ogen), to identify if cathepsins prefer to cleave fibrinogen or 
degrade fibrin. Distinguishing between these two mechanisms can elucidate if cathepsins 
can cleave FpA to cause fibrin gelation, as there was no gelation of fibrin in our studies 
using cathepsin.  
There are limitations with my approach, for example, the amount of cathepsins was 
not varied to find optimal concentrations. Higher concentrations of papain degrade the 
fibrinogen; thus, a maximum concentration of 1ug/mL was used. My studies used 1ng/µL, 
so future directions should include working with serial concentrations of cathepsins K, L, 
and S to identify cleavage sites and characterize the fibrin structures formed. 
9.2.2 Biomechanical and biochemical properties of cathepsins 
My dissertation identified unique biomechanical regulatory properties of cathepsins 
using the microvasculature networks corroborating previous work about cathepsin 
mechanosensitive properties [6, 28, 152]. Although flow (~2Pa) increased total cathepsin 
L, it also increased cystatin C the endogenous inhibitor and reduced the amount of active 
cathepsins. In this case, flow served as a protective mechanism by reducing cathepsin 
activity. Cystatin C and cathepsins play a role in elastin degradation and atherosclerosis 
[26]. Future work can include using a bioreactor to induce shear stress on ECs or fibroblast 
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cultured on fibrin to see how the presence of fibrin affects cathepsin activity while 
underflow. Identifying cathepsin mechanism of sensitivity biomechanical properties of 
cathepsins could have implications in vascular remodeling.  
9.2.3 Understand the role of cathepsins in vasculogenesis/angiogenesis  
Active cathepsins were identified in microvascular networks, and their active was 
inhibited using biomechanical and biochemical approaches. There was also some 
preliminary evidence of using cathepsin inhibitors as an approach to prevent network 
regression (i.e.: decreased lumen diameter and vessel density). Future work could consider 
adding cathepsin inhibitors during earlier stages of development to see the role of 
cathepsins in initial stages of vascularization. There is already evidence that cathepsins are 
involved in vascular remodeling during wound healing [27, 29, 53, 252]. Using a 
microfluidic model for vascularization could be a way to identify putative roles of 
cathepsins in ECM remodeling during vascularization with applications in understanding 
uncontrolled vasculogenesis and angiogenesis in diseases. 
Tip/stalk (sprouting) ECs can be derived from embryonic stem cells [169], and have 
increased active MMP-2 and cathepsin L compared to phalanx (non-sprouting) ECs. 
Knowing that cathepsins in endothelial cells are biomechanically regulated [28], these EC 
subtypes could be further characterized by using a bioreactor to see how laminar and 
oscillatory shear stress increases or decreases cathepsin and MMP expression and activity. 
Using a more proliferative EC phenotype would be better for studying vasculogenesis and 
angiogenesis, and the microfluidic device used to develop engineered microvascular 
networks is a good platform to study this. Biochemical and biomechanical properties can 
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be altered to study mechanisms of cathepsins in determining their role in the angiogenic 
switch in sprouting and non-sprouting ECs. 
9.2.4 Control cathepsin-mediated fibrinolysis in fibrin-based constructs 
One major finding is that catL adsorbs to fibrin. A study using Fasciola hepatica 
catL demonstrates that during clotting, there are interactions between catL and fibrinogen 
that are resistant to boiling even with SDS and mercaptoethanol present [12]. This appears 
to be a conserved mechanism of catL between different species and is worth exploring 
further. This interaction was demonstrated using recombinant proteases, as well as in vitro 
with endothelial cells and fibroblasts, which suggests it can occur in more complex 
systems, like microvascular networks. Fibrin serving as a substrate to sustain active 
cathepsins over extended periods of time can hinder the development of fibrin-based 
engineered constructs.  
This is how I envision a bioactive reservoir is formed in microvascular networks 
and potentially other fibrin-based constructs: Engineers place cells in a fibrin-based matrix; 
remodeling will occur which is facilitated by proteases, including cathepsins, continually 
being secreted by these cells. Cathepsins will remodel the matrix creating lumen, but 
because fibrin is present their active lifetime is extended. Eventually, cathepsins will 
remodel the matrix to the point where the cathepsins start degrading the matrix, which 
causes the matrix to destabilize and eventually collapse, no longer able to support the 
lumen. Researchers now have a new class of proteases to consider inhibiting, aside from 
MMPs and plasmin, and I hope with the information collected, they will consider novel 
cathepsin inhibition strategies to help improve design for longevity. 
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Fibroblasts made more cathepsins compared to ECs, suggesting they are key 
producers of cathepsins in microvascular networks. Addition of stromal cells has been a 
proven strategy to improve microvessel architecture [15], so it would not be a good 
approach to reduce active cathepsins in these systems. Addition of flow increased cystatin 
C production, which bound to upregulated cathepsins and reduced its activity. To control 
proteolytic activity of microvascular networks over time, perhaps fibroblasts can be 
engineered using tetracycline systems to control expression of cystatins. The engineered 
fibroblasts can be combined with ECs and fibrin in a microfluidic device where tetracycline 
free media can be used during initial development period then switched to tetracycline 
growth media to induce cystatin C production until the tetracycline is depleted. This will 
give engineers more control over proteases in systems, similar to how other design 
parameters are used to control network architecture (i.e.: using stromal cells for paracrine 
signaling to increase branching). 
 One of the goals I initially set was preventing microvessel regression in 
microvascular networks to improve their longevity, but chose to focus on quantifying 
cathepsin activity in microvascular networks. Regenerative medicine’s promise of 
replacement tissue and organ development has been challenged by lack of vascularization, 
as required for thick, complex tissues to overcome diffusional transport limitations [91, 
93]. Pre-vascularization using microfluidic systems may be one strategy for generating 
more complex, highly organized microvascular networks. These systems are advantageous 
for generating microvessels in vitro, allowing for their development and maintenance 
within a controlled environment [100-102, 176]. These microvessels are easily maintained, 
but show regression [14, 15], as characterized by decreased microvessel diameter, number 
 155 
of perfusable branches, and vessel density, following several weeks in culture. There were 
preliminary results adding E-64 to microvascular networks for 48 hours- it was observed 
that vessel diameter was preserved in microvascular networks with cystatin C or E-64 
added, with little decrease in microvessel density. This is exciting, as I might have 
identified a novel approach using cathepsin inhibitors to prevent regression which can help 
maintain in vitro vessels for prolonged periods of growth in the future, something the fields 
of tissue engineering can benefit from. 
9.2.5 Elucidate the role of human cysteine cathepsins in the coagulation cascade 
 There is clinical relevance for cathepsin-mediated fibrin(ogen)olysis in the 
coagulation cascade after vessel injury. The proteases thrombin and plasmin are considered 
responsible for the initiation and degradation of fibrin, respectively, However, this work 
shows cysteine cathepsins should be studied especially because cysteine cathepsins are 
known to be involved in other vascular related injuries and vascular remodeling [2, 24, 83, 
143, 151, 153, 181, 252-254]. My thesis has some foundational evidence for the roles of 
cysteine cathepsins in the coagulation cascade. I should acknowledge the limitation with 
my studies is that I looked at one aspect of the coagulation cascade. Figure 9-1 illustrates 
additonal parts in the coagulation cascade that lead up to fibrinogen cleavage, including 
inhibitors which block the cascade.  
 In the sickle cell disease model I hypothesized that increased plasma levels of FpA 
in SCD is due to cysteine cathepsin cleaving fibrinogen. This case studies cathepsins 
serving only as a procoagulant, which is a limited scope considering the complexity of the 
coagulation cascade. Studies focused on cathepsin G, a serine protease, in the neutrophils 
which are involved in thrombosis response. Interestingly, cathepsin G served as both a pro- 
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and anti-coagulant during the same thrombin generation time course [255]. It is possible 
cathepsins K, L, or S could cleave or degrade other factors in the coagulation cascade, 
serving as a pro- and/or anti-coagulant. Our work showed that there is an increased amount 
of active cathepsins circulating in plasma under sickle cell anemia conditions, and they can 
be acting on any substrates (i.e.: factor X or thrombin-antithrombin) present. Even the 
proteases, thrombin or plasmin, could be substrates for cathepsins, which would inhibit 
fibrin formation and degradation. As an example, plasminogen as a substrate for cathepsin 
cleavage was explored briefly in Chapter 8. Cathepsins could hinder aspects of fibrin 
formation or fibrin degradation directly or indirectly. Direct mechanisms are defined as 
cathepsins cleaving fibrinogen or degrading fibrin; both of which were studied using 
recombinant proteases in Chapters 3 and 5. Indirect mechanisms for fibrin formation could 
include cathepsins degrading natural anticoagulants. 
 Prothrombin time, a measure of how long it takes for blood to clot which can 
indicate if abnormal clotting is occurring, is elevated in sickle cell anemia [31, 116, 256]. 
Elevated prothrombin times mean blood is taking longer to clot. This led me to hypothesize 
that cathepsins are competing with existing proteases in the coagulation cascade (Fig 9-
1A), rather than working together. One would assume the opposite is happening- more 
proteases means faster clotting times. However, our lab has shown that because more 
proteases are present, does not mean their effects are additive [257]. In other words, if two 
or more cathepsins are in the presence of the same substrate, simultaneously, it does not 
mean more substrate will be degraded. Cathepsins could be blocking the “normal 
coagulation proteases”, thus slowing the clotting process down. 
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 Cathepsins have been shown to be produced and secreted by endothelial cells that 
line the blood vessel [28]. With cathepsins in close proximity to access the clots, the roles 
of cysteine cathepsins and their putative activity to degrade clots should be considered in 
physiological and pathophysiological conditions. Plasmin degrades fibrin into two main 
fragments, D-dimer and fibrin E fragment, and cells with higher levels of fibrin degradation 
products (FDP) are at the front or leading of wounds and aortic atherosclerotic plaques 
during invasion [258]. FDPs aid angiogenesis; specifically, fibrin E fragment is a pro-
angiogenic factor that stimulates angiogenesis in wounds and plaque development [259], 
and has also been shown to stimulate proliferation, migration, and differentiation of 
microvascular ECs [260]. Cathepsins K, L, and S produce different banding patterns 
compared to plasmin, suggesting that cathepsins cleave fibrin at different sites compared 
to plasmin; this was discussed in Chapter 3. I hypothesize that if cathepsins compete with 
plasmin and cleave fibrin (Fig 9-1B), cathepsins will not produce FDPs that are pro-
angiogenic (i.e.: fibrin E fragment) and hinder angiogenesis during wound healing. 
 There is also clinical evidence of depletion of natural anticoagulants, protein C and 
protein, which work together to inhibit conversion of prothrombin to thrombin. [116, 193, 
261, 262]. Without inhibition, thrombin is continually produced, which cleaves fibrinogen 
and contributes to chronic coagulation conditions seen in sickle cell disease.  Currently, 
the mechanisms of lowered protein C and protein S are unknown [262], and can be pursued 
in a future study. The underlying disease conditions of SCA upregulates cathepsins, which 

















Figure 9-1: Future considerations for cysteine cathepsins in the coagulation cascade 
This schematic illustrates possible locations cathepsins (represented by the red PACMEN) 
where cathepsins could perturb the coagulation cascade based on clinical findings. (A) 
People with SCA have increased prothrombin time, which means it takes longer for their 
blood to coagulate; I hypothesize that there is competition between cathepsins and 
canonical coagulation proteases on fibrinogen Cathepsins could be blocking the “normal 
coagulation proteases” which slows the clotting process. (B) Plasmin is the canonical 
enzyme that degrades fibrin into fibrin fragments that contain pro-angiogenic properties. 
However, if cysteine cathepsins degrade fibrin at different sites and generate fibrin 
degradation products that impair angiogenesis during wound healing. (C) Clinically, 
people with SCA present with lower amounts of anticoagulants, protein C and protein S. I 
hypothesize that cysteine cathepsins can degrade these anticoagulants, and thus clots are 
not resolved which drives chronic coagulation activation. 
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 This is a unique opportunity to study cathepsin plasma levels by treating mice with 
anticoagulants or inhibitors for tissue factor, prothrombin/thrombin, factor X etc. or cross 
breeding cathepsin deficient mice with some of the mouse models discussed in Section 
2.4.5 of the literature review (i.e.: fibrinogen deficient, protease active receptor (PAR) -1 
and -2 (thrombin receptors). Blood could also be taken from the SCD mouse models, and 
their coagulation factors could be depleted from their plasma. Then the plasma can be 
spiked with increasing amounts of cathepsins, and clotting can be assessed to see if 
cathepsins serve as pro- or anti-coagulants. 
 A question yet to be answered is identifying which cell types are secreting the 
cathepsins. Past work in the lab has identified cathepsins in the arteries of SS mice [89], 
suggesting that ECs could secrete cathepsins basally, into the artery wall. This work 
quantified the amount of active cathepsins in plasma, suggesting that cathepsins are also 
being secreted from ECs on the apical side into the lumen. Also, SS PBMCs induce active 
cathepsins in endothelial cells [40]. To understand the role of the monocytes, sickle mice 
can be treated with clodronate liposomes to deplete monocytes. An approach to understand 
the role of ECs, could include creating a sickle cell mouse with EC-specific deletion of a 
cathepsin gene. Also, bone marrow transplants (BMT) can be used, where bone marrow 
containing hematopoietic stem cells, can be transplanted from SS mice into catK KO mice. 
These mice would contain SS RBCs and myeloid cells (monocytes/macrophages) and 
resident catK KO ECs, and if active cathepsins are identified in the plasma this would 
suggest the source of the cathepsins are from PBMCs. The model could also be flipped 
where bone marrow from catK KO mice are transplanted into SS mice. These BMT models 
would also have clinical relevance, as bone marrow transplants are used for treatments with 
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people with sickle cell anemia have seen success with disease-free and overall survival 
rates of 85% and 97%, respectively [263]. BMTs as a treatment option for many patients 
is limiting as it is hard to find donor matches [264], however, BMT experiments could be 
leveraged to provide answers to understanding cathepsins role in SCA. 
9.2.6 SCA treatment approaches with cathepsin inhibitors 
In the humanized Towne’s model, cathepsins are biomarkers that can be 
pharmacological targets, with their plasma levels reduced by using E-64. Anticoagulant 
approaches to reduce vaso-occlusion and chronic coagulation activation have not been very 
successful, particularly because of bleeding complications [129, 130]. By targeting the 
cathepsins as a treatment strategy, there is no reduction in natural coagulants, thus bleeding 
and hemorrhagic risks are lowered. This could have broader impacts for eliminating use of 
anticoagulants for treatment of other blood disorders. 
9.2.7 Correlating cathepsins and coagulation markers in Townes sickle mice 
 Another idea that was not fully explored in my dissertation was looking at 
additional coagulation markers with our SCD mouse model, aside from quantifying FpA. 
Future work should consider correlating active cathepsins with other markers of 
coagulation action activation, such as TAT, D-dimers, protein C, and protein S. To see if 
there is any relation between active cathepsins before and after sickle pain crisis, mice can 
be placed in a deoxygenation chamber to simulate pain crisis condition, with blood 
collected/plasma isolated immediately before and after. These experiments could also be 
done with the cathepsin deficient mouse with sickle cell disease mouse to further elucidate 
the role of cathepsins in blood clotting mechanisms. 
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9.2.8 Sex as a basis for variability in future studies 
 A noteworthy finding in this dissertation was male and female differences in active 
cathepsins in SS mice. Sex differences exist in cardiovascular diseases [265, 266]. Lorenz 
et al. [267] did whole genome expression analysis in HUVECs subjected to shear, and 
compared gene transcription levels between males and females. Female HUVECs had 
more of a transcription response compared to male HUVECs, where numerous genes were 
regulated in the opposite direction, demonstrating sexual dimorphisms in gene expression 
in ECs could contribute to differences in EC function. Moreover, our studies and this work 
demonstrates the importance of differentiating between male and female for in vitro and in 
vivo research. This can help us understand why there are differences in how SCD and other 














APPENDIX A. FULL PACMANS TOP SCORING TABLES FOR 
CATHEPSIN ON PLASMINOGEN 
The following tables are the top 5% of PACMANS scores for plasminogen cleaved by 
cathepsins K (Table A-1), L (Table A-2), S (Table A-3), and V (Table A-4).  
 
The kringle domains (K1, K2, K3, K4, and K5) amino acid sequences were determined 
based on an image in Figure 8-1 (denoted by the colored lines and circles). Known cleavage 
sites for elastase, aureus V8 protease, and cleavage site that generates plasmin were also 
determined from the plasminogen figure (circled in black in Figure 8-1). Figure 8-1 is 
missing the first 20 amino acid sequences, and the sequence numbers used in PACMAN 
align with the sites/numbers for the plasminogen site sequence in Uniprot; Table 8-1 
denotes these differences, which was used for the analysis. 
 
TABLE A-1. Sequences for Kringle Domain and Known Protease Cleave Sites 
Kringle Domain / Known 
Protease Cleavage Sites  
Figure 8-1 
Sequence 
Aligned PACMANs Sequence 
(AA sequence from Uniprot) 
K1 84 – 163 104 – 183 
K2 165 – 265 185 – 265 
K3 255 - 335 275 - 355 
K4 357 - 436 377 - 456 
K5 461 - 541 481 - 561 
elastase 1  76 - 83 96 - 103 
aureus V8 protease 162 - 169 182 - 189 
elastase 2 335 - 342 355 - 362 
elastase 3 351 - 358 371 - 378 
elastase 4 437 - 445 457 - 465 
pepsin 542 - 549 562 - 569 
cleavage site that  
generates plasmin 
558 - 566 578 - 586 
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TABLE A-2. Top 5% of PACMANS predicted plasminogen cleavages sites by 




Cumulative Score Normalized Score
K3 274 QCLKGTGE 281 2052 0.934
K1 & aureus V8 protease 177 DILECEEE 184 2026 0.922
light chain 667 ALLKLSSP 674 1980 0.902
light chain 747 GHLAGGTD 754 1979 0.901
light chain 713 AGLLKEAQ 720 1953 0.891
light chain 714 GLLKEAQL 721 1909 0.869
light chain 635 VILGAHQE 642 1878 0.855
light chain 669 LKLSSPAV 676 1866 0.85
--- 39 KQLGAGSI 46 1859 0.847
K1 145 EGLEENYC 152 1848 0.842
--- 467 VVLLPDVE 474 1838 0.837
K5 549 RKLYDYCD 556 1834 0.836
K5 524 AGLEKNYC 531 1833 0.836
--- 12 LFLKSGQG 19 1822 0.829
K2 227 KNLKKNYC 234 1796 0.818
light chain 780 WGLGCARP 787 1731 0.787
light chain 596 VSLRTRFG 603 1711 0.779
elastase 2 360 EQLAPTAP 367 1693 0.771
K4 419 AGLTMNYC 426 1688 0.77
--- 51 AKCEEDEE 58 1678 0.767
elastase 1 91 VVLFEKKV 98 1675 0.763
light chain 655 SRLFLEPT 662 1667 0.76
light chain 733 EFLNGRVQ 740 1654 0.754
--- 468 VLLPDVET 475 1653 0.753
K4 449 CNLKKCSG 456 1629 0.74
light chain 719 AQLPVIEN 726 1628 0.742
K2 202 SGLECQAW 209 1621 0.738
elastase 3 368 PELTPVVQ 375 1616 0.735
--- 31 ASLFSVTK 38 1611 0.735
light chain 772 YILQGVTS 779 1609 0.732
light chain 622 HCLEKSPR 629 1607 0.731
K1 & elastase 1 98 VYLSECKT 105 1605 0.731
--- 20 EPLDDYVN 27 1579 0.719
K3 317 KNLDENYC 324 1578 0.719
light chain 657 LFLEPTRK 664 1575 0.717
K5 546 ANPRKLYD 553 1558 0.711
light chain 616 WVLTAAHC 623 1555 0.707
light chain 609 GTLISPEW 616 1552 0.707
light chain 666 IALLKLSS 673 1545 0.703
--- 10 LLLFLKSG 17 1545 0.704
Plasminogen Sequence
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TABLE A-3. Top 5% of PACMANS predicted plasminogen cleavages sites by 








light chain 667 ALLKLSSP 674 2787 0.96
K4 459 ASVVAPPP 466 2680 0.923
light chain 669 LKLSSPAV 676 2593 0.891
K3 274 QCLKGTGE 281 2519 0.864
light chain 635 VILGAHQE 642 2508 0.862
light chain 747 GHLAGGTD 754 2504 0.862
light chain 714 GLLKEAQL 721 2491 0.858
--- 39 KQLGAGSI 46 2440 0.839
--- 12 LFLKSGQG 19 2385 0.819
light chain 780 WGLGCARP 787 2369 0.811
elastase 2 360 EQLAPTAP 367 2360 0.812
light chain 713 AGLLKEAQ 720 2333 0.804
K1 & aureus V8 protease 177 DILECEEE 184 2260 0.776
light chain 609 GTLISPEW 616 2193 0.756
--- 471 PDVETPSE 478 2190 0.753
light chain 655 SRLFLEPT 662 2140 0.736
light chain 737 GRVQSTEL 744 2118 0.73
elastase 2 362 LAPTAPPE 369 2114 0.728
light chain 763 PLVCFEKD 770 2103 0.725
--- 10 LLLFLKSG 17 2091 0.72
light chain 772 YILQGVTS 779 2078 0.712
K5 536 GDVGGPWC 543 2076 0.715
elastase 4 460 SVVAPPPV 467 2069 0.712
plasmin generation 
cleavage site
580 RVVGGCVA 587 2066 0.709
--- 468 VLLPDVET 475 2064 0.711
K5 495 TTVTGTPC 502 2063 0.708
--- 467 VVLLPDVE 474 2038 0.702
--- 31 ASLFSVTK 38 2037 0.703
light chain 709 GTFGAGLL 716 2029 0.7
K3 287 VAVTVSGH 294 2026 0.698
light chain 775 QGVTSWGL 782 2024 0.696
light chain 596 VSLRTRFG 603 2008 0.691
light chain 623 CLEKSPRP 630 2006 0.688
light chain 616 WVLTAAHC 623 2005 0.686
elastase 4 465 PPVVLLPD 472 2003 0.69
light chain 622 HCLEKSPR 629 2002 0.686
K4 449 CNLKKCSG 456 1991 0.681
light chain 733 EFLNGRVQ 740 1976 0.68
light chain 684 ACLPSPNY 691 1975 0.681
light chain 666 IALLKLSS 673 1970 0.677
Plasminogen Sequence
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TABLE A-4. Top 5% of PACMANS predicted plasminogen cleavages sites by 







light chain 667 ALLKLSSP 674 3090 0.996
K3 274 QCLKGTGE 281 2929 0.943
light chain 714 GLLKEAQL 721 2867 0.924
light chain 635 VILGAHQE 642 2847 0.917
light chain 669 LKLSSPAV 676 2831 0.912
--- 39 KQLGAGSI 46 2771 0.892
--- 12 LFLKSGQG 19 2739 0.882
light chain 747 GHLAGGTD 754 2725 0.878
elastase 4 459 ASVVAPPP 466 2693 0.869
light chain 780 WGLGCARP 787 2648 0.851
elastase 2 360 EQLAPTAP 367 2617 0.844
light chain 713 AGLLKEAQ 720 2604 0.84
K1 177 DILECEEE 184 2595 0.836
light chain 655 SRLFLEPT 662 2568 0.828
light chain 616 WVLTAAHC 623 2533 0.814
K3 287 VAVTVSGH 294 2483 0.8
--- 10 LLLFLKSG 17 2428 0.782
--- 467 VVLLPDVE 474 2417 0.779
K1 145 EGLEENYC 152 2410 0.777
--- 466 PVVLLPDV 473 2408 0.777
--- 471 PDVETPSE 478 2403 0.775
--- 31 ASLFSVTK 38 2402 0.775
light chain 737 GRVQSTEL 744 2392 0.772
light chain 622 HCLEKSPR 629 2385 0.767
light chain 609 GTLISPEW 616 2379 0.768
--- 8 LLLLLFLK 15 2379 0.767
light chain 772 YILQGVTS 779 2375 0.764
light chain 775 QGVTSWGL 782 2369 0.764
elastase 4 465 PPVVLLPD 472 2364 0.763
--- 7 VLLLLLFL 14 2364 0.762
light chain 742 TELCAGHL 749 2363 0.761
elastase 3 368 PELTPVVQ 375 2354 0.759
light chain 596 VSLRTRFG 603 2336 0.753
K2 202 SGLECQAW 209 2327 0.75
light chain 733 EFLNGRVQ 740 2281 0.736
--- 6 VVLLLLLF 13 2280 0.735
elastase 4 460 SVVAPPPV 467 2275 0.734
--- 468 VLLPDVET 475 2274 0.733
elastase 1 91 VVLFEKKV 98 2267 0.731
K5 524 AGLEKNYC 531 2266 0.732
Plasminogen Sequence
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TABLE A-5. Top 5% of PACMANS predicted plasminogen cleavages sites by 








light chain 667 ALLKLSSP 674 1509 0.914
K3 274 QCLKGTGE 281 1460 0.884
elastase 4 459 ASVVAPPP 466 1447 0.877
light chain 669 LKLSSPAV 676 1442 0.873
K1 & aureus V8 protease 177 DILECEEE 184 1405 0.851
light chain 747 GHLAGGTD 754 1403 0.85
light chain 635 VILGAHQE 642 1402 0.849
light chain 713 AGLLKEAQ 720 1400 0.848
--- 12 LFLKSGQG 19 1378 0.834
light chain 714 GLLKEAQL 721 1365 0.826
--- 39 KQLGAGSI 46 1365 0.826
elastase 2 360 EQLAPTAP 367 1303 0.789
light chain 609 GTLISPEW 616 1286 0.779
light chain 655 SRLFLEPT 662 1285 0.778
light chain 622 HCLEKSPR 629 1283 0.777
--- 471 PDVETPSE 478 1273 0.771
light chain 780 WGLGCARP 787 1269 0.768
K2 227 KNLKKNYC 234 1265 0.766
light chain 596 VSLRTRFG 603 1261 0.763
K4 449 CNLKKCSG 456 1252 0.758
--- 10 LLLFLKSG 17 1243 0.753
K5 524 AGLEKNYC 531 1234 0.747
light chain 666 IALLKLSS 673 1231 0.745
elastase 2 362 LAPTAPPE 369 1231 0.746
K5 549 RKLYDYCD 556 1228 0.744
--- 467 VVLLPDVE 474 1223 0.741
--- 468 VLLPDVET 475 1213 0.735
--- 31 ASLFSVTK 38 1204 0.729
elastase 1 91 VVLFEKKV 98 1203 0.728
K1 145 EGLEENYC 152 1175 0.711
elastase 4 460 SVVAPPPV 467 1159 0.702
elastase 4 465 PPVVLLPD 472 1157 0.701
light chain 763 PLVCFEKD 770 1156 0.7
light chain 733 EFLNGRVQ 740 1152 0.698
K2 254 WELCDIPR 261 1139 0.69
light chain 719 AQLPVIEN 726 1138 0.689
light chain 742 TELCAGHL 749 1137 0.688
light chain 772 YILQGVTS 779 1137 0.688
light chain 684 ACLPSPNY 691 1129 0.684
K2 202 SGLECQAW 209 1128 0.683
Plasminogen Sequence
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TABLE A-6. PACMANS top scored plasminogen cleavage sites by cathepsins K, L, 










S light chain 667 ALLKLSSP 674 3090 0.996
L light chain 667 ALLKLSSP 674 2787 0.96
S K3 274 QCLKGTGE 281 2929 0.943
K K3 274 QCLKGTGE 281 2052 0.934
S light chain 714 GLLKEAQL 721 2867 0.924
L K4 & elastase 4 459 ASVVAPPP 466 2680 0.923
K K1 & aureus V8 protease 177 DILECEEE 184 2026 0.922
S light chain 635 VILGAHQE 642 2847 0.917
V light chain 667 ALLKLSSP 674 1509 0.914
S light chain 669 LKLSSPAV 676 2831 0.912
K light chain 667 ALLKLSSP 674 1980 0.902
K light chain 747 GHLAGGTD 754 1979 0.901
L light chain 669 LKLSSPAV 676 2593 0.891
K light chain 713 AGLLKEAQ 720 1953 0.891
V K3 274 QCLKGTGE 281 1460 0.884
V elastase4 459 ASVVAPPP 466 1447 0.877
V light chain 669 LKLSSPAV 676 1442 0.873
S elastase 4 459 ASVVAPPP 466 2693 0.869
L K3 274 QCLKGTGE 281 2519 0.864
L light chain 635 VILGAHQE 642 2508 0.862
V K1 & aureus V8 protease 177 DILECEEE 184 1405 0.851
S elastase 2 360 EQLAPTAP 367 2617 0.844
K K1 145 EGLEENYC 152 1848 0.842
S K1 & aureus V8 protease 177 DILECEEE 184 2595 0.836
K K5 549 RKLYDYCD 556 1834 0.836
K K5 524 AGLEKNYC 531 1833 0.836
K K2 227 KNLKKNYC 234 1796 0.818
L elastase 2 360 EQLAPTAP 367 2360 0.812
S K3 287 VAVTVSGH 294 2483 0.8
V elastase2 360 EQLAPTAP 367 1303 0.789
S K1 145 EGLEENYC 152 2410 0.777
L K1 & aureus V8 protease 177 DILECEEE 184 2260 0.776
K elastase 2 360 EQLAPTAP 367 1693 0.771
K K4 419 AGLTMNYC 426 1688 0.77
V K2 227 KNLKKNYC 234 1265 0.766
S elastase 4 465 PPVVLLPD 472 2364 0.763
K elastase 1 91 VVLFEKKV 98 1675 0.763
S elastase 3 368 PELTPVVQ 375 2354 0.759
V K4 449 CNLKKCSG 456 1252 0.758
S K2 202 SGLECQAW 209 2327 0.75
V K5 524 AGLEKNYC 531 1234 0.747
V elastase2 362 LAPTAPPE 369 1231 0.746
V K5 549 RKLYDYCD 556 1228 0.744
K K4 449 CNLKKCSG 456 1629 0.74
K K2 202 SGLECQAW 209 1621 0.738
K elastase 3 368 PELTPVVQ 375 1616 0.735
S elastase 4 460 SVVAPPPV 467 2275 0.734
S K5 524 AGLEKNYC 531 2266 0.732
S elastase 1 91 VVLFEKKV 98 2267 0.731
K K1 & elastase 1 98 VYLSECKT 105 1605 0.731
V elastase1 91 VVLFEKKV 98 1203 0.728
L elastase 2 362 LAPTAPPE 369 2114 0.728
K K3 317 KNLDENYC 324 1578 0.719
L K5 536 GDVGGPWC 543 2076 0.715
L elastase 4 460 SVVAPPPV 467 2069 0.712
V K1 145 EGLEENYC 152 1175 0.711
K K5 546 ANPRKLYD 553 1558 0.711
L plasmin cleavage site 580 RVVGGCVA 587 2066 0.709
L K5 495 TTVTGTPC 502 2063 0.708
V elastase4 460 SVVAPPPV 467 1159 0.702
V elastase4 465 PPVVLLPD 472 1157 0.701
L K3 287 VAVTVSGH 294 2026 0.698
V K2 254 WELCDIPR 261 1139 0.69
L elastase 4 465 PPVVLLPD 472 2003 0.69
V K2 202 SGLECQAW 209 1128 0.683
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